










The handle http://hdl.handle.net/1887/53235 holds various files of this Leiden University 
dissertation. 
 
Author: Tummers, Q.R.J.G. 
Title: Fluorescence-guided cancer surgery using clinical available and innovative tumor-
specific contrast agents 





using clinical available and innovative tumor-specic contrast agents
Quirijn Tummers




46151 Tummers cover.indd   1 09-08-17   11:17

Fluorescence-guided cancer surgery
using clinical available and innovative tumor-specic contrast agents
Quirijn Tummers
46151 Quirijn Tummers.indd   1 16-08-17   13:01
© Q.R.J.G. Tummers 2017
ISBN: 978-94-6332-197-6
Lay-out: Ferdinand van Nispen, Citroenvlinder DTP & Vormgeving, my-thesis.nl
Printing: GVO Drukkers & Vormgevers
All rights reserved. No parts of this thesis may be reproduced, distributed, 
stored in a retrieval system or transmitted in any form or by any means, without 
prior written permission of the author.
The research described in this thesis was nancially supported by the Center 
for Translational Molecular Imaging (MUSIS project), Dutch Cancer Society and 
National Institutes of Health.
Financial support by Raad van Bestuur HMC Den Haag, Quest Medical 
Imaging, On Target Laboratories, Centre for Human Drug Research, Curadel, 
LUMC, Nederlandse Vereniging voor Gastroenterologie, Karl Storz Endoscopie 
Nederland B.V., ABN-AMRO and Chipsoft for the printing of this thesis is 
gratefully acknowledged.
46151 Quirijn Tummers.indd   2 16-08-17   13:01
Fluorescence-guided cancer surgery
using clinical available and innovative tumor-specic contrast agents
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnicus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 11 oktober 2017
klokke 15:00 uur
door
Quirijn Robert Johannes Guillaume Tummers
geboren te Leiden
in 1986
46151 Quirijn Tummers.indd   3 16-08-17   13:01
Promotor  Prof. dr. C.J.H. van de Velde 
Co-promotor  Dr. A.L. Vahrmeijer 
Leden promotiecommissie Prof. dr. J. Burggraaf 
 Prof. dr. V.T.H.B.M. Smit 
 Prof. dr. C.W.G.M. Löwik (Erasmus MC, Rotterdam) 
 Prof. dr. G.M. van Dam (UMCG, Groningen)  
 Dr. K.N. Gaarenstroom
46151 Quirijn Tummers.indd   4 16-08-17   13:01
46151 Quirijn Tummers.indd   5 16-08-17   13:01
TABLE OF CONTENTS
Chapter 1 General introduction and thesis outline 9
Part I Exploring clinical available uorescent contrast 
agents in cancer surgery
19
Chapter 2 Near-infrared uorescence sentinel lymph node 
detection in gastric cancer: a pilot study
21
Chapter 3 Real-time intraoperative detection of breast cancer 
using near-infrared uorescence imaging and 
Methylene Blue
39
Chapter 4 First experience on laparoscopic near-infrared 
uorescence imaging of hepatic uveal melanoma 
metastases using indocyanine green
57
Chapter 5 Intraoperative identication of normal pituitary gland 
and adenoma using near-infrared uorescence imaging 
and low-dose indocyanine green 
69
Chapter 6 Intraoperative near-infrared uorescence imaging of a 
paraganglioma using Methylene Blue: a case report
85
Chapter 7 Intraoperative guidance in parathyroid surgery using 
near-infrared uorescence imaging and low-dose 
Methylene Blue.
97
Chapter 8 The value of intraoperative near-infrared uorescence 
imaging based on enhanced permeability and 
retention of indocyanine green: feasibility and false-
positives in ovarian cancer
113
46151 Quirijn Tummers.indd   6 16-08-17   13:01
Part II Clinical translation of innovative tumor-specic 
uorescent contrast agents
131
Chapter 9 Intraoperative imaging of folate receptor alpha positive 
ovarian and breast cancer using the tumor specic 
agent EC17
133
Chapter 10 A novel tumor-specic agent targeting the folate 
receptor-alpha for intraoperative near-infrared 
uorescence imaging: a translational study in healthy 
volunteers and patients with ovarian cancer
155
Part III 179
Chapter 11 Summary and future perspectives 181
Appendices 193
Nederlandse samenvatting en toekomstperspectieven 195
List of publications 209
Curriculum Vitae 215
Dankwoord 219
46151 Quirijn Tummers.indd   7 17-08-17   20:40




46151 Quirijn Tummers.indd   9 16-08-17   13:01
46151 Quirijn Tummers.indd   10 16-08-17   13:01
General introduction and thesis outline 11
Over the past decades multiple preoperative imaging modalities have become 
available that have the ability to non-invasively detect tumors, improve 
accuracy of staging and preoperative planning, and can identify sentinel lymph 
nodes (SLN) of various tumor types or vital structures1;2.
However, during surgery, translation of these preoperative obtained images 
can be challenging due to altering in body position and tissue manipulation by 
the surgeon. Therefore surgeons mainly have to rely on their eyes and hands 
to identify structures that need to be resected or spared. Distinction between 
malignant and healthy tissue based on inspection and palpation can often be 
very dicult.  Therefore, incomplete resections (R1) still occur in a signicant 
number of cancer patients. In breast cancer for example, the number of patients 
with positive resection margins ranges from 11% to 46% after resection of 
the primary tumor3. Because complete resections are the cornerstone of 
curative cancer surgery, this leads to unfavorable patient outcomes, resulting 
in additional surgical procedures, delays in adjuvant treatment, increased 
morbidity rates and increased healthcare costs, and most likely decreased 
quality of life. 
Next to imaging solitary tumors, improving the detection of metastasized 
disease could also improve patient outcomes. In metastasized ovarian 
cancer for example, identication of malignant lesions can improve staging 
procedures and facilitate treatment decisions between primary surgery and 
systemic therapy. Moreover, it can increase the number of optimal debulking 
procedures resulting in prolonged survival4-6. In metastasized uveal melanoma, 
intraoperative identication of hepatic metastases can assist in selecting 
patients that will benet from resection, and expedite adjuvant systemic 
therapies for patients with miliary disease7-9. 
Moreover, minimally invasive procedures are increasingly applied in daily 
clinical practice, limiting the possibility to palpate tissue and making the visual 
inspection more important for identication of malignant tissue and normal 
structures. Therefore, there is a clear unmet need for imaging modalities that 
facilitate the detection of cancer tissue and vital structures in real time during 
the surgical procedure.
Fluorescence imaging
Fluorescence imaging is an innovative optical imaging technique that can 
assist in the intraoperative identication of tumor tissue, SLNs, and vital 
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structures10. This technique, like medical imaging techniques in general, is 
based on the ability to create a contrast ratio between the tissue of interest 
and its surrounding normal tissue.
Figure 1. NIR uorescence imaging
NIR uorescent contrast agents are administered intravenously. During surgery, the agent is visualized 
using a NIR uorescent imaging system of the desired form factor (above the surgical eld for open 
surgery or encased within minimal invasive surgery). All systems must have adequate NIR excitation 
light, collection optics, lter sets and a camera sensitive to NIR uorescent emission light. An optimal 
imaging system includes simultaneous visible (white) light illumination of the surgical eld, which can 
be merged with the generated NIR uorescence images. The surgeon’s display can be one of several 
form factors, including a standard computer monitor, goggles or a wall projector. Abbreviations: LED, 
light emitting diode; NIR, near-infrared. Illustration and caption are depicted from Vahrmeijer et al., Nat 
Rev 201310.
Fluorescence can be captured by a specialized imaging system and made 
visible for the human eye in real-time. Advantages of this technology include 
high sensitivity and high resolution. Depending on the wavelength of the 
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emission light, penetration into tissue can be micrometers in the visible light 
spectrum (400 – 600nm), up to several millimeters to a centimeter in the near-
infrared (NIR) light spectrum (700 – 900nm)11;12.
For intraoperative uorescence imaging, both an imaging system and 
uorescent contrast agent are needed. Moreover, the combination of imaging 
device and optical properties of the uorophore is of paramount importance 
for successful intraoperative imaging. The imaging system contains an 
excitation light source and a detection device to capture emitted uorescence 
from the exited uorophores. Several imaging systems, either investigational 
or commercially available, have been developed over the past years for 
intraoperative uorescence imaging13. As uorescence imaging is gaining more 
attention, systems optimized for open surgery14-19 and endoscopic surgery20-23 
are available at present.  
With respect to uorescent contrast agents, there are only a few that have 
become clinically available over the past decades. These include uorescein24, 
methylene blue (MB)25, 5-aminolevulinic acid (5-ALA)26 and indocyanine 
green27. Although some of these contrast agents possess properties to 
specically accumulate inside or around tumors, they are not ligand- targeted 
contrast agents. This limits the clinical applicability of these compounds for a 
broad application. 
Tumor imaging
For intraoperative tumor imaging, accumulation of a contrast agent in or 
around the tumor is essential to dierentiate between tumors and surrounding 
normal structures. Several mechanisms are described that could facilitate this. 
Ideally, a contrast agent solely binds cancer specic proteins, while getting 
excreted from the rest of the body. Development of this kind of contrast agents 
is an expensive, time-consuming process and requires specic knowledge, 
experience in drug-development and an advanced infrastructure. Therefore, it 
is important to exploit clinically available contrast agents, such as ICG and MB 
whenever possible. As these contrast agents are not linked to tumor-targeted 
ligands, other mechanisms such as the enhanced permeability and retention 
(EPR) eect28;29, dierence in vascular pattern30-32, disturbed excretion proles33 
and favorable biodistribution of compounds with comparable biophysical 
properties34 can be explored. 
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For several indications, these mechanisms may be sucient for tumor 
imaging33;35-38. However, there are many more indications that require 
tailor-made tumor-specic uorescent ligands. These ligands can either be 
monoclonal antibodies, antibody fragments, such as single-chain (scFv) or fab 
fragments, small peptides or structure-inherent targeting uorophores39-42. 
If these ligands target proteins that are only present on cancer cells, and not 
on healthy tissue, they could facilitate optimal contrast ratios during imaging. 
Hanahan and Weinberg elaborated on these hallmarks of cancer, comprising of 
biological capabilities acquired during the multistep development of human 
tumors43. Over the past years multiple tumor-specic agents targeting these 
hallmarks are developed and validated in various animal models. However, 
only a few compounds have currently been introduced in clinical studies44-48. 
This underlines the diculty of bringing tumor-specic contrast agents to the 
clinic.
In conclusion, the objective of this thesis is to explore surgical indications 
where clinically available contrast agents can be used to improve tumor 
imaging and cancer surgery. Besides, newly developed tumor-specic contrast 
agents will be investigated in patients and healthy subjects, to assess their 
tolerability, pharmacokinetics and pharmacodynamics, and to determine their 
ability to visualize tumor tissue.
THESIS OUTLINE
This thesis is divided in two parts; Part 1 focuses on the exploration of clinically 
available NIR uorescent contrast agents for tumor imaging. Part 2 describes 
the rst in human introduction of newly developed tumor-specic uorescence 
contrast agents in both healthy subjects and subsequently patients.
Chapter 2 describes the intraoperative use of indocyanine green (ICG) 
absorbed to nanocolloid for the detection of sentinel lymph nodes in gastric 
cancer. Chapter 3 describes the successful detection of breast cancer tissue 
using methylene blue (MB) at dierent time points. Chapter 4 shows the 
identication of hepatic uveal melanoma metastases during laparoscopic 
liver surgery using ICG. Chapter 5 demonstrates the intraoperative distinction 
between normal pituitary gland and pituitary adenoma based on dierences 
in vascular perfusion patterns during endoscopic transsphenoidal surgery 
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using a low-dose of ICG. Chapter 6 shows the intraoperative detection of a 
paraganglioma and otherwise undetectable local metastases using MB. 
Chapter 7 reports the detection of parathyroid adenomas and normal 
parathyroid glands using MB and Chapter 8 described the intraoperative 
identication of ovarian cancer metastases using enhanced permeability and 
retention of ICG. 
Chapter 9 reports the identication of ovarian cancer metastases and 
primary breast cancer using the tumor-specic folate receptor alpha (FRα) 
targeting agent EC17. Chapter 10 describes the successful clinical translation 
of a new tumor-specic contrast agent in the near-infrared spectrum targeting 
the FRα in healthy subjects and patients.
In Chapter 11, all results are summarized and the future perspectives are 
discussed.
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ABSTRACT
Aim: To investigate feasibility and accuracy of near-infrared uorescence 
imaging using indocyanine green:nanocolloid for sentinel lymph node (SLN) 
detection in gastric cancer.
Methods: A prospective, single-institution, phase I feasibility trial was 
conducted. Patients suering from gastric cancer and planned for gastrectomy 
were included. During surgery, a subserosal injection of 1.6mL ICG:Nanocoll was 
administered around the tumor. NIR uorescence imaging of the abdominal 
cavity was performed using the Mini-FLARE™ NIR uorescence imaging 
system. Lymphatic pathways and SLNs were visualized. Of every detected 
SLN, the corresponding lymph node station, signal-to-background ratio and 
histopathological diagnosis was determined. Patients underwent standard-of-
care gastrectomy. Detected SLNs outside the standard dissection planes were 
also resected and evaluated.
Results: Twenty-six patients were enrolled. Four patients were excluded 
because distant metastases were found during surgery or due to technical 
failure of the injection. In 21 of the remaining 22 patients, at least 1 SLN was 
detected by NIR uorescence (mean 3.1 SLNs; range 1-6). In 8 of the 21 patients, 
tumor-positive LNs were found. Overall accuracy of the technique was 90% 
(70-99%; 95% CI), which decreased by higher pT-stage (100%, 100%, 100%, 
90%, 0% for respectively Tx, T1, T2, T3, T4 tumors). All NIR-negative SLNs were 
completely eaced by tumor. Mean uorescence signal-to-background ratio of 
SLNs was 4.4 (range 1.4-19.8). In 8 of the 21 patients, SLNs outside the standard 
resection plane were identied, that contained malignant cells in 2 patients.
Conclusions: This study shows successful use of ICG:Nanocoll as lymphatic 
tracer for SLN detection in gastric cancer. Moreover, tumor-containing LNs 
outside the standard dissection planes were identied.  
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INTRODUCTION
Gastric cancer is still one of the most frequent causes of cancer deaths 
worldwide with an incidence rate varying between countries1;2. The highest 
estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 
100,000 in women), the lowest in North America (2.8 and 1.5, respectively)3.
Surgical resection of the tumor is the only curative treatment option. 
Depending on the size, inltration depth, and location of the tumor, surgery 
can be performed endoscopically, or by partial or total gastrectomy. In addition 
to resection of the aected part of the stomach, a lymph node (LN) dissection 
is typically performed. This can either be done by extensive lymphadenectomy 
or by a sentinel lymph node (SLN) procedure, depending on T status and 
size of the tumor. Nodal involvement in gastric cancer occurs in only 2-18% 
when the depth of cancer invasion is limited to the mucosal or submucosal 
layer (T1), and in about 50% when tumors invade the subserosal layer (T2)4. 
In patients with tumor-negative lymph nodes, a SLN procedure could avoid 
the risk of morbidity and mortality of an unnecessary lymphadenectomy. 
Additionally, in patients who are undergoing a partial or total gastrectomy 
combined with lymphadenectomy, identication of potentially involved LNs 
outside the standard plane of resection is possible by detecting the SLN. In 
this way, also in tumors with higher T stages, one can nd the true rst tumor 
draining LN(s), and not leaving them in situ. As the lymphatic drainage route 
of gastric cancer is generally multidirectional and complicated5, intraoperative 
assistance in identication of potentially involved lymph nodes could improve 
gastric cancer treatment.
SLN detection in gastric cancer was rst described by Kitagawa et al.6 Since 
then, multiple studies were performed. A prospective multicenter trial in 433 
patients with T1 or T2 stadium tumors showed an accuracy rate of 99% for 
identication of metastasis in SLNs with the use of a dual tracer consisting of 
radiolabeled tin colloid and blue dye7. 
Near-infrared (NIR) uorescence imaging is an innovative technique to 
visualize tumors, vital structures, lymphatic channels, and LNs8. Soltesz et al.9 
in a preclinical setting and Kusano et al.10 in a clinical setting were the rst to 
report the SLN procedure in gastric cancer using NIR uorescence imaging. 
Since then, multiple studies conrmed the feasibility of this technique for 
both open and laparoscopic surgery11-15. All clinical studies reported to date 
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utilized indocyanine green (ICG) as the lymphatic tracer. However, the use of 
ICG resulted in detection of more uorescent lymph nodes per patient than 
expected due to migration through the SLN to second tier nodes. Consequently, 
resection and pathological assessment of multiple nodes was still needed. 
Adsorption of ICG to a nanocolloid (ICG:Nanocoll) increases its hydrodynamic 
diameter, which may result in better retention of the lymphatic tracer in the 
SLN, and thereby staining less second-tier nodes. This results in intraoperative 
identication of true SLNs, and avoids analyzing non-SLNs during pathological 
assessment for tumor-status of the SLN. This principle was already successfully 
described for breast cancer16 and skin melanoma17.
The aim of this study was to investigate feasibility of ICG adsorbed to 
nanocolloid as a lymphatic tracer for the intraoperative detection of the 
SLN in gastric cancer patients with dierent pT stages, and to determine the 
prognostic utility of the detected SLN.
MATERIALS AND METHODS
Tracer preparation
ICG:Nanocoll was prepared by diluting 25mg ICG (Pulsion Medical Systems, 
Munich, Germany) in 5ml water and diluting 0.5mg Nanocoll (GE Healthcare, 
Eindhoven, the Netherlands) in 3ml saline. Portions of these solutions were 
mixed to obtain 1.6ml ICG:Nanocoll containing 0.05mg ICG and 0.1mg Nanocoll. 
Preparation was performed in the operating room, following preparation 
instructions of the institutional pharmacist.
Clinical trial
The trial was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and was performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. Registration within the Netherlands Trial 
Register was performed (NTR4280).
Twenty-six patients with dierent T stages of gastric cancer, planned for 
a partial or total gastrectomy, were included between February 2013 and 
March 2015. Patients underwent standard-of-care preoperative imaging using 
a Computed Tomography (CT) scan. No standard endoscopic ultrasound 
or staging laparoscopy was performed. All procedures were performed by 
surgeons with broad experience in gastric cancer surgery.
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After opening of the abdominal cavity the tumor was exposed without 
causing damage to lymphatic vessels around the tumor as much as 
possible. When no metastasized disease was found, 1.6ml ICG:Nanocoll was 
administered subserosally in 4 quadrants around the tumor. Directly after 
injection NIR uorescence images of lymphatic pathways were acquired using 
the Mini-FLARETM NIR uorescence imaging system18. Fluorescence imaging 
was performed on multiple time points during surgery. A SLN was dened as 
uorescent hotspot that appeared after injection of the tracer. When multiple 
uorescent hotspots appeared in the same LN basin all uorescent LNs were 
dened as SLNs. The anatomical location of the uorescent hotspots was 
determined using the lymph node stations as dened by the Japanese Research 
Society for the Study of Gastric Cancer19. Patients underwent a standard-of-care 
partial or total gastrectomy with modied D2 resection, consisting of resection 
of the peri-gastric LNs and LN station 7,8 and 9. After resection, the specimen 
was analyzed ex vivo using the FLARETM NIR uorescence imaging system at 
the Pathology Department. The marked uorescent hotspots were resected 
from the specimen, transected, xed in formalin and embedded in paran for 
routine hematoxylin and eosin staining, and analyzed for tumor status.
The in vivo signal-to-background ratio (SBR) of the SLN was calculated by 
dividing the uorescence intensity of the SLN by the uorescence intensity of 
the directly surrounding fatty tissue. Accuracy rate was dened by the number 
of patients in which tumor-negative SLNs were found when no tumor-positive 
lymph nodes were found in the entire specimen and the number of patients 
in which tumor-positive SLNs were found when tumor-positive lymph nodes 
were found in the whole specimen divided by the total number of patients. 
Accuracy rate was expressed as percentage with a 95% condence interval. A 
false-negative patient was dened as a patient in whom tumor-negative SLNs 
were found, while tumor-positive LNs were found in the resection specimen.
Condence intervals for the binomial proportions were calculated using 
exact binomial condence intervals. Numerical data were summarized with 
median (range).
Intraoperative near-infrared uorescence imaging
Intraoperative imaging procedures were performed using the Mini-
Fluorescence-Assisted Resection and Exploration (Mini-FLARETM) image-
guided surgery system, as described earlier18. Briey, the system consists of 
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2 wavelength isolated light sources: a “white” light source, generating 26,600 
lx of 400 to 650 nm light, and a “near-infrared” light source, generating 1.08 
mW/came of ≈760 nm light. Color video and NIR uorescence images are 
simultaneously acquired and displayed in real time using custom optics and 
software that separate the color video and NIR uorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR uorescence 
images is also displayed. The imaging head is attached to a exible gooseneck 
arm, which permits positioning of the imaging head at extreme angles virtually 
anywhere over the surgical eld. For intraoperative use, the imaging head and 
imaging system pole stand are wrapped in a sterile shield and drape (Medical 
Technique Inc., Tucson, AZ).
RESULTS
Patient characteristics
Twenty-six patients with gastric cancer undergoing partial or total gastrectomy 
were included in this study (Table 1). Median age was 64 years (range 30–82) 
and 19 patients were male. T-stadium of tumors were pTx, pT1, pT2, pT3, and 
pT4 in respectively 2, 5, 5, 10, and 4 patients. Median tumor size was 31 mm 
(range 10 – 90). Tumors were located in the cardia in 8, corpus in 6 and antrum 
in 12 patients. Eleven patients underwent a total gastrectomy, 14 patients 
underwent a partial gastrectomy and in 1 patient no resection was performed 
due to metastasized disease. Twenty-three patients received neoadjuvant 
chemotherapy consisting of Epirubicine, Oxaliplatin and Capecitabine or 
Epirubicine, Cisplatine and Capecitabine. 
Sentinel lymph node detection
Three patients (#3, #12, and #16) did not receive an injection of ICG:Nanocoll 
because metastatic disease was found during surgery. In 1 patient (#8), 
ICG:Nanocoll was injected through the wall of the stomach. After this technical 
failure, this patient was excluded for further analysis. 
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Table 1. Patient and tumor characteristics
Characteristic Median Range
Age 64 30 - 82
Tumor size (in mm) 35 10 – 90
N (n = 26) %
Gender
   M






   Cardia
   Corpus








   pTx
   pT1
   pT2
   pT3












   Total gastrectomy
   Partial gastrectomy







Preoperative CTx 23 88
Table 2 shows the characteristics of the intraoperatively detected SLNs in 
each patient. In 21 of the remaining 22 patients (95%, 77–100 95% CI interval), 
at least 1 SLN was found during surgery (mean of 3.1 SLNs per patient; range 
1-6). SLNs were identied as bright uorescent spots in the surrounding tissue 
of the stomach. Figure 1A shows a bright uorescent spot, which was found 
histologically to be a tumor-negative lymph node. Figure 1B shows an example 
of a tumor-positive lymph node and visualization of lymphatic vessels running 
from the injection site to the lymph node. The mean SBR of the SLNs was 4.4 
(range 1.4–19.8). In total, 533 LNs were identied in the resection specimens by 
the pathologist, resulting in a mean number of 24 resected LNs (range 11 - 44) 
per patient. 
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Figure 1. Identication of SLNs using NIR uorescence imaging 
A. Identication of SLN (arrow) 15 min after injection of ICG:Nanocoll using NIR uorescence imaging. 
The injection site around the tumor is indicated by a dashed arrow. B. Patient with tumor-positive lymph 
node (indicated by arrow). Injection sites and uorescent SLN are clearly detected. Lymphatic vessels 
are also visible between the injection site and SLN. The SLN is marked using sutures.
In 19 out of 21 patients, an accurate SLN was found. The overall accuracy 
of the SLN procedure was 90% (70 – 99 95% CI) and a higher pT-stadium was 
associated with a lower accuracy rate. Accuracy rates for pTx, pT1, pT2, pT3, and 
pT4 were respectively 100, 100, 100, 90, and 0%. 
Histological analysis of the SLNs showed lymph node metastases in 8 out of 
21 patients. In 6 patients, the SLNs that were identied using NIR uorescence 
imaging were tumor-positive (true positive). In the other 2 patients, tumor-
positive lymph nodes were not identied using NIR uorescence imaging (false-
negative). One false-negative patient (#2) had a T4 tumor. The tumor positive 
lymph nodes (3 out of 33 LNs) in this patient were found in the peripancreatic 
fatty tissue and in lymph node station 3, where a SLN was also detected. The 
second false-negative patient (#10) had a T3 tumor. Four out of 11 LNs that 
contained tumor cells were not detected by NIR uorescence imaging. Of 
particular importance, all 7 tumor-positive LNs that were not detected by 
NIR uorescence imaging were completely eaced by tumor tissue and no 
lymphatic tissue could be identied. 
In 8 patients, SLNs outside the standard resection plane were identied. 
In 4 patients these were located in the hepatoduodenal ligament (LN station 
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12), in 2 patients near the border of the pancreas (LN station 14), in 1 patient 
outside the standard plane near LN station 9 and in 1 patient in LN station 11. 
In 2 patients, the extra-detected lymph nodes outside the standard plane of 
resection contained tumor cells (#21 and #22)(Figure 2). 
No adverse events regarding the use of ICG:Nanocoll or NIR uorescence 
imaging were encountered.
Figure 2. Identication of tumor-positive SLNs outside the standard dissection planes 
Identication of tumor-positive SLNs (arrow) outside the standard resection specimen in patient #21. 
LNs are identied after gastrectomy and located outside the standard dissection plane near LN station 
9.
DISCUSSION
The current feasibility study demonstrates that the SLN detection in gastric 
cancer, using ICG adsorbed to nanocolloid as the lymphatic tracer, is feasible 
and safe. In 21 out of 22 patients at least 1 SLN was identied, and in 19 out of 
21 patients an accurate SLN was found.
In fewer than 50 percent of patients with a T1 or T2 tumor, lymph nodes 
show tumor involvement. In these patients, the SLN procedure has the 
potential to avoid an unnecessary lymphadenectomy, and its associated 
potential morbidity and mortality. Kitagawa et al reported an accuracy of nodal 
evaluation for metastasis of 99 percent7, underlining the clinical applicability 
of the technique in this selected patient group. The SLN procedure in gastric 
cancer was validated for previously untreated cT1-T2 tumors with a diameter 
of less than 4 mm. However, in the Western world patients often present with 
a higher T stadium, and are often pretreated with chemotherapy. In these 
patients who need an extensive lymphadenectomy, the described technique 
could assist in identifying potentially involved lymph nodes located outside 
the standard plane of resection. Moreover, morbidity and mortality rates 
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increase when a more extended lymph node dissection is performed20. A more 
targeted and personalized treatment, including identication and dissection 
of truly or potentially involved lymph nodes, could result in improved gastric 
cancer treatment. Therefore, in both early gastric cancer and in resectable 
cases of advanced gastric cancer, accurate identication of true SLNs is of great 
importance. 
Many dierent lymphatic tracers have been reported for SLN identication. 
The largest prospective multicenter trial until now used a combination of blue 
dye and radiolabeled tin colloids7. However, both tracers have disadvantages. 
Blue dye could alter the surgical eld by dark staining, and only permits 
identication of supercially located lymph nodes. Moreover, in previous 
studies comparing radiolabeled colloids, blue dye, and NIR uorescence for 
SLN detection in breast cancer patients, only 84 - 88 percent of the identied 
SLNs stained blue compared to 100 percent that were NIR uorescent16;21. For 
the SLN procedure in skin melanoma blue dye staining was successful in only 
73 percent22. Radiolabeled colloids only permit acoustic guidance during SLN 
identication, but no visual guidance. Besides, radioactive isotopes are scarce 
in many areas of the world. NIR uorescence imaging could overcome these 
limitations as it only needs an imaging system and uorescent tracer, and 
allows real-time optical identication of lymph nodes in up to ≈ 6 mm of tissue, 
for example in visceral dense fat tissue8.
Since Kusano et al.10 reported the rst SLN procedure in gastric cancer using 
NIR uorescence imaging, multiple studies conrmed the feasibility of this 
technique for both open and laparoscopic surgery11-15. All reported studies to 
date used ICG alone as lymphatic tracer, which resulted in detection of many 
uorescent lymph nodes per patient. For example, Tajima et al.14 reported a 
mean number of 7.2 ± 7 SLN per patient and Fujita et al.11 a mean number of 
9.3 ± 6.4 SLN per patient when using ICG as lymphatic tracer. This was possibly 
due to migration through the SLN to second tier nodes, and resection and 
pathological assessment of multiple nodes was still needed. 
By combining ICG with nanocolloid, its hydrodynamic diameter increases 
from ≤ 1 nm (ICG) to 20 - 80 nm (ICG:Nanocoll). It has been shown that the 
hydrodynamic diameter of a lymphatic tracer has a major impact on the 
lymphatic migration and accumulation in lymph nodes. Molecules with a 
hydrodynamic diameter less than approximately 10 nm (for example ICG) 
have the potential to migrate through the SLN to second tier nodes, while 
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larger molecules with a hydrodynamic diameter of <100 nm (ICG:Nanocoll) 
are retained in the SLN23. In the current study, a mean number of 3.1 SLN per 
patient was found. This lower number of detected SLNs is in accordance with 
our hypothesis that better retention in SLNs is obtained when a lymphatic tracer 
with a higher hydrodynamic diameter is used. This highly improves the clinical 
applicability of SLN detection using NIR uorescence imaging in gastric cancer.
Although the number of patients was limited in the current study, an 
excellent accuracy rate was obtained in lower pT stages, in which the clinical 
value of a SLN procedure is becoming more and more accepted. These data 
are consistent with previous studies where the SLN procedure was performed 
for T1 and T2 tumors. However, even for advanced gastric cancer, identifying 
the rst draining lymph nodes can be of added value. In the current study, LNs 
from 8 patients were identied outside the standard resection margin using 
NIR uorescence imaging; they would otherwise not have been resected. In 
2 patients, the extra-detected LNs outside the standard plane of resection 
contained tumor cells. These LNs were only resected because NIR uorescence 
imaging identied them. Larger studies are needed to determine the additional 
value of the described technique in advanced gastric cancer. 
In 2 patients, tumor-positive LNs were not identied using NIR uorescence 
imaging. One explanation for the false positivity of these LNs might be the fact 
that these tumors were relatively large, respectively 60 and 45mm diameter, 
and consequently, adequate injection of the tracer in four quadrants around 
the tumor might be hampered. However, other uorescent LNs that that did 
contain tumor cells, were found in tumors with a median size of 52mm (range 
27 – 90). Moreover, all 7 of these LNs were completely eaced by tumor tissue. 
Such LNs lose function, lymph doesn’t ow in or out, and no lymphatic tissue is 
present to trap the uorescent tracer. Subsequently, these tumor-positive LNs 
can’t be identied, a principle that counts for the SLN procedure in all solid 
cancers. In one of these patients however, the identied SLN was found in the 
same LN basin as one of the tumor-involved LNs. This underlines the theory 
that whenever SLNs are visualized, the entire lymph node basin should be 
resected instead of only the SLN by lymph node picking, because it is shown 
that most of the metastatic non-SLNs are positioned in the same basin as the 
detected SLNs24;25. 
A well-known diculty in SLN mapping in gastric cancer is the presence 
of skip metastasis: involvement of extra-perigastric lymph nodes without 
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the detection of perigastric lymph node metastasis. The incidence of skip 
metastasis among patients with gastric cancer and metastasis is reported to 
be as high as 11%26. The described technique could assist in identifying these 
potentially involved extra-perigastric lymph nodes.
One of the limitations of this study is the administration technique, which is 
performed during surgery in the subserosal layer of the gastric wall. Opening 
the abdominal cavity, and exposing the aected part of the stomach could 
damage lymphatic vessels. This potentially hampers lymphatic ow to SLNs and 
was overcome as much as possible by avoiding dissections near the primary 
tumor. Besides, injecting the tracer in the submucosal layer seems more 
appropriate in case of tumor invasion limited to the mucosa or submucosa. 
However, it is shown that subserosal injection leads to drainage of the tracer 
to the same lymph nodes as submucosal injection, because of communication 
through vertical connections of lymphatic vessels in the gastric wall27.  These 
limitations could be overcome by submucosal endoscopic administration of 
the lymphatic tracer before surgery. One of the additional advantages of this 
administration technique is that it allows visual tumor demarcation during 
surgery through the stomach wall, which assists in intraoperative tumor 
identication, and determination of resection margins. Especially in patients 
who experience good response on neoadjuvant chemotherapy this could be 
of added value. 
Another limitation of the current feasibility study is that no true SLN 
procedure was performed, but instead intraoperative detection of SLNs. 
However, all uorescent hotspots that were detected during surgery were 
directly marked using sutures. After the surgical procedure, they were mapped 
from the specimen for pathological assessment. By doing this, the same LNs 
were analyzed as if they would have been resected directly during surgery, and 
feasibility of ICG:Nanocoll as lymphatic tracer could still be showed. 
Finally, pathological assessment of the LNs consisted of standard-of-care 
transection and hematoxylin and eosin staining. Multiple transections and 
additional keratin staining could possibly have resulted in the detection 
of tumor-tissue in the SLNs of the 2 false-negative patients, and thereby 
increasing accuracy rate. However, small tumor deposits in the detected SLNs 
were unlikely to be present as the tumor-positive LNs in the specimen were 
completely eaced by tumor.
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In conclusion, this is the rst study using ICG combined with nanocolloid as 
lymphatic tracer for the detection of the SLN in gastric cancer patients by NIR 
uorescence imaging. In T1 and T2 gastric tumors, an excellent accuracy was 
observed. Moreover, this technique allowed identication of tumor-positive 
lymph nodes outside the standard dissection planes.
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ABSTRACT
Background: Despite recent developments in preoperative breast cancer 
imaging, intraoperative localization of tumor tissue can be challenging, resulting 
in tumor-positive resection margins during breast conserving surgery. Based 
on certain physicochemical similarities between Technetium(99mTc)-sestamibi 
(MIBI), an SPECT radiodiagnostic with a sensitivity of 83-90% to detect breast 
cancer preoperatively, and the near-infrared (NIR) uorophore Methylene Blue 
(MB), we hypothesized that MB might detect breast cancer intraoperatively 
using NIR uorescence imaging. 
Methods: Twenty-four patients with breast cancer, planned for surgical 
resection, were included. Patients were divided in 2 administration groups, 
which diered with respect to the timing of MB administration. N = 12 patients 
per group were administered 1.0 mg/kg MB intravenously either immediately 
or 3 h before surgery. The mini-FLARE imaging system was used to identify 
the NIR uorescent signal during surgery and on post-resected specimens 
transferred to the pathology department. Results were conrmed by NIR 
uorescence microscopy. 
Results: 20/24 (83%) of breast tumors (carcinoma in N=21 and ductal carcinoma 
in situ in N=3) were identied in the resected specimen using NIR uorescence 
imaging. Patients with non-detectable tumors were signicantly older. No 
signicant relation to receptor status or tumor grade was seen. Overall tumor-
to-background ratio (TBR) was 2.4 ± 0.8. There was no signicant dierence 
between TBR and background signal between administration groups. In 2/4 
patients with positive resection margins, breast cancer tissue identied in 
the wound bed during surgery would have changed surgical management. 
Histology conrmed the concordance of uorescence signal and tumor tissue.
Conclusions: This feasibility study demonstrated an overall breast cancer 
identication rate using MB of 83%, with real-time intraoperative guidance 
having the potential to alter patient management. 
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INTRODUCTION
Breast cancer is the most common malignancy in women worldwide and is 
a leading cause of cancer-related mortality1. More than 1.2 million cases 
are diagnosed every year, aecting 10–12% of the female population and 
accounting for 500,000 deaths per year worldwide.
In early breast cancer, breast conserving surgery (BCS) is the preferred 
standard of care. Despite preoperative imaging modalities such as CT and 
MRI, intraoperative identication of breast cancer tissue can be challenging. 
Previous studies reported that the incidence of tumor cells at or near the cut 
edge of the surgical specimen ranged from 5% to 82%, with the majority of 
studies indicating positive resection margins in 20%–40% of patients after 
resection of the primary tumor2. Positive margins may lead to additional 
surgical procedures, delays in adjuvant treatment, increased morbidity, poor 
aesthetic results, and increased healthcare costs. Therefore, there is an urgent 
need for new technology to identify breast cancer tissue intraoperatively.
Technetium(99mTc)-sestamibi (MIBI) is a lipophilic cation used for 
preoperative, non-invasive identication of malignant tissue via SPECT 
imaging3. Using 99mTc-MIBI, preoperative identication of breast cancer is 
possible in approximately 83-90% of patients3-5. Based on the lipophilic, 
cationic structure of Methylene Blue (MB), and the fact that like 99mTc-MIBI, MB 
can function as a perfusion tracer in vivo6;7, we hypothesized that it too might 
be able to detect breast tumors.  Importantly, MB is a clinically available tracer 
that can be used at relatively low dose (0.5-1 mg/kg) as a uorescent tracer 
during NIR uorescence imaging. NIR uorescence imaging is a promising 
technique to assist in the intraoperative identication of sentinel lymph nodes, 
tumors, and vital structures8. 
During 99mTc-MIBI SPECT imaging, early (within 30 min after tracer 
administration) and delayed (3 h post tracer administration) imaging is 
performed in succession5;9. The reason for this is to dierentiate more accurately 
between malignant and benign lesions because it is presumed that tracer 
uptake in malignant lesions might persist, whereas clearance from benign 
lesions would be more rapid. Delayed imaging could thereby result in higher 
tumor-to-background ratios (TBRs) from lower background signal. 
The aim of this study was to determine the feasibility of using MB as an NIR 
uorescent tracer for the identication of breast tumor intraoperatively, and to 
compare early and delayed imaging protocols.




Breast cancer patients planning to undergo breast surgery were eligible for 
participation in the trial. Patients planned for either breast conserving surgery 
(BCS) or modied radical mastectomy (MRM) were included. Consent was 
performed at the department of Surgery. Exclusion criteria were pregnancy or 
lactation, and various contraindications to MB including the use of serotonin 
reuptake inhibitors, serotonin and noradrenalin reuptake inhibitors and/or 
tricyclic antidepressants, severe renal failure, a G6PD-deciency or a known 
allergy to MB. All patients gave informed consent and were anonymized. 
Clinical trial
This clinical trial was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. 
Patients were divided in 2 administration groups, which diered with respect 
to the timing of MB administration. 12 patients per group were administered 
1.0 mg/kg MB intravenously over 5 min either immediately before surgery, or 
3 h before surgery. Distribution between groups was based on the logistics of 
the operating room time on a particular day. Patients scheduled to be rst on 
the day’s surgical program were administered MB immediately before surgery 
(early imaging). Patients scheduled later in the day were administered MB 3 h 
before surgery (delayed imaging). 
The mini-FLARE imaging system was used to identify the uorescent signal 
during surgery and on post-resected specimens transferred to the Pathology 
department. During surgery, images were obtained from the surgical eld, 
resected specimen, and wound bed after resection. When uorescent signal 
was observed, the operating surgeon could decide whether to resect the 
uorescent tissue or not, based on clinical judgment of the tissue. The resected 
specimen was sliced at the pathology department, where images from the 
bisected tumor were obtained. When possible, snap frozen tissue was collected 
for uorescence microscopy images.
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Intraoperative near-infrared uorescence imaging system (Mini-FLARE)
Imaging procedures were performed using the Mini-Fluorescence-Assisted 
Resection and Exploration (Mini-FLARE) image-guided surgery system, as 
described earlier10. Briey, the system consists of 2 wavelength isolated light 
sources: a “white” light source, generating 26,600 lx of 400–650 nm light, and a 
“near-infrared” light source, generating 1.08 mW/came of ≈ 670 nm light. Color 
video and NIR uorescence images are simultaneously acquired and displayed 
in real time using custom optics and software that separate the color video 
and NIR uorescence images. A pseudo-colored (lime green) merged image 
of the color video and NIR uorescence images is also displayed. The imaging 
head is attached to a exible gooseneck arm, which permits positioning of 
the imaging head at extreme angles virtually anywhere over the surgical eld. 
For intraoperative use, the imaging head and imaging system pole stand are 
wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Ex vivo imaging and uorescence microscopy of resected lesion
After slicing of the resected lesion at the Pathology department, uorescence 
imaging was again performed with the mini-FLARE imaging system. 
Fluorescence microscopy images were obtained with the Odyssey Infrared 
Imaging System (LI-COR, USA). 
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 20.0, Chicago, 
IL) was used. Graphs were generated using GraphPad Prism Software (Version 
5.01, La Jolla, CA). TBRs were calculated by dividing the uorescent signal of 
the tumor by uorescent signal of surrounding tissue. Patient age and body 
mass index (BMI) were reported in median and range and TBR was reported in 
mean and standard deviation. To compare patient characteristics, independent 
samples t-test and chi-square tests were used. To compare TBR and background 
signal between dose groups, independent samples t-test was used. P < 0.05 
was considered signicant. 
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RESULTS
A total of 24 patients were included in this study. Patient and tumor 
characteristics are detailed in Table 1. Mean patient age was 60 years (range 
44 - 82 years); 21 patients were planned for BCS, 3 patients received an 
MRM. Histopathological analysis showed 14 patients with inltrating ductal 
adenocarcinoma, 4 patients with inltrating lobular adenocarcinoma, 3 
patients with ductal carcinoma in situ, 1 patient with a primary mucoepidermoid 
carcinoma, 1 patient with a mucinous adenocarcinoma, and in 1 patient, no 
tumor was found in the resected specimen even though a preoperative biopsy 
showed inltrating adenocarcinoma. Although patients were not assigned to 
a specic administration group by randomization, groups were comparable as 
no signicant dierences in patient or tumor characteristics were found (Table 
1). All patients received preoperative ultrasound, and 9 patients also underwent 
preoperative MRI scan.
In 20 out of 24 patients (83%), breast tumors (carcinoma in N=21 and ductal 
carcinoma in situ in N=3) were identied in the resection specimen with NIR 
uorescence imaging after bisection in the Pathology department. Tumors 
were identied as a bright uorescent spot in the sliced specimen (Figure 1). 
Table 2 shows patient and tumor characteristics related to detectability of 
the tumor. Patients with non-detectable tumors were signicantly older (mean 
age 68 years old versus 58 years old; P=0.03). Both inltrating ductal type 
adenocarcinoma and inltrating lobular type adenocarcinoma were detectable. 
In patients with mucinous adenocarcinoma or primary mucoepidermoid 
carcinoma, no uorescent tumor was found. No signicant relation was found 
regarding receptor status or tumor grade.
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Characteristic Mean Range Mean Range Mean Range P
Age 60 (44-82) 59 (44-82) 60 (46-71) 0.97
Body mass index 24 (19-37) 24 (19-37) 27 (22-37) 0.16
Pathological tumor size (mm) 15 (6-33) 14 (7-27) 16 (6-33) 0.58
N % N % N %
Clinical Stage 0.22
 Stage 0 3 13 3 25 0 0
 Stage 1A 13 54 7 58 6 50
 Stage 1B 1 4 0 0 1 9
 Stage 2A 4 17 2 17 2 17
 Stage 2B 2 8 0 0 2 17
 Stage 3C 1 4 0 0 1 9
Type of operation 0.54
 Mastectomy 3 13 1 9 2 17
 Wide local excision 21 87 11 92 10 84
Histological type 0.22
  Inltrating ductal type 
adenocarcinoma
15 63 6 50 9 75
  Inltrating lobular type 
adenocarcinoma
4 17 2 17 2 17
 Mucinous adenocarcinoma 1 4 1 9
  Primary mucoepidermoid 
carcinoma
1 4 1 4
 Ductal carcinoma in situ 3 12 3 25
Receptor status
ER positive 19 79 8 67 11 92 0.83
PR positive 11 46 6 50 5 42 0.26
HER2/NEU positive 1 4 0 0 1 9 0.38
Triple Negative 2 8 1 9 1 9 0.95
Histological grade (Bloom-Richardon) 0.34
 I 5 21 1 9 4 34
 II 9 38 5 42 4 34
 III 4 16 2 17 2 17
 No grading possible 6 25 4 34 2 17
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Figure 1. NIR uorescence imaging of a tumor resection with negative margins
A. Resected specimen after wide local excision. No uorescent signal was seen at resection margins. B. 
Inspection of wound bed after resection. No uorescent signal was seen at resection margins. C. Sliced 
resection specimen at Pathology department. A clear uorescent spot (arrow) was seen at the location 
of the tumor. Tumor was an inltrating ductal adenocarcinoma, grade 2, ER+ PR+ Her2/neu-.
The overall TBR was 2.4 ± 0.8 (Figure 2A). There was no signicant dierence 
between administration groups in TBR (2.5 ± 0.9 vs. 2.3 ± 0.5; P=0.50) or 
background signal in arbitrary units (333 ± 215 vs. 262 ± 134; P = 0.37, data not 
shown) in the sliced specimens.
Four patients (17%) were found to have positive resection margins. In case 1, 
tumor tissue was identied both on the surface of the resected specimen 
(Figure 3A) and intraoperatively in the wound bed using NIR uorescence 
imaging (Figure 3B). Direct re-resection was performed, and histopathological 
analysis conrmed that the uorescent resected tissue was tumor (data not 
shown). Both primary resected and re-resected tumor tissue was an inltrating 
lobular adenocarcinoma, grade 2, ER+ PR- Her2/neu -. 
In case 2, no uorescent tumor signal was seen on the surface of the resected 
specimen. In the bisected specimen, no uorescent signal was seen at location
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Characteristic Mean Range Mean Range
Age 58 (44-71) 68 (56-82)
Body mass index 26 (19-37) 24 (22-26)
Pathological tumor size (mm) 16 (6-33) 10 (7-12)
N % N %
Clinical Stage
       Stage 0 2 8 1 4
       Stage 1A 10 42 3 13
       Stage 1B 1 4 0 0
       Stage 2A 4 17 0 0
       Stage 2B 2 8 0 0
       Stage 3C 1 4 0 0
Histological type
 Inltrating ductal type adenocarcinoma 14 59 1 4
 Inltrating lobular type adenocarcinoma 4 17 0 0
 Mucinous adenocarcinoma 0 0 1 4
 Primary mucoepidermoid carcinoma 0 0 1 4
 Ductal carcinoma in situ 2 8 1 4
Receptor status
ER positive 17 71 2 8
PR positive 9 38 2 8
HER2/NEU positive 1 4 0 0
Triple Negative 2 4 0 0
Histological grade (Bloom-Richardon)
 I 4 17 1 4
 II 9 37 0 0
 III 3 13 1 4
 No grading possible 4 17 2 8
of the tumor. This could have been because of lack of uptake or intracellular 
conversion of MB to its leuco 11, non-uorescing form, but either way explains 
the lack of uorescent signal in the tumor-positive resection margin. Tumor 
was a DCIS grade 3. In case 3, only images of the sliced specimen were available 
due to logistics, so no intraoperative uorescent images were available. In case 
4, clear uorescent spots were identied in the wound bed intraoperatively, 
however, the operating surgeon believed that they were a false positive and 
did not resect them. Histopathology, though, conrmed positive margins at the 
location of the uorescent spots. Afterwards, patient underwent a mastectomy 
in which the residual lobular inltrating adenocarcinoma was found near the 
lumpectomy cavity.
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Figure 2. Tumor-to-Background Ratio and microscopic images of resected lesion 
A. Overall Tumor-to-Background Ratio (TBR) and TBR per administration group are shown. No 
dierences in TBR between administration groups were observed (P = 0.50; 95% CI -0.49 – 0.96). B. 
Microscopic images of Hematoxylin and Eosin staining of the resected lesion and uorescent signal 
(Odyssey Infrared Imaging System, LI-COR). At the NIR uorescent image, uorescent signal is seen 
as white, where surrounding breast tissue remains black. A clear overlay between uorescent signal 
and tumor tissue was seen. Normal breast tissue was indicated by an asterisk (*). Tumor (indicated by 
arrowhead) was an inltrating ductal adenocarcinoma, grade 2, ER + PR + Her2/neu -.
Figure 3. NIR uorescence imaging of a tumor resection with positive margins
A. Resected specimen after wide local excision. Fluorescent signal was seen at the deep margin of the 
resection specimen, indicated by arrows. B. Inspection of wound bed after resection. Fluorescent signal 
was seen at resection margins indicated by arrows. Direct re-resection of the uorescent tissue was 
performed, which contained malignant tumor tissue. Tumor was an inltrating lobular adenocarcinoma, 
grade 2, ER+ PR- Her2/neu -.
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In the patients with negative resection margins, median minimal distance 
of tumor tissue to resection margin was 3 (range 1-20). 
Histological validation of MB positive tumors with uorescence microscopy 
showed a clear overlay between uorescent signal and tumor tissue (Figure 2B). 
Three patients in the early administration group experienced transient 
mild pain of the lower arm during administration of MB, which disappeared 
after ushing the intravenous cannula with saline. No other adverse reactions 
associated with the use of MB or the Mini-FLARE™ image-guided surgery 
system were observed.
DISCUSSION
The current study demonstrated feasibility of real-time identication of breast 
cancer using NIR uorescence imaging and MB. In 83% of patients, tumor 
demarcation as identied by NIR uorescence imaging corresponded to 
histological presence of tumor. In addition, in one case surgical management 
was changed based on intraoperative NIR uorescence ndings, which avoided 
the need for re-resection. 
During breast cancer surgery, the distinction between healthy and 
malignant tissue is often not evident, resulting in positive resection margins in 
up to 40% of patients undergoing breast conserving surgery12;13. Despite major 
improvements in preoperative imaging, real-time intraoperative imaging 
modalities are lacking2. Therefore, breast cancer surgeons often still have to 
rely on palpation and previously obtained mammography or MRI to determine 
the extent of resection. Optical imaging using exogenous contrast agents 
could usher in a new era in surgical oncology. However, to successfully use this 
modality both a clinical-grade intraoperative uorescence imaging system and 
a tumor-specic NIR probe are obligatory. To date multiple camera systems 
have become clinically available, however FDA/EMA approved tumor-specic 
probes are still lacking. Therefore, it is important to exploit clinically available 
contrast agents, such as indocyanine green and MB14 whenever possible.
Several papers have reported the intraoperative use of MB for identication 
of various tumors. As early as 1971, MB was used at high concentration as a 
visible blue dye to stain parathyroid adenomas after systemic administration15. 
Thereafter, it was shown that there was a high uptake of the tracer in various 
kinds of neuroendocrine tumors16-18. One of the disadvantages of using MB is 
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that the high dose (7.5 mg/kg) used in these prior studies, which was needed 
for visualization of the blue colored dye the human eye, brings substantial risk 
of serious adverse events, such as toxic metabolic encephalopathy19.
NIR uorescence imaging permits visualization of MB at low concentration 
because MB uoresces at 700 nm. In transgenic mice, Winer et al.20 showed 
intraoperative identication of insulinoma, a pancreatic neuroendocrine tumor, 
using NIR uorescence imaging and MB. In a clinical setting, this technique has 
been used for the intraoperative identication of parathyroid adenomas and a 
solitary brous tumor of the pancreas21;22. In these prior studies, a dose of only 
0.5 - 0.1 mg/kg MB was used, which resulted in clear uorescent signal in the 
identied lesions. Although we did not explore dose in this feasibility study, our 
results suggest that a formal study of dose, which includes higher doses than 
1.0 mg/kg, is warranted. Such a study could answer denitively if the 17% of 
tumors that were not identied using MB were because the dose was too low.
The exact mechanism of tracer uptake in these tumors is unclear. The 
physicochemical similarities of MB and 99mTc-MIBI, both lipophilic and cationic, 
suggest a possible common mechanism. Lipophilic captions were originally 
developed as myocardial perfusion agents, and subsequently used as tumor-
seeking agents in a variety of tumors23. They emerged as suitable tools to 
explore specic cellular processes and functions in malignant tumors. In several 
studies, it was shown that lipophilic cations show passive inux into cells with 
large negative plasma membrane and mitochondrial membrane potentials23;24, 
with inux being reversible. Cellular processes that are associated with uptake 
of these tracers are apoptosis, proliferation, P-glycoprotein expression, and 
neoangiogenesis. However, it has to be further explored whether any of these 
mechanisms result in MB accumulation in breast cancer tissue. 
Using 99mTc-MIBI, a breast tumor identication rate of 83-90% has been 
reported. Although our present study was small (N = 24 subjects), our 
identication rate is in agreement with the sensitivity of 99mTc-MIBI described 
in the literature. Based on clinical experience with 99mTc-MIBI in breast cancer, 
early and delayed imaging is used to discriminate between malignant and 
benign lesions, as tracer accumulation is prolonged in malignant lesions. This 
is in contrary to MR imaging of breast malignancies, where malignant lesions 
tend to enhance but also washout quicker than benign lesions25. This is caused 
by endothelial fenestration in microvasculature, which leads to increased 
capillary leakage, and connections between the arteriolar and venular systems 
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(arteriovenous shunting), which leads to less perfusion of the capillary bed. 
Complicating the understanding of mechanism even further is the fact that MB 
can be converted to a non-uorescent leuco form under certain intracellular 
redox and pH conditions11. Because the exact mechanism of 99mTc-MIBI and MB 
uptake in breast tumors is still unclear, future studies have to be done regarding 
this eect. In the present study, though, no dierence was seen between 
dierent administration groups in TBR and background signal, suggesting that 
the more convenient early imaging protocol could be used in future studies.
As NIR uorescence imaging is a surface technology (≈ 5 mm penetration 
depth), it is important to understand its capabilities and limitations. To date, 
research and development of new imaging modalities for oncology mainly 
focus on the detection of small tumor deposits in the human body. In breast 
cancer, these small tumor deposits can change surgical decision making, 
but do not provide such prognostic relevance in breast conserving surgery, 
as postoperative radiation eliminates microscopic tumor deposits in most 
cases26. For example, the rate of small tumor deposits is 2–3 times higher than 
the incidence of local recurrence using preoperative MR imaging, resulting in 
mastectomies that may not be benecial to patient survival27. On the other hand, 
adequate visualization of tumor margins intraoperatively would be benecial 
to lower the number of R1 resections and to avoid the need for re-resections 
and radiotherapeutic boost therapy28. Using intraoperative NIR uorescence 
imaging, it is not possible to image the whole breast for small tumor deposits 
due to the limited penetration depth. However, the optical properties of NIR 
uorescence are very well suited for the visualization of possible residual tumor 
cells at the resection margin. Additionally, NIR uorescence has an exceptionally 
high spatial resolution compared to conventional imaging techniques. 
To benet from the full potential for NIR uorescence imaging several 
factors are of paramount importance and need to be optimized: 1) the 
concentration of the NIR uorophore in the target tissue, 2) minimizing photon 
absorption and scattering in the tissue, 3) maximizing excitation power of NIR 
excitation without inducing photobleaching or photo damage to tissue, and 
4) the sensitivity of the CCD chip on the detector. Methylene Blue becomes 
a moderate-strength uorophore when used at low concentrations, with an 
excitation maximum of 670 nm. Contrast agents with an emission peak of ≈700 
nm have several limitations compared to 800 nm uorophores with respect to 
quantum yield, penetration depth, and autouorescence. It is hoped that new 
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tumor-specic “800 nm” contrast agents will become widely available during 
the next few years, although MB could ll the gap in the meantime. Improved 
laser or LED light sources and cameras are under constant development to 
overcome the imaging system associated factors.
Another important consideration is extraneous NIR uorescence generated 
from other drugs in the surgical eld. During this study we found that Patent Blue, 
used for sentinel lymph node mapping, exhibited a weak NIR uorescence at 
700 nm that could confound the MB results (data not shown). Because we have 
previously demonstrated that blue dye can be omitted from sentinel lymph 
node mapping when indocyanine green (ICG) is used29, and the FLARE imaging 
system is capable of imaging 2 independent channels of NIR uorescence, e.g., 
NIR Channel 1 for MB-guided breast cancer resection and NIR Channel 2 for 
ICG-guided sentinel lymph node mapping, it should be possible to eliminate 
Patent Blue from future protocols and thus eliminate this potential confounder.
The primary endpoint of this study was the identication ratio of breast 
cancer using NIR uorescence and MB and optimization of injection timing. 
As it was the rst feasibility study with MB in breast cancer, no outcomes data 
were collected to correlate with intraoperative NIR uorescence ndings. 
Therefore, it is not possible to draw conclusions on the prognostic relevance 
of the technology, although one might ponder that true negative MB uptake 
selected for tumors of low perfusion and relatively low metastatic potential. 
Thereby only one patient directly benetted from this technique with respect 
to direct resection of residual tumor tissue due to the reasons mentioned 
above. Future studies will need to address this and other remaining questions. 
In conclusion, this is the rst study to demonstrate the use of low dose MB 
for the real-time identication of breast cancer using NIR uorescence and 
MB. No dierence was seen between dierent administration groups in TBR 
and background signal, suggesting that the more convenient early imaging 
protocol could be used in future studies. Although larger studies are necessary 
to determine patient benet, results with MB are promising and improved 
contrast agents will likely become available in the future. 
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ABSTRACT
Background: Uveal melanoma is the most common primary intraocular tumor 
in adults and up to 50% of patients will develop liver metastases. Complete 
surgical resection of these metastases can improve 5-year survival, but only a 
few patients are eligible for radical surgical treatment. The aim of this study was 
to introduce a near-infrared (NIR) uorescence laparoscope during minimally 
invasive surgery for intraoperative identication of uveal melanoma hepatic 
metastases and to use it to provide guidance during resection.
Methods: Three patients diagnosed with one solitary liver metastasis from 
uveal melanoma are presented. Patients received 10 mg indocyanine green 
(ICG) intravenously 24 h before surgery. A NIR uorescence laparoscope was 
used to detect malignant liver lesions.
Results: In all 3 patients, laparoscopic NIR uorescence imaging using ICG 
successfully identied uveal melanoma metastases. In 2 patients, multiple 
additional lesions were identied by inspection and NIR uorescence imaging, 
which were not identied by preoperative conventional imaging. In one patient, 
one additional lesion, not identied by computed tomography, magnetic 
resonance imaging, laparoscopic ultrasonography and inspection, was 
observed with NIR uorescence imaging only. Importantly, NIR uorescence 
imaging provided guidance during resection of these metastases.
Conclusions: We describe the successful use of laparoscopic identication 
and resection of uveal melanoma liver metastases using NIR uorescence 
imaging and ICG. This procedure is minimally invasive, and should be used as 
complementary to conventional techniques for the detection and resection of 
liver metastases.
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INTRODUCTION
Uveal melanoma is the most common primary intraocular tumor in adults and 
up to 50% of patients will ultimately develop distant metastases1. In 90-95% 
of these patients, the metastases will involve the liver2;3. Complete resection of 
these metastases can prolong survival, however only few patients are eligible 
for radical surgical treatment4-6. Therefore, it is of great importance to select 
and treat these patients carefully, to prevent unnecessary laparotomies and 
to fully resect sites of metastasis. Minimally invasive procedures have become 
important in daily clinical practice, are increasingly used for liver surgery, and 
might help to optimize the resection of malignant disease.
Near-infrared (NIR) uorescence imaging using indocyanine green (ICG) 
is a promising technique to assist in the intraoperative identication of 
liver metastases in real time7-10. ICG is excreted exclusively into the bile after 
intravenous injection and it has been hypothesized that colorectal liver 
metastases can be visualized due to passive accumulation of ICG caused 
by hampered biliary excretion, which results in a uorescent rim around 
metastases7;11. 
Several clinical studies describe the use of NIR uorescence imaging to 
visualise primary hepatocellular carcinomas8, as well as liver metastases from 
colorectal12, and pancreatic cancers9 after intravenous injection of ICG, 1 to 14 
days prior to surgery. The dose and interval between ICG administration and 
surgery are key determinants of the remaining background uorescence signal 
in the liver and the uorescent rim surrounding the tumor. A dose nding 
study using an open intraoperative imaging system (Mini-FLARE13) in patients 
with colorectal liver metastases was recently performed in our center12, and 10 
mg ICG administered 24 h before surgery was found to be the most favorable 
dosage and time point of ICG administration. Moreover, in 12.5% of patients 
additional small and supercially located lesions were detected using NIR 
uorescence, which were otherwise undetectable.
Published cases to date for intraoperative detection of liver metastases using 
NIR uorescence and ICG were performed as open procedures. A laparoscopic 
operation is preferable for patients with liver metastases from uveal melanoma, 
due to the high risk of multiple small metastases. When multiple metastases 
are identied during surgery, patients would not benet from liver resection, 
and can be saved an unnecessary laparotomy by performing this minimally 
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invasive technique. This technical report is the rst to describe the use of ICG 
and laparoscopic NIR uorescence imaging to identify and resect melanoma 
liver metastasis during laparoscopic liver surgery.
METHODS
Intraoperative laparoscopic near-infrared imaging system
Intraoperative NIR uorescence imaging of the liver was performed using 
a newly developed laparoscopic high denition (HD) uorescence imaging 
system by Karl Storz GmbH & Co. KG, Germany, which included a plasma light 
guide and a 30 degree angle, 10 mm laparoscope, applicable for white light (WL), 
autouorescence, and ICG-imaging. The system was used for intraoperative 
conventional imaging (WL mode) and real-time uorescence imaging (760 
nm light, ICG mode) and allowed easy switching between WL mode and ICG 
mode by using a foot pedal. No overlay of conventional and uorescent images 
was possible yet, but anatomical orientation could be maintained due to the 
easy switching between light modes, the anatomical translucence during ICG 
mode and the stable position of the laparoscope. Images were recorded using 
a charge-coupled device camera.
Preparation and administration of indocyanine green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, 
Germany) and resuspended in 10 cc of sterile water for injection to yield a 2.5 
mg/ml (3.2 mM) stock solution. Of this stock solution 4 mL, corresponding 
to a dose of 10 mg, was administered intravenously 24 h before surgery. This 
optimal timing was based on previous studies in patients with colorectal liver 
metastases and the Mini-FLARE open quantitative imaging system.
Ex vivo imaging and uorescence microscopy of resected lesion
After slicing of the resected lesion at the Pathology department, uorescent 
imaging was performed with the FLARE imaging system, which was previously 
described14. Fluorescence microscopy images were obtained with the Odyssey 
Infrared Imaging System (LI-COR, USA).
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Preoperative imaging modalities
Patients received standard-of-care preoperative imaging modalities including 
ultrasound (US), computed tomography (CT, Toshiba Aquilion 16), magnetic 
resonance imaging (MRI, Philips Intera 1.5T) and/or positron emission 
tomography (PET, Philips Gemini 64 PET/CT) scans. For PET scan imaging, the 
radiopharmaceutical agent 18F-FDG was used.
Clinical trial
The study was approved by the Local Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. The study was registered in the 
Netherlands Trial Register as NTR3869.
RESULTS
We present three patients; all diagnosed with a solitary liver metastasis 
by preoperative US or CT. One patient was referred from another hospital, 
diagnosed with uveal melanoma and a solitary liver metastasis. Two patients 
were previously treated for uveal melanoma. 
The rst patient was a 75-year old woman, referred from another hospital, 
diagnosed with uveal melanoma of the left eye. By US, CT and PET scans, a 
suspected 28 mm metastasis was found in the right liver lobe. She was planned 
for simultaneous laparoscopic metastasectomy and enucleation of the left eye. 
10 mg ICG was administered intravenously 24 h before surgery. During surgery, 
multiple lesions of 1 to 10 mm were identied on the surface of the left and 
right liver lobe by inspection and by a clear uorescent rim around the tumors 
(Figure 1). One of the suspected lesions proved to be malignant, and no further 
liver resection was performed. Enucleation of the left eye was performed, and 
patient was oered systemic therapy. Patient experienced progressive disease 
under Dacarbazine treatment and subsequent Ipilimumab treatment during 
10 months of follow-up.
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Figure 1. Identication of liver metastases
Multiple uveal liver metastases, identied by inspection and NIR uorescence imaging as a typical 
uorescent rim (arrows) around each lesion, 24 h after intravenous injection of 10 mg ICG. Open arrows 
indicate the preoperative known metastasis.
The second patient was a 66-year-old woman treated 22 months earlier by 
enucleation of the right eye because of uveal melanoma. During 20 months of 
follow-up using US, CT, MRI and PET scans, no liver metastases were seen. Now 
she was diagnosed with a 12 mm liver metastasis in liver segment III on both CT 
and MRI scans. There were no signs of other hepatic or extrahepatic metastatic 
lesions. She was planned for laparoscopic metastasectomy. Ten mg ICG was 
administered intravenously 24 h before surgery. The previously diagnosed 
lesion was detected by inspection, laparoscopic ultrasonography (LUS), and 
NIR uorescence imaging, and was removed under uorescent guidance 
(Figures 2a and 3; supplementary video’s, online available). 
Using NIR uorescence imaging, an additional suspicious lesion in segment 
III was identied, which showed a typical 1.5 mm uorescent rim (Figure 2b). 
This lesion was characterized as a hemangioma by inspection, and was not 
identied with LUS. It was resected under uorescent guidance. Both removed 
lesions proved to be malignant by histological assessment and were radically 
removed (Figure 4). No other lesions were identied by inspection, LUS or NIR 
uorescence imaging. Patient recovered well from surgery, and no recurrent 
disease was seen during 15 months of follow-up. 
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Figure 2. NIR uorescence imaging of uveal liver metastases
A. An uveal liver metastasis (arrow) is clearly identied by a rim around the tumor in vivo. Normal 
liver tissue (arrowhead) shows minimal background uorescence.   B. A small supercial metastasis 
(arrow) was identied by NIR uorescence imaging, but was characterized as a hemangioma by visual 
inspection and was not visible by LUS.
The third patient was a 65-year-old woman treated 6 months earlier 
with ruthenium for uveal melanoma. She was now diagnosed with a 17 mm 
liver metastasis in segment IV on US and CT. There were no signs of other 
liver lesions or extrahepatic disease and she was planned for a laparoscopic 
metastasectomy. Ten mg ICG was administered intravenously 24 h before 
surgery. During surgery, multiple lesions from 1 to 10 mm were identied on 
the surface of the left and right liver lobe by inspection and a clear uorescent 
rim around the tumor using the ICG mode of the laparoscope. Uveal melanoma 
metastases were conrmed by frozen section of two lesions in segments III and 
IVb, respectively. No further resections were performed and the patient was 
oered systemic therapy. Patient experienced stable disease for 16 months 
under protein kinase C inhibitor treatment, whereafter new progression was 
seen.
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Figure 3. Fluorescent guidance during resection
NIR uorescence imaging was used as guidance during resection of uveal liver metastases. Resection 
was performed using an Endo GIA™ 45 reload stapler (Covidien) (asterisk).
Figure 4. Ex vivo imaging and uorescence microscopy of resected lesion 
A. Ex vivo imaging of resected lesion using the laparoscope. B. Ex vivo imaging after slicing under FLARE 
imaging system guidance. C. Microscopic overlay of Hematoxylin and Eosin staining of the resected 
lesion and uorescent signal (Odyssey Infrared Imaging System, LI-COR). A clear uorescent rim was 
observed around the malignant lesion.
No adverse reactions associated with the use of ICG or NIR uorescence 
imaging were observed in any patient. 
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DISCUSSION
Because only 3% 15;16 of patients with uveal melanoma are candidates for 
curative resection of hepatic metastases, a precise and minimally invasive 
method for selecting appropriate candidates is desperately needed. To the best 
of our knowledge, this is the rst paper describing the use of laparoscopic NIR 
uorescence imaging with ICG for the detection and removal of liver metastasis 
in this disease. Due to hampered visibility and the inability to palpate the 
liver surface during laparoscopy, NIR uorescence imaging adds value to the 
procedure itself. In contrast to ultrasonography, which can only show where 
the resection margins can be kept before resection, NIR uorescence imaging 
provides real-time guidance, helps minimize the resection of normal liver 
tissue, and permits inspection of the area to ensure the completeness of tumor 
resection.
In all 3 patients of this study, lesions were found by NIR uorescence that 
were not seen on preoperative US and CT scans. Moreover, in one patient, one 
lesion intraoperatively characterized as hemangioma by visual inspection, 
and not identied by LUS, was successfully identied as metastasis with 
NIR uorescence imaging and could be radically removed under real-time 
uorescence guidance.
A major limitation of NIR uorescence imaging is its limited depth 
penetration of ≈ 5 mm. In gure 4, a depth penetration of at least 5 mm can 
be inferred because the NIR uorescence signal of the lesion was identied at 
the anterior surface of the liver (supplementary video part 1), while the lesion 
itself was located at the posterior surface of the liver. More sensitive imaging 
systems and uorophores with higher quantum yield could potentially 
increase depth penetration even further. Preoperative CT scanning and LUS do 
not have this disadvantage and are consequently more appropriate for deeper 
lesions. However, small and supercially located occult metastases are known 
to be dicult to detect using LUS and inspection. Although LUS is a reliable 
modality to identify liver metastases17, and still required to identify deep (≥ 5 
mm) metastases in the liver, our results suggest that NIR uorescence imaging 
is complementary, and helps to nd small, supercially located lesions. In 
addition, as shown in the supplementary video, NIR uorescence imaging 
becomes of value in the resection of even deep lesions once they are initially 
identied. 
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Further technical developments of laparoscopic NIR imaging systems are 
in progress and aim to improve the real-time intraoperative display of NIR 
uorophores18;19. 
In conclusion, we describe the successful use of a novel NIR uorescence 
laparoscopy procedure for the identication and resection of uveal melanoma 
liver metastasis using 10 mg ICG administered intravenously 24 h prior to 
surgery. This procedure is minimally invasive, relatively easy to perform, and 
is complementary to conventional techniques for the detection and complete 
resection of liver metastases from uveal melanoma.
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ABSTRACT
Background: The intraoperative distinction between normal and abnormal 
pituitary tissue is crucial during pituitary adenoma surgery to obtain a 
complete tumor resection, while preserving endocrine function. Near-Infrared 
(NIR) uorescence imaging is a technique to intraoperatively visualize tumors 
by using Indocyanine Green (ICG); a contrast agent allowing visualization of 
dierences in tissue vascularization. Although NIR uorescence imaging has 
been described in pituitary surgery it has, in contrast to other surgical areas, 
never become widely used.
Objective: To evaluate NIR uorescence imaging in pituitary surgery both 
qualitatively and quantitatively, and to assess the additional value to resect 
adenoma tissue under NIR uorescence guidance.
Methods: We included ten patients planned for transnasal transsphenoidal 
selective adenomectomy. Patients received multiple intravenous 
administrations of 5 mg ICG, up to a maximum of 15 mg per patient. Endoscopic 
NIR uorescence imaging was performed at multiple points in time. The NIR 
uorescent signal in both the adenoma and pituitary gland was obtained and 
the Fluorescence Contrast Ratio (FCR) was assessed.
Results: Four patients had Cushing’s disease, one had Acromegaly and one had 
a Prolactinoma. Four patients had a non-functioning macro-adenoma. In nine 
out of 10 patients with a histologically proven pituitary adenoma, the normal 
pituitary gland showed stronger uorescent signal than the adenoma. A FCR of 
normal pituitary gland to adenoma of 1.5 ± 0.2 was obtained. In two patients, 
adenoma resection actually took place under NIR uorescence guidance, 
instead of under white light.
Conclusion: NIR uorescence imaging can easily and safely be implemented 
in pituitary surgery. Timing of ICG administration is important for optimal 
results and warrants further study. It appears that injection of ICG can best 
be postponed until some part of the normal pituitary gland is identied. 
Subsequent repeated low-doses ICG administration improved the distinction 
between adenoma and gland.
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INTRODUCTION 
In transsphenoidal surgery it is important to be able to distinguish between 
normal pituitary gland and pituitary adenoma tissue for two reasons: 1) to 
obtain a complete tumor resection and 2) to preserve endocrine function. The 
vascular pattern between the normal pituitary gland and tumor tissue diers1;2. 
This dierence can be shown with preoperative magnetic resonance imaging 
(MRI), making use of dynamic administration of gadolinium. Normal pituitary 
tissue is visualized by contrast enhancement3. However, during surgery, the 
identication of normal gland and adenoma is based on dierences in tissue 
characteristics, such as colour and consistency. This dierence can be dicult 
to detect.
Transsphenoidal surgery is an established and relatively safe procedure. More 
than 95% of the pituitary tumors are operated via this approach4. Unfortunately, 
remission rates of hormone secreting tumors are not perfect, while surgery 
induced pituitary deciencies still occur5. Moreover, in patients with initial 
remission, recurrences occur due to endocrine activity of postoperative tumor 
remnants. It is therefore likely that the success rate of surgery can be improved 
by increasing visual dierentiation between adenoma and the normal gland.
Near-infrared (NIR) uorescence imaging is an innovative technique to 
visualize tumors, vital structures, and lymph nodes during surgery6. It is 
currently clinically used for several medical indications. These are intraoperative 
imaging of liver metastases, breast cancer and parathyroid adenomas7-10. 
One of the clinically available NIR uorescent contrast agents is indocyanine 
green (ICG). ICG is an ideal agent for real-time visualisation of dierences in 
tissue vascularisation. The excitation and emission proles of ICG in the NIR 
light spectrum make it possible to visualize blood vessels covered by a few 
millimetres of tissue. At present, ICG-imaging is widely used in a variety 
of surgical procedures6;11, including several cerebrovascular procedures in 
neurosurgical practice12;13.
Litvack et al. rst reported the use of ICG in endoscopic pituitary surgery in 
201214. In this feasibility study, up to 75 mg ICG was administered intravenously 
for each procedure. An endoscopic NIR uorescence imaging system was used 
to capture uorescent signal. The authors concluded that NIR uorescence-
guided endoscopy was a promising intraoperative modality towards visually 
distinguishing adenoma from normal gland tissue and thus possibly facilitating 
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complete tumor resection. Like MRI gadolinium enhancement, NIR uorescence 
imaging showed illumination of the normal gland, and delay in illumination of 
the adenoma. However, unlike gadolinium use for MRI of pituitary tumors, NIR 
uorescence imaging has never become widely accepted in clinical practice.
The aim of the current study was to assess the feasibility and potential value 
of NIR uorescence imaging in endoscopic pituitary surgery. The detection of 
the normal gland, with the aid of low-dose ICG was studied and the detected 
uorescent signal was scored both qualitatively and quantitatively. Moreover, 
the possibility to resect adenoma tissue under only NIR uorescence guidance 
was evaluated.  
METHODS
Patients
Patients included in the study were those diagnosed with a pituitary gland 
adenoma and having rst been scheduled for their initial endoscopic 
transnasal transsphenoidal surgical resection between January 2013 and 
March 2014. Only one endoscope and light cable suitable for NIR uorescence 
imaging were available, allowing a maximum of one patient per day to be 
included. All patients gave informed consent. Exclusion criteria were previous 
transsphenoidal surgery, pregnancy, lactation, renal impairment (eGFR<55) or 
an allergy to iodine or ICG. 
Clinical trial
This clinical trial was performed at the Leiden University Medical Center, a 
tertiary referral center. The study was approved by the local Medical Ethics 
Committee and was performed in accordance with the ethical standards of the 
Helsinki Declaration of 1975. 
Patients underwent a standard-of-care endoscopic transnasal 
transsphenoidal selective adenomectomy, conducted by a team of two 
neurosurgeons with a vast experience in pituitary surgery. During the 
procedure, 5 mg ICG was administered intravenously at dierent time points. 
The rst ICG gift was after exposure of the sellar dura, but prior to opening. The 
NIR compatible endoscopic device (Image Hub I by Karl Storz GmbH & Co. KG 
Germany) was used to identify the uorescent signal. After opening the dura, 
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the resection of the adenoma was performed making alternating use of visual 
and uorescence guidance. Additional boluses of 5 mg ICG were administered 
after partial resection of the adenoma, in order to obtain new NIR uorescence 
images. At the surgeons’ judgment of complete resection, new NIR uorescence 
imaging was performed to ensure identication of any residual adenomatous 
tissue. For analysis of uorescence signal, images were obtained 45 seconds 
after ICG administration.
Intraoperative endoscopic near-infrared uorescence imaging system
Intraoperative NIR uorescence imaging of the pituitary gland was performed 
using a newly developed endoscopic high denition (HD) uorescence 
imaging system by Karl Storz GmbH & Co. KG Germany, the Image Hub I. 
This system consists of a plasma light guide and a 0-degree angle 5.4-mm 
endoscope, applicable for white light (WL), autouorescence and ICG-imaging. 
The system was used for intraoperative conventional imaging (WL mode) and 
real-time uorescence imaging (760-nm light, ICG mode).  It allows for easy 
switching between WL mode and ICG mode using a foot pedal. The overlay 
of conventional and uorescent images is not yet possible but anatomical 
orientation could be maintained due to the easy switching between light 
modes. Images were recorded using a charge-coupled device camera.
Statistical and image analysis
SPSS statistical software package (Version 20.0, Chicago, IL) was used for 
statistical analysis. Fluorescent signal of pituitary adenoma and normal gland 
were reported both qualitatively and quantitatively. Snapshots were taken 
from the recorded operating videos, for further analysis. For qualitative analysis, 
uorescent signal was classied as ++, +, +/- and -. Two observers – M.V. (one 
of the operating neurosurgeons) and Q.T. – scored the uorescent signal 
independently. Where scoring discrepancies occurred, agreement was reached 
by reassessing the images. Quantitative uorescent signal was measured using 
ImageJ version 1.49b (a public domain Java-based image processing program 
developed at the National Institute of Health). With ImageJ, regions of interest 
(RoI) were drawn circumventing the uorescent signal of the adenoma and 
normal pituitary tissue. Fluorescence Contrast Ratios (FCRs) were calculated 
by dividing the uorescent signal of both RoIs. FCRs were reported as mean. 
Patient age was reported as median and range. 
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RESULTS
In the inclusion period 58 patients underwent a transnasal transsphenoid 
operation. Fourteen patients had a dierent pathology than adenoma. Six 
patients had been operated before. One patient was allergic to iodine. Ten 
patients refused participation in the study for a variety of reasons.
The light cable was temporarily broken leading to an inclusions stop for 
4 weeks and subsequently exclusion of 7 patients. From the remaining 20 
patients always the rst patient of the two cases scheduled for surgery that day 
was included, leading to 10 included patients.
Median age was 50 years, ranging between 28 and 74. Six patients were 
female. Patients had either clinical features and imaging consistent with Non-
Functioning macro-Adenoma (NFMA) (N=4), or were biochemically diagnosed 
with a functional adenoma (Cushing’s disease (N=4), Acromegaly (N=1) and 
Prolactinoma (N=1)). Patient and tumor characteristics are shown in Table 1. All 
resected lesions were histologically proven to be a pituitary adenoma. 
The rst NIR uorescence images were obtained before opening of the 
dura. Figure 1 shows an example of uorescent images of the dura. A clear 
uorescent signal in the blood vessels was visible, however no discrimination 
between normal gland and the adenoma was possible at this point. Enhanced 
vascularity due to dural invasion of the tumor was not present in our series.
Figure 1. NIR uorescence imaging of the dura
NIR uorescence imaging of the unopened dura mater after administration of 5 mg ICG. Fluorescent 
vessels are visible on the dura. No identication of adenoma or normal pituitary gland is observed. 
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Table 1. Patient and tumor characteristics
Characteristic Median Range
Age 50 28 - 74
N (n = 10) %
Gender
   M








   No decits
   Minor decits








   None
   Total N.III OS
   Mild N.III OD
   Moderate N.III, slight N.VI OD








   1*
0
   1*
Pituitary Function
   No decits
   Hypogonadism








   None
   ACTH
   PRL










   Biochemical
      NFMA
      Cushing’s disease
      Acromegaly
      Prolactinoma
   IHC
      GH+; PRL +
      ACTH+
      LH+

















Abbreviations: ACTH, adrenocorticotropic hormone; DI, Diabetes Insipidus; GH, Growth hormone; IHC, 
immunohistochemistry; LH, Luteinizing hormone; N/A, not applicable; OD, oculus dextra; OS, oculus 
sinistra; PRL, prolactin.
* Recovered completely after 6 months
After opening of the dura, the normal pituitary gland showed a more 
intense uorescent signal than the adenoma in nine of the ten patients. In one 
patient intercavernous sinus venous bleeding prevented assessment of the 
uorescent signal. Figure 2 shows images of the uorescent signal in adenoma 
and normal gland during resection. In general, during resection, a bright 
uorescent normal gland became visible after ICG administration. 
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Figure 2. NIR uorescence imaging of a pituitary adenoma
A. NIR uorescence imaging of adenoma and normal gland after partial resection of the adenoma. 
ICG was administered just before opening of the dura, a second bolus of ICG was planned just after 
making this image. In the color image, a dark red colored remnant of the adenoma is visible. In the NIR 
uorescence image, a slightly uorescent normal gland is visible (circle). The adenoma remnant does 
not stain uorescent. B. NIR uorescence imaging of the same patient 60 seconds after the second ICG 
administration. A bright uorescent normal pituitary gland is visible. The adenoma remnant remains 
still non-uorescent (dashed circle).
Fluorescence intensities were measured 45 seconds after administration. 
Fluorescent signal with optimal contrast ratios were present for 1-2 minutes, 
where after the signal slowly decreased over time. The adenomas showed no, 
or only a weak uorescent signal. After complete resection of the adenoma, 
a bright, consistent uorescent pituitary gland was visible, and no non-
uorescent remnants of adenoma tissue were present anymore (Figure 3). 
Figure 3. NIR uorescence imaging after pituitary adenoma resection
NIR uorescence imaging after resection of the adenoma. A complete uorescent normal pituitary 
gland is visible. No non-uorescent adenoma remnants can be identied.
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Table 2 shows the imaging characteristics of the detected lesions. In ve 
patients, no uorescent signal was observed in the adenoma. In three patients, 
only weak uorescence (qualitatively rated as +/-) was observed and in the case 
of one patient, uorescent signal was rated as + (#9). The observed FCRs were 
conrmed by quantitative analysis, wherein a mean FCR of normal pituitary 
gland to adenoma of 1.5 ± 0.2 was obtained. In addition, two patients suering 
from a microadenoma (#6 and #7) exhibited an FCR of 1.3 and 1.4 respectively. 
In one patient (#2), no discrimination in NIR uorescent signal between normal 
gland and adenoma could be observed due to suboptimal timing of the 
imaging. In this patient, NIR uorescence imaging was performed according 
to protocol just before opening of the dura. During resection of the adenoma, 
venous bleeding occurred that stopped after resection of the adenoma. After 
the second ICG administration and imaging, no remnant tissue was observed. 
Therefore, no NIR uorescent images of the adenoma could be obtained.
Table 2. Imaging characteristics
Patient 
ID













































































1 Cranial on top of adenoma NP IV 10 R ++ - 1.4
2 Stalk R; clear normal gland R Normal IIBE left 10 L No distinction possible




IIIa 10 R ++ +/- 1.7
4 Stalk R; no normal gland Normal IIC 10 Mid - L + - 1.8
5 Stalk R; clear normal gland R Normal IIAE left 10 L + - 1.3
6 Stalk mid; clear normal 
gland
Normal I 10 R + +/- 1.3
7 Stalk mid; clear normal 
gland
Normal I 10 R + +/- 1.4
8 Stalk R; clear normal gland R Normal IIAE left 10 L + - 1.4




IIB 5 R ++ + 1.5




IIBE right 15 R ++ - 1.8
Abbreviations: FCR, Fluorescence Contrast Ratio; L, left; mid; midline; N/A, not applicable; NP, not 
performed; R, right; WH-class, Wilson-Hardy classication
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The total individual dose of ICG varied, depending on the ease of surgical 
resection of the adenoma. The initial ICG gift was prior to tumor removal, 
the second gift at the end of the procedure, to control for completeness of 
resection. Most patients thus received a total dose of 10 mg ICG. In one patient, 
NIR uorescence imaging showed tumor remnants, which were subsequently 
removed. A third ICG dose was administered to again check for remnants. 
The longest time-interval between ICG administration and obtaining images 
in uorescence mode was 62 minutes (#12). At this point, weak uorescence 
signal was still present, but did not show any contrast ratio. According to study 
protocol, this led to additional administration of ICG. 
Tumor resection was typically done with conventional white light. In two 
patients (#1 and #3) we performed the tumor resection using predominantly 
the blue light of NIR uorescence imaging (up to 9:15 minutes after ICG 
administration). Although visibility under these lighting conditions is clearly 
much poorer than with conventional white light, tumor resection seemed 
facilitated. It was possible to remove the pituitary adenoma in a standard way 
with curretes and suction. Tumor resection was deemed complete when the 
gland showed an even bright enhancement under NIR uorescence imaging. 
In one of these two patients, a Cerebro Spinal Fluid (CSF) leakage occurred at 
the opening of the dura and was not related to the resection of the tumour 
under NIR uorescence imaging.
In this limited number of patients, we did not nd a relation between tumour 
type and ICG signal. No adverse reactions associated with the use of ICG or the 
NIR uorescence imaging system, were observed. Complications associated 
with the surgical procedure included: 1) leakage of intraoperative CSF in one 
case (#3); and 2) intraoperative venous bleeding in another case (#9).
DISCUSSION
In this study, successful identication of the normal pituitary gland and pituitary 
adenomas was possible using endoscopic NIR uorescence imaging using low 
dose ICG. In all assessable patients with a histologically proven adenoma, a 
contrast ratio between adenoma and normal gland was observed. In the only 
one study on NIR uorescence imaging in pituitary surgery of Litvack et al.14 the 
administered dose of ICG (up to 75 mg) was relative high for NIR uorescence 
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imaging. In comparison, in other studies an ICG dose between 2.5 mg, or 0.2 – 
0.5 mg/kg was demonstrated successful for the assessment of tissue perfusion 
after intravenous administration15-17. For tumor imaging of colorectal or uveal 
melanoma liver metastases, intravenous administration of 10 mg ICG proved 
to be sucient7;18. Furthermore it allows for repeated injections, so that NIR 
uorescence imaging can be used during various phases of the tumor resection. 
The lower dose used in this study compared to the dose used by Litvack et al. 
appears sucient and leads to satisfactory results within the timing windows 
of imaging we used.
The observed FCR between normal gland and tumor tissue was 1.5 ± 
0.2. The dynamic character of the imaging facilitated detection of a clear 
gradient between the normal pituitary gland and the adenoma. Our obtained 
quantitative ratios cannot be compared to results obtained by others, because 
only semi-qualitative results are reported yet14. To the best of our knowledge, 
to-date, no quantitative analysis of NIR uorescence imaging in pituitary 
surgery had been reported. In future studies, quantitative analysis of NIR 
uorescence imaging in pituitary surgery should become a standard in order 
to further objectively assess the additional value of this technique. A contrast 
ratio above 2 is generally considered optimal for intraoperative dierentiation 
between tissues. For example, in colorectal liver metastases18, breast cancer10 
and parathyroid adenomas9 imaging, FCRs of respectively 7.0, 2.4 and 6.1 are 
reported. The FCR in pituitary surgery is thus relatively low, although sucient. 
In the future hopefully improved contrast agents and imaging systems could 
potentially further enhance the FCR in pituitary surgery as well.
Optimal timing of ICG administration is crucial to obtain optimal distinction 
between normal and abnormal tissue. In the current research protocol, 
the rst ICG administration was performed before opening of the dura. The 
vascularisation of the dura was thereby visualised, but no additional value for 
identication of the gland or the adenoma was obtained. In our experience, this 
rst gift of ICG was too early. It may help to assess changes in the vascularisation 
of the dura, suggesting invasive growth of the adenoma. However, we believe 
that the optimal timing of ICG administration is when the surgeon detects 
dierences in tissue colour and consistency, suggesting that the normal 
pituitary gland may be identied. The FCR was sucient to reliably dierentiate 
adenoma from normal gland. Interestingly, adenoma resection only under 
NIR uorescence guidance, e.g. without alternating between white and blue 
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light, was technically possible. Possibly tumor resection under continuous NIR 
uorescence guidance, instead of only checking for tumor remnants at the end 
of surgery may be the best way to use NIR uorescence guidance in pituitary 
surgery. From the current study, no optimal interval between ICG administration 
and peak uorescence signal can be recommended. For all measurements, an 
interval of 45 seconds was taken to obtain and analyse uorescent signal. In 
our experience, the uorescent signal and contrast ratio stayed optimal for 
1-2 minutes in all patients, and than slowly decreased over time. Timing of ICG 
administration warrants further systematic study.
For NIR uorescence imaging during pituitary surgery a special endoscope 
is needed equipped with an excitation light source to excite uorophores, 
and a detection device to capture emitted uorescence from the exited 
uorophores. The dimensions and functionality of this scope are otherwise 
identical with the regular HD Storz endoscope. ICG was readily available at 
the pharmacy. The technique of imaging was not complicated and was not 
associated with any sided eects. In one patient cavernous sinus bleeding 
prevented assessment of the uorescence. As long as venous bleeding is 
well controlled, NIR uorescence imaging can be used to remove adenoma 
tissue from the cavernous sinus. NIR uorescence imaging during endoscopic 
pituitary surgery is easily implemented in current daily practice. As ICG can be 
visualized under specially equipped surgical microscopes, which are already 
clinically available, NIR uorescence imaging is also possible in microscopic 
transsphenoidal procedures.
Although transsphenoidal surgery is an established, relatively safe 
procedure, iatrogenic pituitary dysfunction is still a considerable drawback. 
A postoperative rate of hypopituitarism of 22% is reported4. Diabetes 
insipidus (DI) and pituitary insuciency are commonly reported following 
transsphenoidal surgery. DI can be divided in temporary DI (incidence if 10 - 
60%) and the uncommon permanent DI (0.5 – 15%)4. The cause of DI has been 
ascribed to stalk manipulation during surgery, and is more common after 
resection of microadenomas. Postoperative pituitary insuciency is reported 
in 1-10% of patients; however outliers of 27% are documented4. In a recent 
structured review and meta-analysis of the available literature, Roelfsema et al. 
reported the onset of new, surgery-related pituitary insuciency in 6.9 ± 1.8% 
of patients treated for prolactinoma, 6.7 +/- 1.6 for acromegaly, 12.5 +/- 4.6 % 
for NFA and 25.4 +/- 3.6 % for Cushing’s disease5.
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Furthermore, surgical remission is not always achieved after resection of 
a functional adenoma and recurrence of a pituitary adenoma after apparent 
cure is also frequently reported5. Mean remission values and ranges of 68.8% 
(27-100) in prolactinoma, 47.3% (3-92) in NFA, 61.2% (37-88) in acromegaly, 
and 71.3% (41-98) in Cushing’s disease, are reported. Overall remission rates 
of 53–64% for macroadenomas and 84-88% for microadenomas are reported4. 
Patients can suer from recurrent disease, with the incidence peaking 
between 1 and 5 years after surgery. It is suggested that recurrence originates 
from small postoperative tumor remnants5. Consequently, there is a clear 
unmet need for improved peri-operative identication of pituitary adenomas, 
normal gland and surrounding structures, so as to improve surgical outcomes. 
A more aggressive attempt to attain complete adenoma resection will increase 
the number of patients achieving biochemical remission but will also increase 
the likelihood of postoperative complications such as DI and hypopituitarism. 
Thus, it is plausible to postulate that improved optical guidance during surgery 
could assist in resecting the adenoma in total while minimizing iatrogenic 
injury.
Only a limited number of imaging techniques during surgery, are described 
to improve completeness of tumor resection; for example intraoperative MRI19 
and intraoperative transcranial-transdural real-time ultrasonography20. Both 
techniques are reported as complementary imaging techniques and require 
the use of dierent, additional imaging devices that until now, interfere with 
the normal surgical procedure. Moreover, both techniques do not allow 
real-time merging of the surgical eld and additional tumor imaging. NIR 
uorescence imaging, as we describe here, has shown the ability to overcome 
these constraints.
We noticed several limitations to the described technique. Firstly, NIR 
uorescence imaging identication was based on the principle that the normal 
gland stained after ICG administration, whereas tumor tissue stains to a lesser 
degree and with a time delay. For high-sensitive identication of adenomas 
and especially microadenomas, uorescence signal in tumor tissue instead 
of healthy tissue would be of greater value. Should tumor tissue be stained, 
only uorescent tissue has to be resected. The development of tumor-specic 
contrast agents targeting specic ligands could potentially facilitate this. 
Secondly, the imaging system used in the current study did not allow real-time 
overlay of color (white light) and NIR (blue light) images. Therefore, anatomical 
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orientation was dicult in some procedures and surgery under uorescence 
guidance could only be performed when sucient uorescent signal was 
present. This would also allow a more detailed analysis of the optimal window 
between administration of ICG and peak uorescence measurements, and gives 
a better insight in the decrease of uorescent signal over time, as uorescent 
signal can be measured all procedure long. In addition, to improve visual 
contrast, the uorescence images displayed by the endoscopy system as blue 
on black could be converted to white on black. Further technical developments 
of endoscopic NIR uorescence imaging systems are in progress and aim to 
improve the real-time intraoperative display of NIR uorophores17;21;22. 
One limitation in the study was that only one endoscope and light cable 
suitable for NIR uorescence imaging was available. Therefore only one patient 
could be included daily, potentially leading to selection bias. An aselect 
procedure was used to prevent this bias: always the rst patient of the day was 
included, the order of cases was determined by chance.
CONCLUSION
NIR uorescence imaging using intraoperative intravenous administration of 
low-dose ICG, can safely and easily be implemented in daily clinical practice. A 
useful dierentiation between adenoma and pituitary gland was possible with 
NIR uorescence.
Timing of the ICG administration warrants future study to optimize this 
technique. Better discrimination of tumor versus normal pituitary tissue, will 
likely facilitate improved surgical remission rates and reduced surgical morbidity 
after endoscopic transnasal transsphenoidal selective adenomectomy. With 
improved techniques and imaging protocols, we advocate that the potential 
additional value has to be evaluated prospectively in a randomized study 
design.
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ABSTRACT
Introduction: Intraoperative identication of tumors can be challenging. Near-
infrared (NIR) uorescence imaging is an innovative technique that can assist in 
intraoperative identication of tumors, which may otherwise be undetectable.
Presentation of case: A 19-year-old patient with symptoms, normetanephrine 
levels and radiological ndings suspicious for a paraganglioma, a rare 
tumor arising from extra-adrenal chroman cells within the sympathetic 
nervous system, is presented. Intraoperative NIR uorescence imaging using 
intravenous administration of Methylene Blue (MB) assisted in intraoperative 
detection of the tumor, and even identied a smaller second lesion, which was 
not identied during surgery by visual inspection. 
Discussion: Although the exact mechanism of MB accumulation in 
neuroendocrine tumors is unclear, it is described in both preclinical and clinical 
studies.
Conclusion: In this report, we describe the rst case of intraoperative NIR 
uorescence imaging of a paraganglioma using MB, which identied an 
otherwise undetectable lesion.
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INTRODUCTION
Paragangliomas are rare tumors arising from extra-adrenal chroman cells 
within the sympathetic nervous system1-3. They can be found anywhere from 
the neck to the pelvis in the vicinity of sympathetic ganglions, and belong 
to the family of neuroendocrine tumors. An incidence rate of 2-8 cases per 
million is reported, and tumors can be either functional or non-functional. 
When functional there can be production of catecholamine, epinephrine, or 
norepinephrine. 
The only curative treatment of paraganglioma is complete surgical 
resection. To help localize all sites of disease, preoperative identication can 
be performed using dierent anatomical and functional imaging modalities4. 
However, no specic imaging modalities are available for the intraoperative 
identication of these tumors. 
Near-infrared (NIR) uorescence imaging is a promising technique to assist 
in the intraoperative identication of sentinel lymph nodes, tumors, and vital 
structures5. Advantages of this optical imaging technique include real-time 
imaging, high sensitivity, and high resolution, with penetration depths several 
millimeters into tissue. 
Methylene Blue (MB) is a clinically available tracer, which can be used at 
low dosage as a uorescent tracer during NIR uorescence imaging. Winer 
et al.6 described the successful identication of insulinomas, a pancreatic 
neuroendocrine tumor in transgenic mice, and clinically, the intraoperative 
identication of parathyroid adenomas was described7.
Based on these results, we explored the possibility to identify paragangliomas 
during surgery, using NIR uorescence imaging and MB.
PRESENTATION OF CASE
A 19-year-old female patient presented with complaints of fainting, nausea, 
vomiting, headaches, excessive sweating, ushing attacks, hand tremors, and 
heart palpitations. She had a negative family history for endocrine diseases 
or paragangliomas. While volunteering to donate blood, her systolic blood 
pressure was found to be 180 mm Hg. After referral, physical examination 
revealed a blood pressure of 180/110 mm Hg on the left arm, 190/115 mm Hg 
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on the right arm, but no other abnormalities. Laboratory evaluation showed a 
normetanephrine level of 3227 umol/mol creatinine (norm. value 64 - 260) in 
the urine.
CT scan showed a 46 x 38 mm retroperitoneal mass, just caudal to the 
aortic bifurcation (Figure 1). Cranial to this, a smaller lesion of 6 mm was seen, 
which was characterized as a para-aortic lymph node. MRI scan conrmed 
the retroperitoneal mass just caudal to the aortic bifurcation, with features 
suspicious for a paraganglioma. A slight encasement of the common iliac vein 
was seen. The cranially located smaller lesion was not clearly identied by MRI.
Figure 1. Preoperative imaging of paraganglioma
Preoperative CT, T2 weighed MRI and MIBG scan of the paraganglioma (dashed circle), retroperitoneal 
located, just caudal to the aortic bifurcation.
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A 123I-metaiodobenzylguanidine (MIBG) scan was performed to search for 
lesions located elsewhere in the body. Strong accumulation of the tracer was 
seen in the lesion just caudal to the aortic bifurcation, but no other uptake was 
seen (Figure 1). 
The patient was scheduled for resection. She was successfully pretreated 
with doxazosine, a selective alpha1-receptor blocking sympatholytic drug, 
metoprolol, a beta-receptor blocking sympatholytic drug, and nifedipine, a 
dihydropyridine, in order to prevent a hypertensive crisis during surgery. 
Intraoperative NIR uorescence imaging
The current study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the clinical 
standards of the Helsinki Declaration of 1975. Written informed consent was 
obtained.
During surgery, and directly after exposure of the lesion distal to the aortic 
bifurcation, MB was administered intravenously (0.5 mg/kg; 33 mg in 3.3 mL 
of water; 10 mg/ mL nal stock solution concentration) over 5 min and NIR 
uorescence imaging was performed using the Mini-FLARE image-guided 
surgery system as described previously8. Directly after infusion, imaging was 
performed at xed time points (0, 1, 2, 3, 4, 5, 15, 30 and 45 min). 
NIR uorescence imaging showed a strong, but patchy, uorescent signal 
corresponding to the suspected lesion (Figure 2A, lesion indicated by dashed 
circle). Moreover, the additional small lesion that was only identied by CT but 
not by MRI or by visual inspection during surgery, was clearly identied using 
NIR uorescence imaging, located approximately 5 cm cranial to the main 
lesion (indicated by arrow). This lesion was otherwise undetectable. Already 
two minutes after administration, a Tumor-to-background batio (TBR) of 
approximately 3.5 was reached for both lesions, which slowly decreased over 
the next 30 min (Figure 3).
After en bloc resection of the 2 lesions, the specimen was sent to Pathology 
for further evaluation. After surgical treatment, symptoms disappeared and 
normetanephrine levels normalized. 
No surgical complication or adverse reactions associated with the use of MB 
or uorescence imaging were observed.
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Figure 2. Intraoperative and ex vivo NIR uorescence imaging of primary and metastatic paragangliomas
A. Intraoperative NIR uorescence imaging of the surgical eld. A bright, patchy uorescent signal was 
identied at the location of the tumor (dashed circle). A second, small, lesion located approximately 5 
cm cranial to the main lesion, was also identied using NIR uorescence imaging (arrow). B. Ex vivo (T = 
45 min) imaging of the resection specimens. Fluorescent signal was seen in the large (dashed circle) and 
small lesion (arrow). A weaker uorescent intensity was seen than in vivo, because uorescent signal 
decreased over time during surgery. C. Ex vivo imaging of the bisected main lesion. Bright uorescent 
signal was seen throughout the paraganglioma (dashed circle).
Figure 3. Tumor-to-background ratio of resected lesions
Tumor-to-background ratio of the large main lesion and small second lesion over time after intravenous 
administration of MB.
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Ex vivo imaging of resected lesion and sliced specimen
Ex vivo imaging of the resected specimens was performed at the Pathology 
department using the FLARE imaging system, which was previously described9. 
Images showed a uorescent signal in both lesions (Figure 2B). Of special note, 
the intensity of the uorescent signal decreased signicantly over time, so a 
much weaker uorescence signal was measured during ex vivo imaging (i.e., T = 
45 min after MB injection). The patchy uorescent signal of the main tumor was 
seen both in vivo and ex vivo. This was due to brous connective tissue lying 
over the paraganglioma. After bisection of the resected main lesion, a clear 
uorescent signal was seen throughout the tumor (Figure 2C).
Histopathology
Macroscopically, a nodular lesion was seen, yellow to black on cross section 
and surrounded by a thin capsule. The maximum diameter was 65 mm. Cranial 
from this lesion, a smaller lesion of 12 mm was seen, suspicious for a tumor-
positive lymph node (gure 2B). The excised tissue was xed in formalin, 
embedded in paran and tissue slides were stained with hematoxylin and 
eosin (HE). Immunohistochemical staining was also performed (Figure 4). Based 
on histopathological ndings, both lesions were diagnosed as paraganglioma 
with diameters of 65 and 12 mm, respectively.
Figure 4. Histopathological staining of resected lesions
Hematoxylin and Eosin, Laguesse, S100 and SDHB staining of the resected specimen. Microscopy 
showed a characteristic pattern of cell nests. This pattern was accentuated by a reticulin stain. The cells 
had a moderate amount of eosinophilic cytoplasm and nuclei with nely clumped chromatin. Dispersed 
throughout the lesion, hemorrhagic foci were seen. The second, small, cranially located lesion showed 
the same characteristics as the larger lesion, without the presences of surrounding lymphoid tissue. 
Additional immunohistochemical staining for S100 showed the presence of sustentacular cells around 
the nests. SDHB staining was not conclusive.
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DISCUSSION
Despite many preoperative imaging modalities, intraoperative identication 
and demarcation of paragangliomas can be challenging. Because complete 
surgical removal of the tumor is the only curative treatment option, real-time 
intraoperative imaging modalities which can assist in tumor identication 
are desperately needed. To the best of our knowledge, this is the rst report 
showing the intraoperative identication of paragangliomas using NIR 
uorescence imaging and MB in a clinical setting.
In the presented patient, the main lesion just caudal to the aortic bifurcation 
was clearly identied by CT, MRI, and MIBG-scan. CT also showed a cranially 
located smaller lesion, which was not identied by MRI or MIBG, and not 
recognized as a paraganglioma, probably due to its small size and/or lack of 
adequate tracer photon ux from small tumors3;10. Importantly, intraoperative 
identication of all tumors is of paramount importance for the complete 
surgical resection and thereby curative treatment. Although not identied 
by MRI or MIBG, the second, smaller, lesion was intensely uorescent and was 
conrmed histologically to be paraganglioma. In daily practice, there still is a 
discrepancy between identication of lesions during preoperative imaging and 
intraoperative recognition of these lesions, especially when they are smaller 
sized. Intraoperative NIRF imaging could potentially overcome this gap.
 The pharmacokinetics of MB in the observed lesions are consistent with a 
perfusion eect, but not for a retention eect, because TBR decreases rapidly 
over time after initially high values. This makes the administration of MB for 
intraoperative identication of paragangliomas very useful for the direct 
identication of lesions, and apparently local metastases or second primary 
tumors. 
Although the exact mechanism of MB accumulation in tumors and especially 
neuroendocrine tumors is mainly unclear, it has been described in several 
studies. Previous clinical studies show staining of neuroendocrine tumors and 
parathyroid adenomas using MB as a visible dye using high concentrations11-14 
and with NIR uorescence imaging using low-dose MB7. Also in breast cancer, 
identication of tumors by NIR uorescence imaging using MB is described15. 
The mechanism behind this accumulation is based on physicochemical 
similarities between MB and sestamibi, a nuclear tracer used for MIBI-scans. 
Reports which describe the identication of paragangliomas using MIBI-scan 
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are rare16;17, but strengthens the hypothesis that MB and sestamibi have a 
comparable biodistribution. A better understanding of the exact mechanism 
would be of obvious clinical importance, since this technique could potentially 
enhance patient cure rates.
CONCLUSION
In conclusion, we describe the successful use of NIR uorescence imaging for 
the intraoperative identication of a paraganglioma using MB. This procedure 
is easy to perform and could result in an increased number of complete 
resections in paraganglioma surgery. In general, this technique could usher in 
a new era of optical assistance in the detection of tumors during surgery.
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ABSTRACT
Background: Identication of diseased and normal parathyroid glands during 
parathyroid surgery can be challenging. The aim of this study was to assess 
whether near-infrared (NIR) uorescence imaging using administration of a 
low-dose Methylene Blue (MB) at the start of surgery could provide optical 
guidance during parathyroid surgery and assist in the detection of parathyroid 
adenomas.
Methods: Patients diagnosed with primary hyperparathyroidism planned 
for parathyroid resection were included. Patients received 0.5 mg/kg MB 
intravenously directly after start of anesthesia. During surgery, NIR uorescence 
imaging was performed to identify parathyroid adenomas. Imaging results 
were compared to a previous published feasibility study in which 12 patients 
received MB after surgical identication of the adenoma. 
Results: 13 patients were included in the current study. In 10/12 patients with 
a histologically proven adenoma, the adenoma was uorescent. Mean Signal 
to Background Ratio (SBR) was 3.1 ± 2.8. Mean diameter of the resected lesions 
was 17 ± 9 mm (range 5 - 28 mm). Adenomas could be identied up to 145 
minutes after administration, which was the longest timespan until resection. 
Interestingly, in 3 patients, a total of 6 normal parathyroid glands (median 
diameter 2.5 mm) with a SBR of 1.8 ± 0.4 were identied using NIR uorescence 
imaging. 
Conclusion: Early administration of low dose MB provided guidance during 
parathyroid surgery by identifying both parathyroid adenomas and normal 
parathyroid glands. In patients where dicult identication of the parathyroid 
adenoma is expected, or when normal glands have to be identied, 
administration of MB could improve surgical outcome. 
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INTRODUCTION
Primary hyperparathyroidism is a common endocrine disorder caused by 
parathyroid adenomas or hypertrophic parathyroid glands1. Complete surgical 
resection of these lesions is the only curative treatment. For diagnosis and 
surgical planning, preoperative imaging can be performed with several imaging 
modalities. Available imaging modalities currently consist of ultrasound (US), 
radionuclide scanning, magnetic resonance imaging, and both conventional 
and “4 D” computed tomography2. In daily practice, various combinations of 
these imaging options are used. 
During surgery, adequate identication of parathyroid adenomas and 
parathyroid glands is of utmost importance for a curative treatment and 
to minimize the need for surgical exploration of the neck. However, few 
intraoperative imaging modalities are available. In 1971 Dudley et al. reported 
the use of intravenous administration of high dose Methylene Blue (MB) for 
the intraoperative identication of parathyroid adenomas3. Since then, this 
technique has been repeated by many groups4-6. However, administration of 
high dose MB (7.5 mg/kg) is associated with serious adverse events such as 
toxic metabolic encephalopathy7 and can lead to blue staining of the complete 
surgical eld due to leakage when surgical procedures takes longer. 
Besides the use of high dose MB, several intraoperative imaging modalities 
are described, all with their own disadvantages. Radio-guided identication 
using 99mTc-sestamibi and hand-held gamma probes lacks real-time visual 
guidance5;8;9. Moreover, nuclear isotopes are scarce in large areas of the world. 
Aminolevulinic acid (ALA) was successfully tested in clinical studies, but can 
cause phototoxic reactions for which patients have to be protected from direct 
light exposure for 48 hours10-12. Moreover, ALA is mainly uorescent in the 
visual light spectrum, which leads to high absorption and scatter of visible light 
in living tissue. 
One of the techniques that could overcome these issues is near-infrared (NIR) 
uorescence imaging. NIR uorescence imaging is an innovative technique to 
visualize tumors, vital structures and lymphatic channels and lymph nodes13. 
Recently, our research group showed feasibility of intraoperative identication 
of parathyroid adenomas using NIR uorescence imaging and low dose MB 
as uorescent tracer14. In this previous study, parathyroid adenomas were 
identied by surgical identication; whereafter 0.5 mg/kg MB (low-dose) was 
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administered intravenously to assess feasibility. In 9 out of 12 patients, the 
exposed adenoma became uorescent after MB administration within 5 - 10 
minutes. For intraoperative guidance in parathyroid surgery, it would be of 
great added value if MB could be administered before surgical exploration, 
resulting in faster identication of parathyroid adenomas. 
Therefore, the aim of this study was to assess whether early MB administration 
provides guidance in parathyroid adenoma identication during surgery. 
Subsequently, the obtained results were compared with previous published 
data to compare early and late MB administration protocols.
MATERIALS AND METHODS
Clinical study
This study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. All patients planning to undergo 
a resection of a parathyroid adenoma for primary hyperparathyroidism were 
eligible for participation in the study. Exclusion criteria were pregnancy or 
lactation, the use of serotonin reuptake inhibitors, serotonin, and noradrenalin 
reuptake inhibitors and/or tricyclic antidepressants, severe renal failure, G6PD-
deciency, or an allergy to MB. All patients gave informed consent and were 
anonymized. Patients received standard of care diagnostic work-up, which 
for our center included a preoperative cervical US and a preoperative 99mTc-
sestamibi-SPECT, combined with a low-dose computed tomography (CT) scan 
for preoperative surgical planning.
Directly before or after start of anesthesia, 0.5 mg/kg MB was administered 
intravenously over 5 minutes. During surgery, after subplatysmal dissection, 
retraction and initial exploration, visual inspection combined with NIR 
uorescence imaging was used for identication of parathyroid adenomas 
and normal parathyroid glands. After identication and resection of the 
adenoma, an intraoperative parathyroid hormone (PTH) assay was performed. 
Postoperative histopathological assessment of the resected specimen 
served as gold standard for parathyroid adenoma identication. No standard 
intraoperative frozen section analysis was performed.
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Intraoperative NIR uorescence imaging
For NIR uorescence imaging, the Mini-FLARE imaging system was used15. 
Briey, the system consists of 2 wavelength isolated light sources: a “white” 
light source, generating 26,600 lx of 400 to 650 nm light, and a “near-infrared” 
light source, generating 1.08 mW/came of ≈ 670 nm light. Color video and 
NIR uorescence images are simultaneously acquired and displayed in real 
time using custom optics and software that separate the color video and NIR 
uorescence images. A pseudo-colored (lime green) merged image of the 
color video and NIR uorescence images is also displayed. The imaging head 
is attached to a exible gooseneck arm, which permits positioning of the 
imaging head at extreme angles virtually anywhere over the surgical eld. 
For intraoperative use, the imaging head and imaging system pole stand are 
wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Comparison between early and late MB administration protocol
The obtained results were compared to the previous performed and published 
feasibility trial (NTR3403)14. This trial was performed using the same imaging 
system and identical surgical workup. In both studies, patients received 0.5 
mg/kg MB. The only dierence was that in the previous published study, MB 
was administered directly after surgical exposure of the suspected parathyroid 
adenoma. In the current study, MB was administered directly after start of 
anesthesia, before the surgical incision and assisted with parathyroid adenoma 
identication.
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 20.0, 
Chicago, IL) was used. Signal-to-background ratios (SBR) were calculated by 
dividing the uorescent signal in the parathyroid adenoma by uorescent 
signal of surrounding healthy tissue. Patient age and body mass index (BMI) 
were reported in mean and range and SBR was reported in mean and standard 
deviation. To compare characteristics between dierent administration 
protocols, the independent-sample t test and chi-square test were used was 
used. P < 0.05 was considered signicant. 




Thirteen consecutive patients with primary hyperparathyroidism planned for 
surgical resection of a parathyroid adenoma were included in this study. Patient 
and surgical characteristics are shown in Table 1. Mean age was 53 years (range, 
21 – 75) and 5 patients were male. Mean BMI was 26.6 ± 3.6, mean preoperative 
calcium level was 2.8 ± 0.1 mmol/L and mean preoperative PTH level was 11.9 ± 
7.2 pmol/L. All patients were diagnosed with primary hyperparathyroidism and 
in one patient this was associated with multiple endocrine neoplasia (MEN) 1 
syndrome. One patient was treated for recurrent disease, after earlier resection 
of a parathyroid adenoma.  The mean diameter of the resected lesions was 17 
± 9 mm (range 5 - 28 mm).
Preoperative imaging
Table 2 shows the preoperative imaging characteristics. In 12 out of 13 patients, 
a 99mTc-sestamibi single-photon emission computed tomography (SPECT)/
CT was performed. In 8 of 13 patients, a suspected parathyroid adenoma 
could be localized, whereas in 4 patients no evidence for localization of the 
adenoma was found. In 12 of 13 patients preoperative US was performed. In 5 
patients a lesion suspect for parathyroid adenoma was identied. In 1 patient 
no preoperative US was performed because she was referred from a foreign 
clinical for surgery and 99mTc-sestamibi SPECT/CT showed clear localization of a 
parathyroid adenoma. 
Intraoperative NIR uorescence imaging
In 9 out of 13 patients, intraoperative NIR uorescence imaging clearly 
identied a parathyroid adenoma or hyperplastic parathyroid gland. Figure 
1 shows a representative example of the intraoperative uorescent signal 
in a parathyroid adenoma. The mean SBR of the identied NIR uorescent 
adenomas or hyperplastic parathyroid glands was 3.1 ± 2.8.
46151 Quirijn Tummers.indd   102 16-08-17   13:01


























































































































































































































































































































































































































































































































































































































































46151 Quirijn Tummers.indd   103 16-08-17   13:01
Chapter 7104
















































































1 + + + + 106 1.5
2 - - - + N/A N/A
3 + - + + 102 and 132 5.7 and 2.3
4 + - + + 113 2.3
5 + + + + 115; 
109 and 134
2.4 (adenoma); 
1.4 and 2.0 (normal PTGs)
6 + + + + 34 10.7
7 NP + -* + 60 1.8 (ex vivo)
8 + + + + 87 1.8
9 - - +** + 78 and 78 2.4 and 1.6 (normal PTGs)
10 - - - + N/A N/A
11 - - + + 54 1.7
12 + NP + + 61 and 145;
135 and 136
3.8 and 1.7 (hyperplasia); 1.4 and 1.7 
(normal PTGs)
13 + - + + 41 2.2
Abbreviations: N/A, not applicable; NIRF, Near-infrared uorescence; NP, not performed, PTG, 
parathyroid gland; PTH parathyroid hormone; SBR, Signal-to-Background ratio; SPECT, single photon 
emission computed tomography.
* No in vivo NIRF detection of parathyroid adenoma. Ex vivo, the deepest located part of adenoma 
appeared to be uorescent. ** Identication of normal PTGs only using NIRF imaging.
Figure 1. Intraoperative NIR uorescence-guided resection of a parathyroid adenoma located in the 
neck
During minimally-invasive parathyroid surgery, a 19 mm parathyroid adenoma is identied using NIR 
uorescence imaging (arrow). 
In 1 patient, the intraoperatively identied parathyroid adenoma appeared 
non-uorescent in vivo, but this was caused by a hemorrhage on the ventral 
side of the adenoma. Ex vivo, the deepest located part of this adenoma also 
showed clear uorescence. In 12 patients, histological evaluation conrmed 
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that the resected tissue was parathyroid adenoma (N = 8) or hyperplastic 
parathyroid gland (N = 4). In 2 patients, the resected parathyroid adenoma did 
not uoresce. In summary, in 10 out of 12 patients with a proven parathyroid 
adenoma or hyperplastic parathyroid gland, the lesion was uorescent.
In 1 patient (#9), no adenoma was found during exploration of the neck. 
A thymectomy was performed and 6 non-uorescent lymph nodes were 
removed. During histological assessment of the resected tissue, no parathyroid 
adenomas were identied as well, although her intraoperative PTH assay 
showed a decrease from 25.0 to 1.4 pmol/L. 
Interestingly, in 3 patients, a total of 6 normal parathyroid glands were 
identied using NIR uorescence imaging (median size 2.5 mm, range 1-4). 
Figure 2A and 2B show an example of 2 small (1 and 2 mm) normal parathyroid 
glands located in the left and right thymus. These were not identied without 
NIR uorescence imaging. Both glands were biopsied for frozen section 
analysis and were found histologically to be normal parathyroid glands. 
Subsequently, the non-biopsied part of both glands were re-transplanted in the 
sternocleidomastoid muscle. Mean SBR of the normal parathyroid glands was 
1.8 ± 0.4. The smallest normal parathyroid gland identied by NIR uorescence 
imaging was 1 mm. 
Figure 2. Intraoperative NIR uorescence imaging of normal parathyroid glands
A. A 2 mm normal parathyroid gland (arrow) was identied in the right thymus using NIR uorescence 
imaging after thymectomy. B. A 1 mm normal parathyroid gland (arrow) was identied in the left thymus 
using NIR uorescence imaging after thymectomy. Both glands in A and B could not be identied using 
visual inspection.
46151 Quirijn Tummers.indd   105 16-08-17   13:01
Chapter 7106
Mean time interval between administration of MB and detection of the 
adenoma was 77 ± 34 minutes. Parathyroid adenomas could be identied up to 
145 minutes after administration, which was the longest timespan until resection. 
No adverse eects regarding the use of MB or NIRF uorescence imaging were 
seen.
Correlation 99mTc-sestamibi-SPECT/CT scan and NIR uorescence imaging
In all patients where a suspected adenoma was identied on 99mTc-sestamibi-
SPECT/CT, the resected parathyroid tissue was uorescent (8 out of 8). Moreover, 
when analyzing all patients with an adenoma (N=12) that received a 99mTc-
sestamibi-SPECT/CT (N=11), concordance between 99mTc-sestamibi-SPECT/
CT status and NIR uorescence status of the resected lesion was observed in 
10 out of 11 patients. In 1 patient where the 99mTc-sestamibi-SPECT/CT was 
negative, the adenoma appeared to be uorescent, and in 1 patient where the 
99mTc-sestamibi-SPECT/CT was negative, 2 normal glands were identied using 
NIR uorescence imaging.
Comparison between early and late MB administration protocol
There were no signicant dierences in patient characteristics between of the 
current study and the previous reported study regarding age, gender, BMI, 
preoperative calcium, preoperative PTH and diameter (Table 3). The most 
important dierence, although not signicant, was found in SBR between 
dierent administration protocols. Mean SBR was 3.1 in the early administration 
group versus 6.1 in the group that received MB after surgical exposure of the 
adenoma (P=0.08; mean dierence 2.95; -0.40 - 6.29 95% CI).
Table 3. Comparison between early and late Methylene blue administration






   Female







Age 53 56 0.65
BMI 26.7 27.1 0.82
Preoperative calcium 2.79 2.68 0.42
Preoperative PTH 12.2 119.4 0.22
Diameter 17 16 0.80
SBR 3.11 6.10 0.08
Abbreviations: BMI, Body mass index; MB, Methylene Blue; PTH, parathyroid hormone;  
SBR, signal-to-Background ratio.
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Combining the two groups showed that in 16/25 patients the preoperative 
99mTc-sestamibi-SPECT/CT scan indicated an adenoma. In 15 out of these 16 
patients, the detected adenoma was NIR uorescent, leading to a positive 
predictive value of 94%. The only patient who had a 99mTc-sestamibi-SPECT/
CT positive lesion, that appeared non-uorescent, was a patient who suered 
from parathyroid carcinoma. 
DISCUSSION
Despite the fact that surgical resection of parathyroid adenomas is a commonly 
performed and overall successful surgical procedure, intraoperative detection 
of an adenoma can be challenging. Moreover, the anatomical site where 
parathyroid adenomas are located contains many vital structures like arteries, 
veins, and nerves. When preoperative localization fails, and extended surgical 
neck exploration is needed, the risk of iatrogenic damage to these structures 
and associated complications increase16. Therefore, intraoperative optical 
guidance in parathyroid surgery using exogenous contrast agents could assist 
in a faster and more accurate identication of parathyroid adenomas, without 
causing iatrogenic injury to surrounding vital structures.
Previously our research group showed feasibility of intraoperative 
identication of parathyroid adenomas using NIR uorescence imaging and 
low-dose MB in humans14. In that clinical trial, MB was administered after 
surgical exposure of the adenoma. The current study conrmed the results 
of the previous described study, showing the possibility to intraoperatively 
identify parathyroid adenomas using MB and its correlation with preoperative 
a 99mTc-sestamibi-SPECT/CT scan. Combining the two groups showed that 
16 out of these 25 patients had a 99mTc-sestamibi-SPECT/CT scan indicating 
an adenoma. In 15 out of these 16 patients, the detected adenoma was NIR 
uorescent, leading to a positive predictive value of 94% for a NIR uorescent 
adenoma after a positive 99mTc-sestamibi-SPECT/CT scan. These ndings 
suggest that all patients with a positive 99mTc-sestamibi-SPECT/CT scan should 
receive MB for the improved identication of parathyroid adenomas.
In the current study, 2 parathyroid adenomas did not uoresce. The 
histopathological analysis of these 2 adenomas were comparable with the NIR 
uorescent positive adenomas, so the reason for non-uorescence remains 
unclear.
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Interestingly, we identied normal parathyroid glands, as small as 1 mm, 
during surgical exploration of the neck. These glands were not detected by the 
surgeon by visual inspection or palpation. Normal parathyroid glands can be 
dicult to distinguish during surgery because of their small size, their variability 
in location, and similar appearance to lymph nodes. Detection of these normal 
glands can be of great added value during subtotal parathyroid glands resection 
in the case of MEN1 syndrome, where 3.5 glands are removed and a portion of 
the most normal appearing gland is left in site or is auto-transplanted17. Also 
when normal glands are suppressed by hyperfunctional parathyroid glands, 
as in patient #9 of the current study, imaging can be useful. These glands 
were very small, and located in the thymus on both sides, and would not have 
been auto-transplanted if not detected in the thymectomy specimens by NIR 
uorescence imaging. Improved identication of both parathyroid adenoma 
and normal glands can limit the extent of neck exploration. Especially small 
normal glands are at risk of iatrogenic injury when not identied in time during 
neck exploration. The identication of normal glands using NIR uorescence 
imaging and MB was described by Antika et al.18 in rabbits. They used escalating 
dosages from 0.025 mg/kg to 3 mg/kg (human equivalent dose 0.008 mg/kg 
to 0.97 mg/kg calculated by using allometric dose translation based on body 
surface area19) for identication of thyroid and parathyroid glands. However, 
to the best of our knowledge, this is the rst clinical trial to demonstrate the 
intraoperative identication of normal glands using NIR uorescence imaging 
and MB. 
When early administration of MB is compared to late administration (after 
visual identication of the adenoma), a mean SBR of the adenoma of 3.1 in the 
early administration group versus 6.1 in the late administration group is seen. 
Although this dierence was not signicant (P = 0.08), it shows that MB follows 
the kinetics of a perfusion tracer, and don’t show clear (active) accumulation 
in parathyroid adenomas. Nevertheless, a mean SBR of 3.1 is suitable for 
intraoperative identication of parathyroid adenoma’s and normal glands as 
clearly shown in the current study. 
Developing probes that specically accumulate in parathyroid glands 
could enhance SBR and the time window of which optimal SBRs are achieved. 
A recent published study of our research group showed the high-sensitivity 
identication of parathyroid and thyroid glands in several animal models using 
novel tissue-specic NIR uorophores20. However, probes such as these are not 
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clinically available yet, and development of these probes is expensive and time 
consuming. Therefore, it is important to exploit clinically available contrast 
agents, such as MB21. 
Recently, several studies reported the use of autouorescence characteristics 
of parathyroid tissue for discrimination between dierent tissue types using 
spectroscopy22;23. They found autouorescent properties in parathyroid 
and thyroid glands with a peak uorescence at 822 nm when excited with 
785 nm light. Using autouorescence would make the development of 
exogenous contrast agents superuous. However, no 2-D optical guidance 
from spectroscopy is yet possible. And, although the spectroscopy results were 
validated in a larger patient cohort using a customized endoscopic imaging 
system24, this autouorescent signal has not been seen in previous studies by 
our research group using our imaging system in humans or dierent animal 
species14;20. 
NIR uorescence imaging is a growing eld of interest worldwide, more 
imaging systems have been introduced for both open and endoscopic 
imaging25;26. Prices of NIR uorescence imaging systems are starting from 
$40.000. NIR uorescence imaging in parathyroid surgery has the potential to 
speed up the surgical procedure by assisting in the identication of parathyroid 
adenomas and normal parathyroid gland. In the current study, time interval 
between administration and detection of adenomas are reported, however 
they could not be compared to patients not undergoing NIR uorescence-
assisted surgery. Therefore, randomized controlled trials in which patients are 
receiving NIR uorescence imaging or not are needed. 
To conclude, NIR uorescence imaging using MB can provide guidance 
during parathyroid surgery by identifying both parathyroid adenomas and 
normal parathyroid glands, for at least 145 minutes after MB administration. In 
patients where dicult identication of the parathyroid adenoma is expected, 
or when normal glands have to be identied, administration of MB could 
potentially improve surgical outcome. 
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ABSTRACT
Objective: In ovarian cancer, two of the most important prognostic factors 
for survival are completeness of staging and completeness of cytoreductive 
surgery. Therefore, intra-operative visualization of tumor lesions is of great 
importance. Preclinical data already demonstrated tumor visualization in a 
mouse-model using near-infrared (NIR) uorescence imaging and indocyanine 
green (ICG) as a result of enhanced permeability and retention (EPR). The aim 
of this study was to determine feasibility of intraoperative ovarian cancer 
metastases imaging using NIR uorescence imaging and ICG in a clinical setting.
Methods: Ten patients suspected of ovarian cancer scheduled for staging or 
cytoreductive surgery were included. Patients received 20 mg ICG intravenously 
after opening the abdominal cavity. The mini-FLARE NIR uorescence imaging 
system was used to detect NIR uorescent lesions. 
Results: 6 out of 10 patients had malignant disease of the ovary or fallopian 
tube, of which 2 had metastatic disease outside the pelvis. Eight metastatic 
lesions were detected in these 2 patients, which were all NIR uorescent. 
However, 13 non-malignant lesions were also NIR uorescent, resulting in 
a false-positive rate of 62%. There was no signicant dierence in tumor-to-
background ratio between malignant and benign lesions (2.0 vs 2.0; P=0.99). 
Conclusions: This is the rst clinical trial demonstrating intraoperative 
detection of ovarian cancer metastases using NIR uorescence imaging and 
ICG. Despite detection of all malignant lesions, a high false-positive rate was 
observed. Therefore, NIR uorescence imaging using ICG based on the EPR 
eect is not satisfactory for the detection of ovarian cancer metastases. The 
need for tumor-specic intraoperative agents remains.
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INTRODUCTION
Ovarian cancer has a worldwide incidence of 225,500 making it the 6th most 
common cancer in women. With 140,200 deaths worldwide per year, it has 
the highest mortality rates amongst all gynaecological cancers1-3. In general, 
ovarian cancer can be classied as early stage (FIGO I to IIa) or advanced 
stage (FIGO IIb to IV). Prognosis and treatment are mainly dependent on this 
classication.
Early stage ovarian cancer has a 5 year survival of 75-100%, with the most 
important factors inuencing survival being dierentiation grade of the 
tumor and the completeness of staging1. During surgical staging, blind biopsy 
samples of predened areas and biopsy samples of suspected lesions are 
obtained. The primary aim of the staging procedure is to determine whether 
there is occult metastatic disease not primarily visible by the naked eye. When 
no metastases are present, resection of the primary tumor is the treatment 
of choice and chemotherapy can be avoided4. When metastases are present, 
surgical resection is supplemented with chemotherapy.  Optimal staging 
has been shown to improve survival in low stage ovarian cancer because it 
discriminates true early stage ovarian cancer from occult tumor spread, which 
results in more advanced disease4.
However, most patients (around 75%) present with advanced disease5. The 
most important prognostic factor for overall survival in advanced stage disease 
is the amount of residual tumor after cytoreductive surgery6-8. Therefore 
complete cytoreduction, dened as no visible residual tumor left after surgery, 
or optimal cytoreduction, not consistently dened as a maximal diameter of 
residual tumor of 0-2 cm5;9-11, is the goal for advanced stage ovarian cancer 
surgery.
In order to achieve either optimal staging or complete or optimal 
cytoreduction, visualization of tumor lesions is of great importance. With 
imaging modalities such as CT and MRI, pre-operative identication and 
localization of tumor lesions is reasonably achievable, however intraoperative 
visualization of tumor tissue can be challenging. 
Near-infrared (NIR) uorescence imaging is a promising technique to 
assist in the real time intraoperative identication of malignant lesions12. This 
technique makes use of NIR uorescent light (700-900 nm) emitted by contrast 
agents after excitation by an imaging system able to detect this NIR uorescent 
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signal. NIR uorescence is relatively easy and provides sucient contrast due 
to high tissue penetration and low auto-uorescence13. 
For tumor identication, it is essential that contrast agents accumulate in 
tumor tissue either actively or passively. Active accumulation can be achieved 
by targeting ligands that are over-expressed on tumor tissue. Van Dam et al. 
were the rst to show tumor identication using a folate receptor alpha (FR-
a) targeting agent14. In their series they were able to identify tumor tissue 
in 3 patients with FR-a positive ovarian cancer intraoperatively. However, 
these results have not yet been reproduced in other studies using a FR-a or 
dierent targeting agents. A possible cause for this may be the expensive and 
time-consuming nature of the development of these tumor-specic agents. 
Therefore, it is of great importance to exploit clinically available contrast 
agents, such as indocyanine green (ICG)15.
In vivo ICG binds to serum proteins and therefore behaves as a 
macromolecule in the circulation. It is known that macromolecules accumulate 
in tumor tissue due to increased vascular permeability and reduced drainage. 
This phenomenon is called the “enhanced permeability and retention” (EPR) 
eect and has been observed in most solid tumors16;17. 
Clinical feasibility trials using this eect with ICG in breast cancer patients 
in a pre-operative diagnostic setting and in gastric cancer patients during 
endoscopic surgery showed that it was possible to distinguish tumor from 
surrounding tissue18-23. In addition, Kosaka et al.24 detected small ovarian (1-2 
mm in size) cancer implants using NIR uorescent imaging after intravenous (IV) 
administration of ICG in a mouse model. Pathophysiological heterogeneity of 
solid tumors, for examples in size, presence of necrosis, or presence of vascular 
mediators may inuence accumulation of macromolecules in tumor tissue25;26. 
It is therefore not clear if all preclinical results can be translated to the clinic.
The primairy aim of the current study was to determine the feasibility of 
ovarian cancer metastases detection using ICG and NIR uorescence imaging 
in a clinical setting. Secondary aim was to assess concordance between 
uorescence signal and tumor status on histopathology. In addition, we 
sought to determine if a sucient tumor-to-background ratio (TBR), based on 
the EPR eect, could be obtained to discriminate between malignant and non-
malignant tissue.
46151 Quirijn Tummers.indd   116 16-08-17   13:01
Imaging based on the EPR eect in ovarian cancer 117
MATERIAL AND METHODS
Tracer preparation
ICG was prepared in the operating room following preparation instructions of 
the institutional pharmacist. ICG (25 mg vials, purchased from Pulsion Medical 
Systems Munich, Germany) was diluted in 10 cc of sterile water for injection to 
yield a 2.5mg/ml (3.2 mM) stock solution. 
Clinical trial
The study protocol (S1 and S2 les, online available) was approved by the Local 
Medical Ethics Committee of the Leiden University Medical Center (LUMC) on 
27-06-2012 and was performed in accordance with the ethical standards of the 
Helsinki Declaration of 1975. Due to administrational error, trail registration 
was performed after the start of the study (date trial registration 11-09-2014; 
ISRCTN16945066). This non-randomised study adheres to the Transparent 
Reporting of Evaluations with Non-Randomised designs (TREND) guidelines (S3 
le). The authors conrm that all ongoing and related trials for this intervention 
are registered. Because this study was set up as feasibility study, no formal 
sample size could be calculated. Determination of feasibility was expected 
after inclusion of 15 patients. In case apparent non-feasibility was observed, 
earlier termination of the study could be performed.
Eventually, ten patients presenting at the department of Gynaecological 
Oncology of LUMC between 14 October 2012 and 11 December 2013 suspected 
of either early stage ovarian cancer scheduled to undergo staging surgery or 
of advanced ovarian cancer scheduled to undergo cytoreductive surgery, were 
included. All surgical procedures were performed by laparotomy through 
a midline abdominal incision. All patients gave written informed consent. 
Exclusion criteria were pregnancy, severe renal insuciency (GFR < 55 mL/
min/1.73 m2), or an allergy to iodine or ICG. 
In the operating theatre, after opening of the abdominal cavity, 20 mg of 
ICG was administered intravenously as single bolus by the anaesthesiologist. 
The average time between administration of ICG and imaging of the rst lesion 
was 37 minutes. The last lesion was imaged on average 141 minutes post-
administration of ICG. First the surgical eld was searched for metastases visible 
by the naked eye. After resection of the primary tumor, uterus and ovaries, the 
Mini-FLARE was used to identify NIR uorescent signals. When a uorescent 
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signal was observed, the operating surgeon performed a biopsy or resection 
of the uorescent tissue, unless this would jeopardize patient health or success 
of surgery. In case of non-uorescence, only macroscopically suspected lesions 
were resected. Resected specimens were marked as uorescent or non-
uorescent and were routinely examined by a pathologist for the presence of 
malignant cells. 
Intraoperative near-infrared uorescence imaging
Intraoperative imaging procedures were performed using the Mini-
Fluorescence-Assisted Resection and Exploration (Mini-FLARE) image-
guided surgery system, as described earlier27. Briey, the system consists of 
2 wavelength isolated light sources: a “white” light source, generating 26,600 
lx of 400 to 650 nm light, and a “near-infrared” light source, generating 1.08 
mW/came of ≈ 760 nm light. Color video and NIR uorescence images are 
simultaneously acquired and displayed in real time using custom optics and 
software that separate the color video and NIR uorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR uorescence 
images is also displayed. The imaging head is attached to a exible gooseneck 
arm, which permits positioning of the imaging head at extreme angles virtually 
anywhere over the surgical eld. For intraoperative use, the imaging head and 
imaging system pole stand are wrapped in a sterile shield and drape (Medical 
Technique Inc., Tucson, AZ).
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 20.0, Chicago, 
IL) was used. TBRs were calculated by dividing the uorescent signal of the 
tumor by uorescent signal of surrounding tissue. Patient age was reported in 
median, standard deviation (SD), and range, and TBR was reported in mean, SD, 
and range. To compare patient characteristics, independent samples t-test and 
chi-square tests were used. To compare TBR and background signal between 
malignant and benign lesions, independent samples t-test was used. P < 0.05 
was considered signicant.
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RESULTS
Patient characteristics
Ten patients were included in this study. Figure 1 shows the CONSORT ow 
diagram for enrollment of patients. Median age was 58 years (range 42-74). 
Table 1 shows the patient characteristics. Seven patients underwent a staging 
procedure (70%), and 3 patients underwent a debulking procedure (30%). All 
staging and debulking procedures were open procedures. 
Figure 1. CONSORT ow diagram for patient enrollment
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Histological assessment by the pathologist of the resected lesions conrmed 
the following diagnosis: 6 patients were diagnosed with either ovarian cancer 
(5) or cancer of the fallopian tube (1), of which the following subtypes were 
diagnosed: serous (3), clear-cell (1), endometrioid (1), mixed (1); one patient 
was diagnosed with endometrial cancer (endometriod type); and 3 patients 
had benign ovarian tumors. An overview of the nal histological diagnoses and 
FIGO stage is given in Table 1. 
Table 1. Patient and tumor characteristics
Study 
number






1 58 Ovary Clearcell 1a Staging No
2 69 Benign disease n.a. n.a. Staging No
3 74 Benign disease n.a. n.a. Staging No
4 73 Ovary Serous 3c Cytoreduction Yes
5 42 Ovary Serous 2c Cytoreduction Yes
6 50 Endometrium Endometrioid 3a Staging No*
7 73 Benign disease n.a. n.a. Staging No
8 58 Ovary Endometrioid 1a Staging No
9 54 Fallopian Tube Serous 1a Staging No
10 50 Ovary Serous, Mucinous 2c Cytoreduction No†
* Staging was performed because an ovarian metastasis was detected at pathology after an earlier 
polipectomy procedure 
† No biopsies were taken due to the presence of adhesions and tumor spill during the procedure, 
therefore dening the tumor stage as IIc with a concomitant indication for postoperative chemotherapy
Metastatic lesions
Two out of the 6 patients with malignant disease of the ovary or fallopian tube, 
suered from histologically proven metastatic disease (patients #4 and #5). A 
total of 8 metastatic lesions, conrmed by the pathologist, were found in these 
2 patients (4 lesions in both #4 and #5). Lesions were localized at the pouch of 
Douglas (N=3), bladder peritoneum (N=2), para iliacal lymphnodes (N=2) and 
omentum (N=1). 
NIR uorescence imaging
A total of 21 uorescent lesions were identied. Figure 2A shows an example 
of a clinically suspected lesion, which was NIR uorescent. This lesion was 
anatomically located next to the right iliac vein. Figure 2B shows the ex vivo 
images of the same NIR uorescent lesion. This lesion was found histologically 
to be a metastasis of serous adenocarcinoma of the ovary. Figure 3A and 3B 
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show 2 NIR uorescent lesions located in the greater omentum of the same 
patient as presented in Figure 2, both containing serous adenocarcinoma. 
Figure 2. Identication of ovarian cancer metastases using NIR uorescence imaging 
A. Identication of ovarian cancer metastases located in a lymph node next to the right iliac vein 
(arrow) using NIR uorescence imaging. The lesion was found histologically to be a metastasis of serous 
adenocarcinoma. B. Ex vivo imaging of the same ovarian cancer metastases located in a lymph node 
next to the right iliac vein (arrow).
Figure 3. Identication of ovarian cancer omental metastases using NIR uorescence imaging 
A. Identication of 2 ovarian cancer metastases located in the greater omentum (arrow and dashed 
arrow) using NIR uorescence imaging. B. Imaging of the same two NIR uorescent lesions removed 
from the omentum (arrow and dashed arrow). Both lesions were found histologically to be metastases 
of serous adenocarcinoma.
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All 8 histologically proven malignant metastatic lesions were NIR uorescent, 
so detection of metastatic lesions of ovarian cancer with ICG had a sensitivity 
of 100% in this study (Table 2). The specicity of NIR uorescence imaging 
could not be calculated, since lesions that were neither clinically suspect nor 
uorescent were not resected.
Table 2. Characteristics lesions found with ICG NIR uorescence imaging

















8 9 2 2 21
Concordance 
histopathology
N (%) N (%) N (%) N (%) N (%)
True-positive 8 (100) 0 (0) 0 (0) 0 (0) 8 (38)
False-positive 0 (0) 9 (100) 2 (100) 2 (100) 13 (62)
Clinically none of these 8 malignant and uorescent lesions had a benign 
appearance; therefore the use of NIR uorescence did not lead to the detection 
of otherwise undetected malignant lesions. In addition 13, on histological 
assessment, non-malignant lesions were also NIR uorescent, resulting in 
a false-positives rate of 62% (Table 2). Of these lesions, 2 were clinically 
characterized as malignant, 6 as suspicious for malignancy, and 5 as not 
suspicious for malignancy. Figure 4 shows an example of a NIR uorescent 
lesion that was found to be histologically benign, thus a false-positive lesion. 
This particular lesion was a calcied lymph node. The localization, clinical 
appearance, pathology, and TBR for each false-positive lesion are listed in Table 
3. Globally these false-positive lesions can be divided into two groups: normal 
tissue (N=10) and tissue with reactive changes (N=3).
Figure 4. Identication of ovarian cancer omental metastases using NIR uorescence imaging 
Identication of a NIR uorescent lesion located in the mesentery of the intestine. The lesion was 
classied clinically as a metastasis but was found histologically to be a calcied lymph node.
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Table 3. Overview of false-positive lesions detected using ICG















s 2 Mesenterium small bowel Uncertain Fibrosis and hemorrhages 2.7




No Mature fat and connective 
tissue, vascular structures, 
inammatory inltrate with 









1 Omentum Yes Fat and connective tissue 2.1
6 Omentum Uncertain Muscle 1.3
8 Peritoneum right Uncertain Connective tissue and some 
tubulair structures 
1.6
8 Iliaca interna right Uncertain Lymph node 1.7
8 Omentum Uncertain Muscle 1.6
1.3
9 Bladder peritoneum No Fat and connective tissue 
9 Rectosigmoid Uncertain Fat and connective tissue 1.3
9 Supercial pelvic right No Lymph node 1.8
9 Supercial pelvic left No Lymph node 2.6
9 High paracolic right No Fat and connective tissue  †
* Image shown in Fig. 4
† TBR could not be calculated
Mean TBR of the uorescent lesions was 2.0 ± 0.6. There was no signicant 
dierence in TBR between histologically conrmed malignant and benign 
lesions (2.0 vs 2.0; P=0.99). Although the numbers are small, within the group 
of false-positive lesions a signicant dierence in TBR (P = 0.003) did exist 
between the histologically normal (1.7 ± 0.4) and reactive tissue (2.7 ± 0.2).
No adverse reactions regarding the use of ICG or NIR uorescence imaging 
were seen. 
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DISCUSSION
In this feasibility study we investigated the use of NIR uorescence imaging 
with the clinically available, non-targeted uorescent tracer ICG in ovarian 
cancer patients who underwent a surgical staging procedure or cytoreductive 
surgery. Malignant metastatic lesions were present in 2 out of 10 patients only, 
but we found that 100% of these histologically proven malignant lesions were 
uorescent using this technique. However, there was also a high false-positive 
rate of 62%.
In cytoreductive surgery, the goal is to remove as much tumor as possible, 
aiming for complete (no tumor visible after surgery) or leastwise optimal 
cytoreduction (residual tumor maximized to 10 mm), because the amount of 
residual tumor is one of the most important prognostic factors for survival in 
advanced stage patients. Van Dam et al.14 already showed that with the use 
of uorescence imaging using a folate receptor alpha targeting probe (that 
is over-expressed in 90-95% of ovarian cancer patients), it was possible to 
identify more tumor deposits than by the naked eye. In our study we could not 
demonstrate such an added value of NIR uorescence using the non-specic 
agent ICG, because all of the uorescent, histologically malignant lesions were 
identied with the naked eye.
Treatment decisions in early stage ovarian cancer patients, for instance 
regarding adjuvant chemotherapy, are based on the presence of occult 
metastases and the extent of disease found during surgical staging 
procedures. If staging is not done properly, this could lead to under treatment 
of the patient. It has been shown that completeness of surgical staging is an 
independent prognostic factor for overall survival in early stage patients4. If 
the use of NIR uorescence imaging leads to more accurate detection of 
(occult) ovarian cancer metastases, more patients could be optimally staged, 
possibly leading to better treatment decision making and overall survival. In 
none of the 3 patients with early stage ovarian or fallopian tube cancer who 
underwent a staging procedure in this study, metastatic disease was found. 
Therefore, no added value of NIR uorescence imaging could be demonstrated 
in this study using ICG. A total of 13 uorescent lesions were observed in the 7 
patients undergoing surgical staging. On pathologic testing, all 13 lesions were 
benign and thus false-positive. To conclude, NIR uorescence imaging could 
not demonstrate added value in staging procedures because no otherwise 
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undetected metastatic disease could be found, but did result in the resection 
of non-malignant lesions. 
The intended eect of NIR uorescence imaging with ICG was based on 
the EPR eect. Due to tumor-induced angiogenesis, solid tumors exhibit leaky 
and immature vessels. Because of this macromolecules are able to permeate 
through the vessels and into tumor tissue where they are retained due to 
impaired lymph drainage16. ICG is not a macromolecule, but behaves like 
one after binding to serum proteins. This, combined with the rapid clearance 
from the circulation, makes ICG a potentially good probe for NIR uorescence 
imaging of solid tumors. This theory has proven to be true for gastric and breast 
cancer18-23. But it should be noted that all the trials in breast cancer patients 
were conducted in a pre-operative diagnostic setting and results may dier 
from intraoperative usage of ICG.
The large number of false-positives found in this study may be due to the 
lack of specicity of the EPR eect. It is known that the EPR eect is inuenced 
by multiple factors, such as size, presence of necrosis, tumor type, presence 
of vascular mediators such as bradykinin or prostaglandins, and location 
(including primary tumor vs metastatic lesion) of the lesion. Moreover, reactive 
processes and cancer have parallels in pathophysiological pathways and 
in vascular mediators. It has been shown that the EPR eect also occurs in 
inammatory lesions25;28;29. This is in agreement with part of the false-positive 
lesions identied in the current study. Especially since the EPR eect in reactive 
tissue is more prominently present hours after injection (coinciding with our 
imaging window) versus days to weeks after injection in tumor tissue26. 
Several studies describe the intraoperative identication of solid tumors 
using clinically available, non-targeted uorescent probes as ICG and 
methylene blue (MB). These studies report higher TBRs than found in the 
current study. For example, imaging of colorectal liver metastases using ICG 
(TBR 7.0)30, parathyroid adenomas using MB (6.1)31 and breast cancer using MB 
(2.4)32 all showed higher TBRs than the observed 2.0. A possible explanation 
for this is that in these studies other mechanisms causing accumulation of the 
uorescent probe in or around tumor tissue played a role in addition to the 
possible EPR eect. The EPR eect on its own may not be sucient in providing 
high enough TBRs for tumor imaging. Finally, the average TBR of false-positive, 
benign lesions was just as high as the average TBR of true positive malignant 
lesions, while the average TBR of reactive benign lesions was even higher 
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than that of malignant lesions. This lack of discriminative power makes NIR 
uorescence imaging based on the EPR eect unsuitable for further clinical 
implementation in ovarian cancer. 
CONCLUSIONS 
This is the rst clinical trial demonstrating the feasibility of intraoperative 
detection of ovarian cancer metastases using NIR uorescence imaging and 
ICG. However, a high number of false-positive lesions that could be explained 
by the lack of specicity of the EPR eect was found. Moreover, no distinction 
between malignant, reactive, or benign tissue based on TBR of the dierent 
lesions could be made. Therefore, the use of ICG, even when optimized, is not 
satisfactory for intraoperative NIR uorescence imaging of ovarian cancer 
metastases and the need for more tumor-specic targeting agents remains. 
These results should be conrmed in other solid tumors where intraoperative 
NIR uorescence imaging based on the EPR eect is being contemplated. 
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ABSTRACT
Introduction: Intraoperative uorescence imaging of the folate-receptor alpha 
(FRα) could support completeness of resection in cancer surgery. Feasibility of 
EC17, a FRα-targeting agent that uoresces at 500nm, was demonstrated in a 
limited series of ovarian cancer patients. Our objective was to evaluate EC17 in 
a larger group of ovarian cancer patients. In addition, we assessed the feasibility 
of EC17 in patients with breast cancer.
Methods: Two-to-three hours before surgery 0.1mg/kg EC17 was intravenously 
administered to 12 patients undergoing surgery for ovarian cancer and to 3 
patients undergoing surgery for biopsy-proven FRα-positive breast cancer. 
The number of lesions/positive margins detected with uorescence and 
concordance between uorescence and tumor- and FRα-status was assessed 
in addition to safety and pharmacokinetics.
Results: Fluorescence imaging in ovarian cancer patients allowed detection of 
57 lesions of which 44 (77%) appeared malignant on histopathology. Seven out 
of these 44 (16%) were not detected with inspection/palpation. Histopathology 
demonstrated concordance between uorescence and FRα- and tumor status. 
Fluorescence imaging in breast cancer patients, allowed detection of tumor-
specic uorescence signal. At the 500nm wavelength, autouorescence of 
normal breast tissue was present to such extent that it interfered with tumor 
identication. 
Conclusions: FRα is a favorable target for uorescence-guided surgery as EC17 
produced a clear uorescent signal in ovarian and breast cancer tissue. This 
resulted in resection of ovarian cancer lesions that were otherwise not detected. 
Notwithstanding, autouorescence caused false-positive lesions in ovarian 
cancer and diculty in discriminating breast cancer-specic uorescence from 
background signal. Optimization of the 500nm uorophore, will minimize 
autouorescence and further improve intraoperative tumor detection.
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INTRODUCTION
Over the past decades multiple imaging modalities have become available 
for preoperative detection of tumors, staging disease and identifying sentinel 
lymph nodes1;2. However, translation of preoperative obtained images to the 
surgical theatre can be challenging. Consequently, surgeons largely have to 
rely on visual inspection and palpation to discriminate between healthy and 
malignant tissue. As a result, incomplete resection of malignant tissue may occur. 
In breast cancer surgery, for example, positive resection margins are reported 
in up to 20% of patients after resection of the primary tumor3. In metastasized 
disease, intraoperative imaging of tumor tissue can be of great advantage. In 
ovarian cancer for example, clear intraoperative detection of metastatic lesions 
can improve staging procedures in early stage ovarian cancer (FIGO I and IIa), 
and facilitate complete or optimal cytoreductive surgery in advanced stage 
disease (FIGO IIb to IV). Both the prevention of positive margins in solid tumors 
and the performance of adequate staging and complete/optimal cytoreduction 
will improve individual patient outcome4-9. Hence there is a clear unmet need 
for intraoperative modalities that can identify tumor tissue with high sensitivity 
and specicity.
An innovative intraoperative optical imaging technique is uorescence 
imaging. Over the past years multiple studies have been performed on tumor 
imaging, sentinel lymph node (SLN) mapping and identication of vital 
structures, using uorescence imaging10;11.
Optical properties of uorescent contrast agents are of importance for 
successful tumor imaging. The wavelength of the uorescent light largely 
determines the degree of penetration of photons into the tissue. Photons in 
the visible light range have a depth penetration limited to a few millimeters 
and are suitable for detection of supercial targets. Conversely photons in 
the NIR range (650-900 nm) can travel more than a centimeter through tissue, 
which also enables detection of targets below the tissue surface12. Moreover, 
the wavelength of the uorescent light also plays a role in autouorescence. 
Autouorescence is uorescence arising from intrinsic tissue components after 
excitation with UV, visible, or NIR radiation of suitable wavelength. To detect 
cancer cells targeted with an optical contrast agent, the signal of the target-
specic uorescence must be signicantly higher than the autouorescence. 
The occurrence of autouorescence is determined by the tissue type and 
excitation wavelength13;14.
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Biological characteristics of uorescent contrast agents are essential to 
achieve target-specic uorescence imaging. Ideally, a contrast agent binds 
exclusively to a cancer specic ligand, while being excreted rapidly from the 
rest of the body. Over the past years, extensive preclinical validation of tumor-
specic contrast agents targeting a variety of ligands was reported, however 
only very few were clinically introduced15;16. For this reason, several clinical 
studies have been performed to explore feasibility of clinically available 
uorescent contrast agents like methylene blue (MB) and indocyanine green 
(ICG) for intraoperative tumor imaging of breast cancer tissue and ovarian 
cancer tissue17;18. These agents do not specically bind to the tumor, but make 
use of other mechanisms such as the Enhanced Permeability and Retention 
(EPR)19;20 eect and disturbed excretion proles causing accumulation in or 
around tumor tissue. Although promising results were described, resection 
of non-malignant lesions due to false positive uorescence proved an 
insurmountable problem in the road to clinical application. Consequently, 
the need for newly developed contrast agents with highly specic binding to 
tumor-specic targets remains.
A promising target for image-guided surgery is the folate receptor alpha 
(FRα). Normally the FRα is expressed only at low levels and due to its location 
on the apical membrane of epithelial cells it is not accessible for molecules 
transported by blood21;22. In contrast, in many types of epithelial cancers, the 
FRα is highly expressed. As a result of the loss of cell polarity in cancer, the 
FRα is easily accessible by blood making it an ideal tumor target. Over 90% 
of all epithelial ovarian cancers over-express FRα, and in ovarian cancers of 
serous morphology this percentage is even higher (90-100%)23-25. Moreover, 
expression is not altered by chemotherapy26;27, allowing use of this target in 
both primary and interval cytoreductive surgical procedures. In breast cancer, 
FRα overexpression is reported in 30% of tumors, this percentage is even higher 
(67%) in tumors with a “triple-negative” receptor prole28. In almost all breast 
cancer patients, preoperative biopsies are available, allowing characterization 
of FRα status before surgery to select patients who will benet from FRα 
targeted imaging agents.
While multiple preclinical studies have been performed on the imaging 
of FRα positive tumors29-31, clinical experience is very limited. Van Dam et al. 
showed feasibility of intraoperative imaging of ovarian cancer metastases 
using EC17, a FRα targeting contrast agent with uorescent properties in 
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the visible light spectrum (500nm). In a limited series of patients undergoing 
surgery for suspected ovarian cancer, uorescent tumor tissue was observed 
intraoperatively after intravenous administration of EC17 in 3 out of 4 
patients with proven ovarian cancer. However, the intra-operative detection 
of additional tumor lesions due to the use of EC17 and uorescence imaging 
was not reported. Moreover, administration of the contrast agents had to be 
interrupted, although the study could be completed, in several (4 out of 10) 
patients due to mild adverse events. As a result the initial dose of 0.3 mg/kg 
was decreased to 0.1 mg/kg, which reduced adverse events while maintaining 
uorescent signal. To demonstrate the tolerability and additional value of 
uorescence imaging using EC17 in ovarian cancer, evaluation in a larger patient 
cohort is required. Although the overexpression of the FRα on selected breast 
cancer cells has been shown, feasibility of uorescence imaging using EC17 in 
patients with FRα positive breast cancer has not yet been demonstrated.
Our objective was to evaluate a relatively low dose of EC17 (0.1 mg/kg) in a 
larger group of ovarian cancer patients and to assess feasibility of intraoperative 
uorescence imaging in patients with FRα positive breast cancer.
RESULTS
Patient characteristics
A total of 13 ovarian cancer patients were included. Surgery was cancelled in 
1 patient due to deterioration of the medical condition of the patient prior to 
surgery. Thus 12 ovarian cancer patients received EC17 and underwent open 
surgery; a tabular overview of the patient characteristics, FIGO status and 
histology of the tumor type is given in Table 1. Six patients underwent a primary 
cytoreductive procedure, 4 patients an interval cytoreductive procedure and 2 
patients a staging procedure. 
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1 71 Primary debulking Serous adenocarcinoma 3c Yes Yes Yes
2 51 Primary debulking Endometroid type adenocarcinoma 3b Yes Yes Yes
3 59 Staging Endometroid type adenocarcinoma 2c No Yes Yes
4 61 Interval debulking Serous adenocarcinoma of 
endometrium
4 Yes Yes Yes




6 71 Primary debulking Serous adenocarcinoma 3c Yes Yes Yes
7 71 Primary debulking Serous adenocarcinoma 3b Yes Yes Yes
8 78 Interval debulking Serous adenocarcinoma 3c Yes Yes Yes
9 57 Interval debulking Serous adenocarcinoma 3c Yes Yes Yes
10 52 Interval debulking Serous adenocarcinoma 4 Yes Yes Yes
11 42 Primary debulking Mucinous adenocarcinoma 3c Yes No No
12 73 Staging Endometroid type adenocarcinoma 2b No Yes Yes
For breast cancer, a total of 53 potentially eligible breast cancer patients 
were selected for characterization of FRα status on preoperatively obtained 
biopsies. Samples of six patients stained positive for FRα (11%). Of the 6 
patients, 2 patients eventually did not meet the inclusion criteria and 1 patient 
declined participation. Three patients were included in the study and their 
characteristics are provided in Table 2.















































































1 54 BCS IBC NST 19 Neg Neg Neg Yes, 9mm Yes Yes*
2 61 BCS Metaplastic 
carcinoma
42 Neg Neg Neg No Yes Yes
3 53 Mastectomy IBC NST 23 Pos Pos Neg No Yes Yes
Abbreviations: BCS, Breast Conserving Surgery; IBC, inltrative breast cancer; NST, No Special Type
* Tumor successfully identied in resection specimen. SLN metastasis not identied due to lack of tissue 
penetration.
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Safety
All patients received 0.1 mg/kg EC17 over 10 minutes, and no infusion was 
intermitted or stopped. Infusion of EC17 was associated with mild, self-limiting 
hypersensitivity reactions in 7 out of 15 patients. The symptoms consisted 
of abdominal discomfort, itching throat and sneezing (for a summary list 
of treatment related adverse events, see Table S1, online available). One 
patient vomited after EC17 administration and received ondansetron 8 mg 
intravenously, followed by the planned surgical procedure. There were no 
clinical relevant changes in blood pressure or pulse rate compared to baseline.
Intraoperative uorescence imaging
Intraoperative uorescence imaging in ovarian cancer patients allowed clear 
detection of ovarian cancer lesions. Figure 1 shows an example of uorescent 
ovarian cancer metastases. 
Figure 1. Identication of ovarian cancer metastases using uorescence imaging
Identication of ovarian cancer metastases located on the intestine and mesentery using uorescence 
imaging. Biopsies of lesions were found histologically to be metastases of serous adenocarcinoma.
In total, 57 uorescent lesions that were identied during surgery were 
resected. Of these resected lesions 44 (77%) appeared to be malignant on 
histopathology. Seven (16%) of these 44 lesions were not detected by visual 
inspection with the naked eye or palpation either because they appeared 
benign or because they were missed during inspection due to small size 
(<10mm) and at nature. These lesions were only removed because these could 
be identied using uorescence imaging. Mean TBR was 7.0 ± 1.2. Fluorescence 
imaging was successful up to about 5.5 hours after EC17 administration, which 
was the longest time interval measured between administration and the end 
of a surgical procedure. 
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Histopathology demonstrated clear concordance between uorescence and 
FRα- and tumor status. Fluorescence microscopy showed clear membranous 
and cytoplasmic accumulation of EC17 in tumor cells (Figure 2).
Figure 2. Histopathological evaluation of uorescence signal in ovarian cancer
Fluorescence signal is indicated with green, blue color represents cell nuclei stained with DAPI. 
Fluorescence microscopy showed clear membranous and cytoplasmic accumulation of EC17 in tumor 
cells .The uorescent signal is located on all sites that stain positive for FRα expression, which is the 
anatomical site that appears to be a metastasis of serous ovarian adenocarcinoma on hematoxylin and 
eosin staining (dashed circle).
The (ex-vivo) assessment of the stills obtained from the videos made during 
the surgical procedure showed that on average (SD) 23.3 (± 11.9) lesions per 
still were identied with the naked eye. When the stills were supplemented 
with the uorescence image, 39.6 (± 22.7) lesions per still were identied, a 
70% increase.
In total, 3 false-negative lesions were identied. These lesions were all 
metastases in the greater omentum. The lesions were considered suspicious for 
malignancy by the surgeons, but showed no intraoperative uorescence signal 
from the outside (Figure 3A). However, upon dissection of the omentum on 
the backtable, strong uorescent signal was identied (Figure 3B), suggesting 
that the intraoperative non-uorescence was caused by the lack of tissue 
penetration at 500nm wavelength.
46151 Quirijn Tummers.indd   140 16-08-17   13:01
Imaging FRα positive ovarian and breast cancer 141
Figure 3. False-negative uorescent signal caused by a lack of depth penetration
A. Example of a metastasized greater omentum, which was clinical suspicious, but showed no 
uorescence signal from the outside. B. After dissecting the omentum, strong uorescent signal was 
identied. This observation shows the lack of tissue penetration at 500nm.
Thirteen out of the 57 (23%) uorescent lesions appeared benign. Five of 
these false positive lesions were identied as normal fallopian tube tissue on 
histopathological evaluation, showing FRα expression. These lesions were 
thus expected to bind EC17, and were resected anyway as part of the standard 
surgical procedure. Six lesions were structures mainly containing collagen, 
which is known to cause autouorescence at 500nm. Mean TBR of the false-
positives was 5.4 ± 1.0. There was no signicant dierence in TBR between 
true-positives and false-positives (7.0 vs. 5.4; P = 0.47). Characteristics of false 
positive and false negative lesions are provided in Table 3.
Also in breast cancer, tumor-specic uorescence signal was observed. 
Median TBR was 2.3 (range 2.1 – 6.2). However, autouorescence of normal 
breast tissue was present to such extent that it interfered with tumor 
identication. Figure 4 shows uorescent signal in breast cancer tissue and in 
normal, autouorescent breast tissue. Fluorescence microscopy showed clear 
membranous and cytoplasmic accumulation of EC17 in tumor cells (Figure 
5). In addition, high background uorescent signal was observed, which is in 
concordance with images obtained with the intraoperative Artemis imaging 
system. 
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Table 3. Characteristics of false positive and false negative uorescent lesions in ovarian cancer 
Patient 
ID
Location lesion False positive 
or negative
Probable cause
1 Fallopian tube False positive FRα expression
2 Iliacal lymph node False positive FRβ expression activated macrophages
2 Ligamentum rotundum False positive Autouorescence collagen containing structure
4 Omentum False negative Inadequate penetration depth
5 Leiomyoma Uterus False positive Autouorescence collagen containing structure
5 Leiomyoma Uterus False positive Autouorescence collagen containing structure
5 Omentum biopsy False positive Unknown
7 Omentum False negative Inadequate penetration depth
8 Omentum False negative Inadequate penetration depth
8 Fallopian tube False positive FRα expression
10 Fallopian tube False positive FRα expression
12 Cervix False positive Autouorescence collagen containing structure
12 Myometrium uterus False positive Autouorescence collagen containing structure
12 Fallopian tube False positive FRα expression
12 Infundibulopelvic 
ligament
False positive Autouorescence collagen containing structure
12 Ovary (contralateral) False positive FRα expression
Figure 4. Identication of breast cancer metastases using uorescence imaging
Identication of a bisected primary breast cancer lesion using uorescence imaging (dashed circles). The 
arrow indicated autouorescence signal from normal breast tissue. The tumor was found histologically 
to be an inltrating breast cancer of no special type.
In one patient with breast cancer, a tumor-positive SLN was found on 
histopathological evaluation. This SLN however was not detected with 
uorescence imaging. After HE and FRα staining, the metastasis appeared to 
be in the center of the SLN, and was therefore not detected due to lack of tissue 
penetration.
Pharmacokinetics
The maximal concentration for each dose was obtained directly after the end 
of the infusion and declined thereafter with a half-life of 86.8 minutes.
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Figure 5. Histopathological evaluation of uorescence signal in breast cancer
A. Fluorescence microscopy showed clear membranous and cytoplasmic accumulation of EC17 in 
tumor cells. Blue color represents cell nuclei stained with DAPI, uorescence signal is indicated with 
green. Also a relatively high diusely uorescent background signal is seen, which is in concordance 
with the uorescence images obtained with the intraoperative imaging system. B. Immunohistological 
staining for FRα expression shows a FRα positive inltrating breast cancer of no special type (example 
in dashed circle). Clear concordance is observed between uorescent signal and FRα positive malignant 
lesions.
DISCUSSION
Intraoperative imaging of tumor tissue may improve patient outcome 
by enhanced identication and subsequent resection of tumor tissue. 
Fluorescence guided surgery using the FRα specic contrast agents EC17 
allowed real time identication of both ovarian- and breast cancer cells. In 
ovarian cancer, the intraoperative use of uorescence imaging resulted in 
the resection of 16% more malignant lesions compared to inspection with 
the naked eye and/or palpation only. Visual identication was improved on 
stills made from intraoperative videos, supporting the notion that uorescent 
imaging improves detection even when other techniques like palpation are 
not available.
The biophysical properties of imaging agents are of paramount importance 
for successful tumor identication. Ideally, high uorescence signal is observed 
in malignant lesions, while normal or healthy tissue shows minimal uorescence 
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because of a low binding constant and fast excretion of the imaging agent 
after initial biodistribution. The size of the compound greatly inuences this 
prole. Currently monoclonal antibodies, antibody fragments, such as single-
chain (scFv) of fab fragments, small peptides or structure-inherent targeting 
uorophores are used for tumor-specic imaging32-36. The biodistribution, 
excretion and binding prole of EC17 shows several great advantages in 
imaging. The maximum concentration (Cmax) of EC17 is observed directly after 
the end of administration and is followed by a rapid excretion from the blood. 
While uorescence signal of the tumor is observed up to more than 5 hours 
after administration of the compound. This short terminal half-life in blood, 
strong tumor specic signal and low background signal allows tumor imaging 
from 2 hours post dosing and during a relative long time.
Around 75% of patients with ovarian cancer present with advanced stage of 
the disease37. Multiple studies have shown that the amount of residual disease 
is the most important prognostic factor for survival in ovarian cancer patients. 
As a result of these studies, consensus exists that all attempts should be made 
to achieve complete cytoreduction i.e. complete removal of all macroscopically 
visible tumor tissue4;6;8;38;39. In this study, real-time visualization of malignant 
lesions using uorescence imaging during surgery led to the detection of 16% 
additional malignant lesions. This may improve cytoreduction and hereby 
patient outcome. The eect of the addition of intraoperative uorescence 
imaging on survival was already shown by Stummer et al. in patients with brain 
glioma. They demonstrated that uorescence imaging with 5-ala not only leads 
to more complete resections but also to improved progression free survival5. 
For ovarian cancer more prospective research is necessary to establish the 
eect on overall survival.
When patients present with clinically early stage ovarian cancer, a staging 
procedure is recommended. During this procedure, biopsies of suspicious 
lesions are taken, supplemented with “blind” biopsies from predened 
locations. Ultimate goal is to identify metastatic lesions whenever present 
in order to give adequate treatment i.e. systemic chemotherapy. Visualizing 
metastatic lesions by uorescence imaging may optimize staging procedures, 
as less “blind” biopsies have to be taken. This could facilitate discrimination 
between true early stage ovarian cancer and more advanced stage with occult 
tumor spread. Especially in minimal-invasive surgery, when tactile information 
(palpation) of lesions cannot be obtained, uorescence imaging could be of 
additional value. 
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In breast cancer, up to 20% of patients have positive resection margins 
after resection of the primary tumor3. Visualizing tumor cells during surgery 
could lower the risk of an incomplete resection as identication of a positive 
margin can result in direct resection of residual tumor tissue. Although this 
will probably not inuence overall survival, as patient with positive resection 
margins are currently treated with a re-resection or more intensive radiotherapy, 
signicantly lower healthcare costs and burden to the patient could result. To 
investigate this concept, both FRα positive breast cancer patients treated with 
BCS and breast ablation were included in the current feasibility study. However, 
for future applicability of uorescence imaging in breast cancer surgery, the 
most added value is to be expected in BCS. Moreover, a signicant number 
of patients with breast carcinoma is pre-treated with neoadjuvant systemic 
chemotherapy to reduce the primary tumor to facilitate BCS instead of radical 
mastectomy40. Although pre-treatment with systemic therapy does not result in 
an increased number of positive resection margins41, recognition of vital tumor 
tissue can be challenging. As FRα status is not changed by chemotherapy27;42, 
uorescence imaging could be of added value in these challenging cases. 
In literature, FRα positive breast cancer lesions are described in up to 30% 
of patient43-45. In our series however, only 11% of the obtained biopsies stained 
positive for FRα. No explanation was found for this lower expression level. A high 
number of normal breast tissue stained weak positive for FRα, mainly located at 
the apical surface of epithelial cells and at myoepithelial cells. This nding has 
been described previously43;45, and does not necessarily cause a pitfall for FRα 
as target for uorescence guided surgery, because the myoepithelium is not 
accessible for blood carried contrast agents. 
Several limitations of the described technique and contrast agent were 
caused by the optical properties of the contrast agent. EC17 uoresces at 
488nm, which does not allow identication of lesions located beneath the 
surface. In 3 patients with ovarian cancer, the greater omentum was suspected 
for malignancy, but only showed uorescence after dissection of the tissue and 
this clearly showed the low tissue penetration of the photons emitted by EC17. 
We identied 23% false-positive lesions in the patients with ovarian cancer. 
The non-malignant lesions that uoresced in this study were in particular 
collagen-containing structures, from which it is known that they can show 
autouorescence in the visible light spectrum14;46. 
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All the above-mentioned limitations could be overcome by conjugating the 
folate analog to a uorophore that uoresces in the NIR spectrum. This allows 
identication of structures located deeper beneath the surface due to a lower 
absorption coecient, and causes less autouorescence of normal tissue47. For 
surface detection of malignant cells, as in breast cancer, depth penetrating 
is less important, but currently the autouorescent signal prevented clinical 
decision-making. Figure S1 (online available) shows uorescence imaging at 
500nm and 800nm of breast tissue containing a tumor. These tissue specimens, 
from patients that were not treated with an exogenous contrast agent as 
EC17, are thus suitable to demonstrate background autouorescence. At 
500nm high background autouorescence is observed, while at 800nm no 
background autouorescence signal is seen (Supplementary Methods, online 
available). This illustrates the need for tumor-specic contrast agents in the NIR 
spectrum. Currently, our research group is performing a rst-in-human clinical 
trial in ovarian cancer patients using the FRα specic near-infrared contrast 
agent OTL38. Preclinical tests comparing OTL38 with EC17 have demonstrated 
superiority of OTL38 in sensitivity and brightness48.
In conclusion, administration of EC17 was reasonably well-tolerated and 
produced clear uorescent signals in ovarian and breast cancer tissue. This 
allowed resection of 16% more ovarian cancer lesions. Notwithstanding, 
autouorescence of benign, predominantly collagen-containing tissues led 
to detection of a signicant proportion of false positive lesions in ovarian 
cancer. Further, autouorescence resulted in diculty in discriminating 
breast cancer tissue specic uorescence from background uorescence. We 
conclude that FRα is a favorable tumor-specic target, but EC17 lacks the full 
set of requirements for uorescence-guided surgery in FRα-positive ovarian 
and breast cancer, especially because of autouorescence and insucient 
penetration depth. Replacing the 500nm uorophore by a uorophore in 
the NIR spectrum could likely further improve optical properties and thereby 
clinical relevance of uorescence-guided surgery.
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METHODS
Investigational agent
EC17 (molecular formula: C42H36N10Na2O10S; On Target Laboratories LLC, West 
Lafayette, USA) consists of a folate analogue conjugated to 5-uorescein 
isothiocyanate (FITC), which is exited between the wavelengths of 465 and 
490nm and uoresces at wavelengths of 520-530 nm. Before administration, 
the frozen vials containing 5 mg/mL EC17 in 3 mL water for injection were 
thawed and diluted in 10 mL sterile saline. Patients received 0.1 mg/kg EC17 
intravenously over 10 minutes, 2-3 hours before surgery.
Patients
Patients suspected of early stage epithelial ovarian cancer presenting at the 
department of Gynecology of the Leiden University Medical Center (LUMC) 
between February 2014 and September 2014 scheduled to undergo staging 
surgery or of advanced epithelial ovarian cancer scheduled to undergo 
cytoreductive surgery, were included in this study. All patients gave written 
informed consent.
For breast cancer, patients presenting at the department of Surgery of 
the LUMC between May 2014 and February 2015 planned for, either breast 
conserving surgery (BCS) or breast ablation, were eligible for participation. After 
selection, preoperatively obtained biopsies of potentially eligible patients were 
stained for FRα expression using immunohistochemistry (IHC). FRα expression 
was assessed by using a membranous scoring method with a scale ranging 
from 0 to 3+, as described by O’Shannessy et al.49 A score of 0 corresponded to 
absence of staining; 1+ equaled faint staining on luminal borders; 2+ equaled 
moderate staining on apical and sometimes lateral borders and 3+ indicated 
strong circumferential staining. The tumor was considered positive when more 
than 10% of malignant cells were positively stained (>0). Assessment of the 
stained biopsies was performed by a pathologist (VTHBMS or TB), and after 
presence of FRα positive tumor cells was conrmed, patients were eligible for 
EC17 administration. All patients gave written informed consent.
Exclusion criteria were age<18, pregnancy (excluded by pregnancy test in 
woman of childbearing potential), renal impairment (dened as eGFR<50 mL/
min/1.73m2), impaired liver function (dened as evidenced by greater than 3x 
the upper limit of normal (ULN) for ALT, AST, or total bilirubin), or a history of 
anaphylactic reaction to EC17, insect bites or uorescein.
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Clinical Trial
The study was approved by the Medical Ethics Committee of the LUMC and 
was performed in accordance with the laws and regulations of the Netherlands. 
Suitability of selected patients was further assessed by a medical screening 
consisting of a medical history, physical examination including vital signs, 
weight, 12-lead ECG, and routine laboratory assessments.
Before administration of EC17, two iv cannulas were inserted. One iv cannula 
was used for study drug administration and the cannula in the contralateral 
arm for PK sampling (Supplementary Methods, online available). After 
administration, safety assessments (blood pressure, pulse, peripheral oxygen 
saturation and temperature) and blood collection for pharmacokinetics were 
performed regularly from just prior to administration up to the end of surgery. 
A stopping rule was dened in the protocol. In case of treatment-related 
serious adverse events or results suggesting futility to continue, the trial would 
be halted or stopped. 
Surgical procedure in ovarian cancer patients
All surgical procedures were performed by laparotomy through a midline 
abdominal incision. After opening of the abdominal cavity, the surgical eld 
was searched for the primary tumor and metastases visible by the naked eye or 
palpation. Thereafter, the Artemis imaging system (see below for details) was 
used to identify uorescent signals. When a uorescent signal was observed, 
the operating surgeon performed a biopsy or resection of the uorescent 
tissue. In case of non-uorescence, only lesions macroscopically suspect for 
malignancy were resected. Resected specimens were marked as clinically 
suspect or not clinically suspect and as uorescent or non-uorescent. All 
resected lesions were examined by a pathologist for tumor status. In addition, 
an immunohistochemical (IHC) staining for FRα expression and uorescence 
microscopy (Leica DM5500B uorescence microscope) were performed to 
assess concordance of uorescence with tumor and FRα presence and to 
evaluate binding sites of EC17 (Supplementary Methods, online available). 
To assess the number of malignant lesions that were identied by the naked 
eye and/or uorescence imaging, stills from intraoperative obtained videos 
were analyzed by three dedicated gynecologic oncologists, experienced in 
ovarian cancer surgery. A total of 5 dierent images were analyzed. Each image 
was analyzed 3 times (normal, horizontally and vertically ipped), leading to a 
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total of 15 images to be analyzed. First, only colour images were used to score 
the number of observed metastatic lesions. When this was completed, colour 
images supplemented with uorescence images were scored. 
Surgical procedure in breast cancer
Patients underwent standard of care breast ablation or BCS both combined 
with SLN biopsy. The Artemis uorescence imaging system was used to identify 
uorescent signal during surgery and on resected specimens transferred to 
the pathology department. Intra-operative images of SLNs, the surgical eld, 
resected specimen, and wound bed after resection were obtained. Following 
standard procedure, the resected specimen was dissected at the pathology 
department, where images from the dissected tumor were obtained as well. The 
resected specimens were routinely examined by a pathologist for tumor status. 
In addition, IHC staining for FRα expression and uorescence microscopy (Leica 
DM5500B uorescence microscope) were performed to evaluate binding site 
of EC17 (Supplementary Methods, online available).
Artemis uorescence imaging system
Imaging procedures were performed using the Artemis uorescence imaging 
system (Quest Medical Imaging, The Netherlands). The system consists of 3 
wavelength isolated light sources: a “white” light source, and a two dierent 
“near-infrared” light sources. For this study, the camera and light engine were 
optimized for EC17 to generate 7.5 mW/cm2 at 490 nm light. Color video and 
uorescence images are simultaneously acquired on separate sensors and 
displayed in real time using custom optics and software showing the separate 
the color video and NIR uorescence images. A pseudo-colored (lime green) 
merged image of the color video and uorescence images is also displayed. The 
intensities of the light sources could be controlled from the Artemis software. 
The camera can be attached to a freely moveable arm head. For intraoperative 
use, the camera and freely moveable arm were wrapped in a sterile shield and 
drape (Medical Technique Inc., Tucson, AZ).
Statistical and Image Analysis
SPSS statistical software package (Version 20.0, Chicago, IL) was used. Patient 
characteristics were reported in median, standard deviation (SD), and range. PK 
parameters (AUC, Cmax, tmax) were statistically summarized including number 
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of subjects, mean, standard deviation (SD), median, minimum and maximum. 
Plasma drug concentrations were plotted versus time per individual using both 
a linear and log y-axis. Additionally, concentration versus time curves were 
plotted as a spaghetti plot with the median added. 
Fluorescent signal in tumor and background was quantied using ImageJ 
(version 1.49b; a public domain, Java-based image processing program 
developed at the National Institute of Health). Regions of interest (RoI) were 
drawn with ImageJ on the stored images to quantify uorescent signal in 
arbitrary units [AU]. Tumor to background ratios (TBRs) were calculated by 
dividing the uorescent signal of the tumor by uorescent signal of surrounding 
tissue. To compare TBR and background signal between malignant and benign 
lesions independent samples t-test was used. TBR was reported in mean, SD, 
and range.
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ABSTRACT
Purpose: Completeness of cytoreductive surgery is a key prognostic factor 
for survival in patients with ovarian cancer. The ability to dierentiate clearly 
between malignant and healthy tissue is essential for achieving complete 
cytoreduction. Using current approaches, this dierentiation is often dicult 
and can lead to incomplete tumor removal. Near-infrared uorescence imaging 
has the potential to improve the detection of malignant tissue during surgery, 
signicantly improving outcome. Here, we report the use of OTL38, a near-
infrared (796 nm) uorescent agent that binds folate receptor alpha, that is 
expressed in >90% of epithelial ovarian cancers.
Experimental design: We rst performed a randomized, placebo-controlled 
study in 30 healthy volunteers. Four single increasing doses of OTL38 were 
delivered intravenously. At xed times following drug delivery, tolerability 
and blood/skin pharmacokinetics were assessed. Next, using the results of 
the rst study, three doses were selected and administered to 12 patients who 
had epithelial ovarian cancer and were scheduled for cytoreductive surgery. 
We measured tolerability and blood pharmacokinetics, as well as the ability to 
detect the tumor using intraoperative uorescence imaging.
Results: Intravenous infusion of OTL38 in 30 healthy volunteers yielded an 
optimal dosage range and time window for intraoperative imaging. In 12 
patients with ovarian cancer, OTL38 accumulated in folate receptor alpha-
positive tumors and metastases, enabling the surgeon to resect an additional 
29% of malignant lesions that were not identied previously using inspection 
and/or palpation.
Conclusions: This study demonstrates that performing real-time intraoperative 
near-infrared uorescence imaging using a tumor-specic agent is feasible and 
potentially clinically benecial. 
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INTRODUCTION
The completeness of surgical tumor removal is an important factor for 
determining the survival of patients with a solid tumor. Despite advances in 
preoperative imaging techniques, during surgery the surgical oncologist must 
rely primarily upon inspection and/or palpation to identify the tumor tissue; 
however, these methods are often inadequate1-3. 
Ovarian cancer has the highest mortality rate of all gynecological cancers4. 
The surgical treatment of advanced-stage ovarian cancer (i.e., International 
Federation of Gynecology and Obstetrics stage IIb through stage IV) typically 
consists of cytoreductive surgery combined with systemic chemotherapy. 
Several studies have shown that the amount of residual tumor that remains 
following cytoreductive surgery is the most important prognostic indicator of 
survival5-9. Thus, because imaging modalities that improve tumor identication 
during surgery can increase the number and thoroughness of metastatic 
lesions resected during cytoreductive surgery, they can signicantly improve 
patient outcome. 
Near-infrared (NIR) uorescence imaging is an innovative technique that 
can be used to detect tumor lesions during surgery10. NIR uorescence is 
invisible to the human eye, but can be detected in the millisecond range using 
a dedicated imaging system. Because the imaging system can be toggled 
on and o rapidly, this approach allows the surgeon to identify malignant 
tissue in real time without altering the surgical eld. In addition, NIR light can 
penetrate tissue on the order of centimeters, allowing the surgeon to delineate 
targets underneath the tissue surface11;12. Despite its high potential in clinical 
applications, NIR uorescence in surgical oncology has been used primarily 
with nonspecic agents previously available for clinical use. For example, 
indocyanine green is retained either in or around tumor tissue due to impaired 
secretion or increased vascular permeability and decreased lymphatic drainage; 
however, indocyanine green does not bind specically to cancer tissue13;14. This 
lack of specicity results in a high rate of intraoperative false positive images in 
patients with ovarian cancer15. Thus, uorescent agents that specically target 
cancer-specic targets are highly desired. 
Folate receptor alpha (FRα) is a promising target, as it is robustly expressed 
on a variety of cancers of epithelial origin, including >90% of epithelial ovarian 
cancers16-18. Moreover, FRα is expressed at relatively low levels in healthy tissue, 
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where it is expressed primarily at the apical membrane of polarized epithelial 
cells, including fallopian tube and endometrial tissue16;19;20. Thus, when targeted 
with a uorescent agent, background uorescence will be low in healthy 
tissue, making this protein an ideal candidate target for uorescence-guided 
ovarian cancer surgery. Importantly, because chemotherapy does not aect 
the expression of FRα, this protein can be targeted in both primary and interval 
cytoreductive surgical procedures21;22. 
The potential of using a folate analog coupled to a dye that uoresces 
outside of the NIR spectrum (e.g., folate-FITC) was demonstrated previously in 
a small patient series, yielding a positive uorescence signal in three out of 
four patients with ovarian cancer23. Although this study showed the feasibility 
of detecting uorescently labeled tumor deposits in real time, the approach 
did not allow the surgeon to detect lesions beneath the tissue surface. In 
addition, we found that using folate-FITC in both ovarian cancer and breast 
cancer produces high autouorescence in healthy tissue (data not shown). This 
nding underscores the need for agents that uoresce in the NIR spectrum.
OTL38 is a folate analog conjugated to a NIR uorescent dye (excitation at 
776 nm, emission at 796 nm); OTL38 has high specicity and anity for FRα. 
Here, we rst examined the tolerability, pharmacokinetics, and tissue and 
blood distribution of increasing doses of OTL38 in healthy volunteers. Based 
upon these results, we then determined the optimal dosage range and the 
imaging time window. We then used these parameters in a study in patients 
with epithelial ovarian cancer in order to determine the correlation between 
uorescence detection and histopathology of the resected lesions. We also 
determined whether the detection of tumors using the traditional surgical 
view was improved with the addition of uorescence imaging. 
MATERIALS AND METHODS
Study design
The primary objective of the study in healthy volunteers was to assess the 
tolerability and pharmacokinetics (in plasma and skin) of a single intravenous 
doses of OTL38; in addition, the results were used to determine the optimal 
dosage range and time window for performing intraoperative imaging in the 
subsequent study in patients with ovarian cancer. For the patient study, the 
46151 Quirijn Tummers.indd   158 16-08-17   13:01
Clinical translation of OTL38 in ovarian cancer 159
objectives were to assess the tolerability and pharmacokinetics of OTL38, the 
ecacy with respect to intraoperative detection of ovarian cancer lesions, and 
the practical feasibility of the technique. The results were used to determine 
the optimal dose for intraoperative imaging. Because both studies were 
exploratory in nature, sample size was not based on a formal calculation of 
statistical power. In the rst study, tolerability and pharmacokinetics of a single 
intravenous dose of OTL38 were used as the endpoints. These same endpoints 
were used in the patient study; in addition, we also measured the ecacy of 
OTL38 in the intraoperative detection of ovarian cancer by measuring the 
following endpoints: TBR (tumor-to-background ratio), dened as the ratio 
between the uorescent signal in the tumor tissue and the uorescent signal 
in the tissue surrounding the tumor; concordance between the pathology 
results with respect to the presence of cancer and the imaging assessment; 
the number and location of FRα-positive, cancerous lesions identied the usual 
visual and/or tactile approaches with or without uorescence imaging; and the 
surgeons’ evaluation of the practical application of the technique. Data of all 
subjects participating in the studies was included in the analyses if the data 
could meaningfully contribute to the objectives of the studies.
For the study in healthy volunteers, we included 30 subjects who were 18-
65 years of age and were considered healthy based on medical screening. For 
the patient study, we included twelve patients who had a high suspicion of 
epithelial ovarian cancer or a tissue-based diagnosis of epithelial ovarian cancer 
and were scheduled for primary or interval cytoreductive surgery. The main 
exclusion criteria were current pregnancy, history of anaphylactic reactions, 
impaired renal function (dened as eGFR <50 ml/min/1.73 m2), and impaired 
liver function (dened as ALT, AST, or total bilirubin levels that exceeded 3X the 
established upper limit of normal).
The study in healthy volunteers was a randomized, placebo-controlled 
design in which subjects were randomized to receive a single intravenous dose 
of 0.025, 0.05, 0.1, or 0.2 mg/kg OTL38 or placebo. The randomization code was 
generated by a study-independent statistician using SAS 9.1.3 for Windows 
(SAS Institute Inc., Cary, NC). The randomization code was made available 
for data analysis only after the study was completed. At xed time points 
following administration, blood samples were collected and used to measure 
pharmacokinetics and to perform routine laboratory tests. Adverse events, 
ECG, and vital signs were recorded. The uorescent signal in supercial skin 
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was measured using the Artemis imaging system at xed time points following 
intravenous administration of OTL38 or placebo (Figure 1). After a dose 
cohort was completed, all data collected up to 24 hours following each dose 
were reviewed prior to increasing the dose. In the event of an unacceptable 
tolerability prole (based on the nature, frequency, and intensity of adverse 
events, as judged by the investigator), the dose was not increased. Subjects 
were assigned to a dosing group based on the order in which they enrolled 
in the study. The study was performed in a double-blind fashion; thus, the 
investigator, sta, subjects, sponsor, and monitor were blinded with respect 
to the treatment until the end of the study. The placebo and OTL38 were 
formulated and packaged identically. The randomization list was made available 
only to the pharmacist who prepared the study drug, the individual who was 
responsible for sample bioanalysis, and the statisticians and programmers who 
prepared the blinded summaries, graphs, and listings to support the dosing 
decisions.
The patient study was a single ascending dose, open label exploratory study. 
The patient study was not randomized, and all patients received the active drug. 
Assignment to the dosage groups was based on the order in which the patients 
enrolled in the study. The patients received a one-hour intravenous infusion of 
OTL38 2-3 hours prior to the start of surgery. A dose-escalating scheme with 
planned doses of 0.025, 0.05, and 0.1 mg/kg (and the possibility to decrease the 
dose to 0.0125 mg/kg) was used. Dose escalation was terminated in the event 
of an unacceptable tolerability prole. Tolerability assessment (blood pressure, 
pulse, peripheral oxygen saturation, respiratory rate, ECG, temperature, and 
skin assessments) and blood collection for pharmacokinetics and routine 
laboratory tests were performed at regular intervals starting just prior to 
administration and lasting until 24 hours post-dosing. Adverse events and the 
concomitant use of other medications were recorded. Cytoreductive surgery 
generally included the removal of the uterine adnexa, uterus, and infracolic 
omentum, as well as resection of all macroscopic tumors, where possible. All 
surgical procedures were open procedures performed by an experienced 
gynecological oncologist using a midline abdominal incision. First, the primary 
tumor and metastases were identied in the surgical eld using standard 
visual and tactile methods. Thereafter, the Artemis imaging system was used 
to identify NIR-uorescent lesions. All tumor tissue identied by visual/tactile 
methods and/NIR uorescence was resected, provided it was both surgically 
feasible and clinically useful. Each resected lesion was marked on a case report 
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form as being either uorescent or non-uorescent and as being either clinically 
suspected of malignancy or not (Figure S1, online available). All resected lesions 
were examined for tumor status by an experienced pathologist. A positive 
tumor that was uorescent was considered a true positive; a negative lesion 
that was uorescent was considered a false positive; and a positive tumor that 
was non-uorescent was considered a false negative. In addition, we performed 
immunohistochemistry to demonstrate FRα and FRβ expression coupled with 
uorescence microscopy in order to evaluate OTL38 binding (Supplementary 
Materials and Methods, online available). 
Figure 1. Fluorescence measurements in the skin of healthy volunteers
A. A researcher measuring skin uorescence using the Artemis imaging system. B. Color (left column) 
and uorescence (right column) images of a healthy volunteer at baseline (upper row) and after 
receiving a dose of OTL38 (lower row). Note that a bright uorescent signal is detected after dosing, and 
uorescence intensity can be measured within a region of interest (ROI) (dashed circle). C. Fluorescence 
intensity (measured in arbitrary units) in an ROI over time (in hours). The uorescence signal reached 
peak levels at approximately 2 hours and was stable for up to 6 hours, then decreased over the following 
48 hours.
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Investigational product 
OTL38 (chemical formula: C61H63N9Na4O17S4; molecular weight: 1414.42 Da) 
consists of a folate analog conjugated to an NIR uorescent dye. OTL38 (>96% 
purity) was obtained from On Target Laboratories (West Lafayette, IN). The drug 
was synthesized and manufactured at Aptuit (Harrisonville, MO) in compliance 
with Good Manufacturing Practices (Figure S2, online available). OTL38 was 
stored in frozen form at -20°C in vials containing 6 mg OTL38 free acid in 3 
ml water. Before administration, the frozen vials were thawed, vortexed, and 
then diluted with 0.9% NaCl or 5% dextrose for intravenous infusion. OTL38 
was diluted in either 20 ml or 220 ml and was infused over 10 or 60 minutes. 
Placebo consisted of a similar volume of 0.9% NaCl or 5% dextrose. 
Intraoperative near-infrared uorescence imaging system
Imaging was performed using the Artemis uorescence imaging system 
(Quest Medical Imaging, Middenmeer, the Netherlands)24. The system consists 
of three wavelength-isolated light sources, including a “white” light source and 
two separate near-infrared light sources. For this study, the camera and light 
engine where optimized for use with OTL38; specically, they were designed 
to generate 7.5 mW/cm2 at 760-nm light. Color video and uorescence images 
were acquired simultaneously using separate sensors and were displayed in 
real time using custom-built optics and software, thereby displaying color 
video and NIR uorescence images separately. A pseudo-colored (lime green) 
merged image of the color video and uorescence images was also generated. 
The intensity of the light source was controlled using the Artemis software. The 
camera was attached to a freely moveable arm. During surgery, the camera and 
moveable arm were enclosed in a sterile shield and drape (Medical Technique 
Inc., Tucson, AZ).
Ethics committee approval
Both studies were performed in accordance with the tenets established by 
the Helsinki Declaration of 1975 (as amended in Tokyo, Venice, Hong Kong, 
Somerset West, Edinburgh, Washington, and Seoul), ICH-GCP guidelines, and 
the laws and regulations of the Netherlands. In addition, both studies were 
approved by a certied medical ethics review board. All subjects provided 
written informed consent prior to the start of any study-related procedures. 
The healthy volunteer study and ovarian cancer patient study were registered 
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in the European Clinical Trials Database under numbers 2013-004774-10 
and 2014-002352-12, respectively; publicly accessible via the CCMO register 
(https://www.toetsingonline.nl/to/ccmo_search.nsf/Searchform?OpenForm).
Practical evaluation
Directly following the surgical procedure, the surgeon was asked to complete a 
questionnaire regarding the practical application of the technique during the 
surgical procedure (Supplementary Materials and Methods, online available). 
Visual detection
Color and uorescence images of seven representative surgical views of 
patients with conrmed ovarian cancer were captured from the videos 
recorded using the Artemis imaging system. Intra-observer variability was 
assessed by including a matching color and uorescence image set twice (one 
set was a horizontal mirror image of the original), resulting in a total of eight 
sets of matching color and uorescence images that were printed in full color; 
representative images are shown in Figure 2. Three experienced gynecological 
oncologists were asked to mark clinically suspected lesions directly on the 
color images; they were then asked to mark clinically suspected lesions on the 
matching uorescence images. Visual detection was performed ex vivo because 
intraoperative assessment of the number of lesions was not feasible. 
Pharmacokinetics analysis
The bioanalysis was performed using validated methodologies in compliance 
with good clinical laboratory practices at Analytical Biochemical Laboratory 
(Assen, the Netherlands). In brief, OTL38 was extracted from human K2EDTA 
plasma samples and urine samples using o-line solid-phase extraction, 
followed by analysis using liquid chromatography-mass spectrometry (APL-
4000, Attodyne Inc., Toronto, Ontario, Canada). The assay’s lower limit of 
quantication (LLOQ) and upper limit of quantication (ULOQ) were 2.00 and 
500 ng/ml, respectively. The coecient of variability for intra-day and inter-day 
plasma LLOQ and urine LLOQ was 8.2% and 13.3%, respectively. 
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Figure 2. Visual detection of tumor deposits ex vivo
A. Representative color (upper panel) and uorescence (lower panel) images used to quantify the visual 
detection of tumor deposits. B. Box plot summarizing the number of tumor lesions detected based on 
the matched color and uorescence images.
Statistical analysis
SPSS statistical software package (version 20.0, IBM Corp., Armonk, NY) 
was used for statistical analyses. The individual OTL38 concentration-time 
proles were analyzed using non-compartmental methods. The obtained PK 
parameters (i.e., AUC, Cmax, and tmax) were summarized per treatment group, 
including the number of subjects, mean values, standard deviation (SD), 
median values, and minimum and maximum values. The uorescence signal 
in the skin (healthy volunteers) or tumor and background tissue (patients) 
was quantied using ImageJ (version 1.49b, National Institutes of Health, 
Bethesda, MD; http://imagej.nih.gov/ij/). Using ImageJ, a region of interest 
(ROI) was drawn on the images and used to quantify the uorescence signal 
in arbitrary units (AU). TBR was calculated by dividing the uorescence signal 
of the tumor by the uorescence signal of the surrounding tissue. To compare 
the TBR values and uorescence background signals between malignant and 
benign (i.e., false positive) lesions and between dierent dose groups, an 
independent samples Student’s t-test was performed. TBR is reported as the 
mean, SD, and range. Patient characteristics are reported as the median, SD, 
and range. Tumor deposits that were marked on the color and uorescence 
images were counted. To compare the number of deposits between the color 
and uorescence images, a paired Student’s t-test was performed.
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RESULTS
Clinical trial in healthy volunteers 
This study included a total of 30 subjects (18 females and 12 males), 18-64 years 
of age with a BMI of 18-30 kg/m2 (see Fig. S3 for the CONSORT ow diagram, 
online available).
Tolerability 
OTL38 at 0.025mg/kg diluted in 20 ml 0.9% NaCl infused for 10 or 60 minutes 
caused moderate hypersensitivity in two out of the four subjects receiving 
this dose. These reactions were not classic allergic reactions, as they were 
not accompanied by an increase in tryptase or IgE, nor did they involve the 
complement system (see Data File S1, online available). Subsequent studies 
using dynamic light scattering and scanning electron microscopy revealed that 
these reactions may have been due to aggregation of the OTL38 compound 
in the 0.9% NaCl solution. This aggregation was reduced considerably when 
OTL38 was diluted in 5% dextrose and when the infusion volume was increased. 
Because OTL38 did not aggregate measurably when diluted to 7.5 μM in 5% 
dextrose, the study was restarted at the lowest dose with OTL38 dissolved in 
220 ml 5% dextrose; this volume was infused for a period of 60 minutes.
Infusion of 0.025, 0.05, and 0.1 mg/kg OTL38 diluted in 5% dextrose was 
associated with mild adverse events that disappeared gradually during and/or 
after the infusion. These adverse events were dose-dependent and suggestive 
of hypersensitivity (e.g., abdominal discomfort, nausea, and pruritus), but 
did not require intervention. All adverse events are listed in Table S1 (online 
available). At the 0.2 mg/kg dose, some subjects developed adverse events of 
moderate severity, which required the temporary interruption of the infusion or 
the administration of an antihistamine (e.g., 1-2 mg clemastine intravenously). 
Overall, more than 80% of these adverse events were mild in severity, and all 
other adverse events were moderate in severity. Despite the development 
of adverse events, the infusion of OTL38 at 0.025-0.2 mg/kg did not cause 
clinically meaningful changes relative to baseline with respect to laboratory 
values, ECG, or vital signs.
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Pharmacokinetics 
The maximum blood plasma concentration was achieved with each dose 
immediately at the end of the infusion and declined thereafter with a half-
life of 2-3 hours (Figure S4, online available). Table S2 summarizes the most 
important pharmacokinetics (PK) parameters in each treatment group (online 
available) OTL38 excreted in the urine (expressed as a percentage of the dose 
administered) increased with increasing dose, and the highest level was 
approximately 11% for the highest dose (0.2 mg/kg). It is therefore reasonable 
to assume that the relatively low recovery is due in part to the lower limit of 
detection for OTL38 in urine.
Pharmacokinetics in supercial tissue 
Figure 1 shows example images obtained using the Artemis imaging system. 
Although OTL38 was cleared from the plasma 2-3 hours after intravenous 
infusion, our analysis of the uorescence signal in the skin revealed that 
uorescence increased initially, remained increased for six hours, and then 
decreased with a half-life of approximately 15 hours (Figure 1). 
Clinical trial in patients with ovarian cancer 
Fourteen patients initially enrolled in this study. However, because the study 
drug was temporary unavailable, one patient could not participate, another 
patient withdrew from the study. Thus, a total of 12 patients, 49 to 77 years of age 
with a BMI of 20-41 kg/m2 received OTL38 (see Figure S5 for the CONSORT ow 
diagram, online available). The surgical procedure, histology, dierentiation 
grade, and International Federation of Gynecology and Obstetrics (FIGO) 
stages are summarized in Table 1.
Dose escalation
Patients 1, 2, and 3 received a starting dose of 0.025 mg/kg. After we reviewed 
the safety and ecacy data, the dose was increased to 0.05 mg/kg in the next 
three patients. However, when the 3 patients 4, 5, and 6 received this higher 
dose, the number and severity of symptoms (primarily consisting of abdominal 
discomfort, nausea, and pruritus) increased. In addition, TBR appeared to 
decrease. Therefore, the dose was decreased to 0.0125 mg/kg for the next three 
patients (patients 7, 8, and 9), yielding fewer, less severe symptoms, as well as 
an increase in TBR. Nevertheless, even at this lowest dose, mild, self-limiting
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adverse events were reported. After reviewing the safety and ecacy data 
collected using all three doses, 0.0125 mg/kg was chosen as the optimal dose 
for the expansion cohort (patients 10, 11, and 12). In retrospect, this lower dose 
was a good choice, as adverse symptoms were minimal and TBR was maximal. 
Table S3 and Figure S6 summarize the TBR results (online available).
Other adverse events 
One patient who received a dose of 0.0125 mg/kg OTL38 developed a case 
of post-operative hospital-acquired pneumonia and coughing-induced 
wound dehiscence. These complications were considered unrelated to OTL38 
administration. The complete list of all adverse events recorded in the patients 
is provided in Table S4 (online available). Administration of OTL38 itself did 
not lead to any obvious changes in laboratory values, ECG, vital signs, or 
temperature.
Pharmacokinetics
The PK prole of OTL38 in patient blood was similar to the prole measured in 
the healthy volunteers. Specically, with each dose, the maximum concentration 
was achieved at the end of the infusion. After stopping the infusion, plasma 
concentration decreased with a half-life of 2-3 hours (Figure S4). 
Intraoperative near-infrared uorescence imaging
Lesions could be detected clearly after OTL38 administration. The optimal 
camera exposure time was dependent on OTL38 dose, with lower doses 
requiring longer exposure times. At higher doses, the longer exposure time led 
to saturated images; however, in all cases it was possible to use a suciently 
brief exposure time in order to obtain real-time images. 
Figure 3 shows an example of uorescent lesions that were subsequently 
conrmed as ovarian cancer metastases on histopathology. A total of 83 
uorescent lesions were resected during the surgeries; 62 of these lesions 
were conrmed as malignant on histopathology (i.e., true positives). Strikingly, 
18 (29%) of these true positive lesions were not detected using standard 
inspection and/or palpation methods. Mean TBR was 4.4 (SD: 1.46, range: 1.7-
9.8), and TBR generally decreased with increasing doses, likely due to increased 
background signal. TBR was constant throughout the surgical procedure, and 
uorescence could be detected for at least six hours after infusion. Importantly, 
using NIR uorescence enabled us to detect malignant lesions up to 8 mm 
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below the tissue surface, showing the added value of using light in the NIR 
spectrum (Movie S1, online available). 
Figure 3. Intraoperative detection of ovarian cancer metastases using uorescence-based imaging
A-B. Color (left column), uorescence (middle column), and merged (right column) images of 
retroperitoneal lymph nodes containing metastases of ovarian cancer (A) and supercial peritoneal 
metastases of ovarian cancer (B).
Histopathology of resected lesions
No malignant disease was found in 21 of the 83 uorescent lesions, corresponding 
to a false positive rate of 23%. These false positive lesions were observed 
primarily in lymph nodes, representing 52% of all false positive lesions (Table 
S5, online available). Additional staining experiments and a closer examination 
of these lymph nodes revealed that activated macrophages, accumulated in 
the sinuses of the lymph node, express folate receptor beta (FRβ), which is also 
a binding target for OTL38. Our immunouorescence experiments revealed 
that the uorescence signal co-localized with FRβ staining (Figure 4). 
Other false positive results arose due to the expression of FRα on the apical 
membrane of non-cancerous epithelial cells in the uterus and fallopian tubes, 
which are routinely resected during cytoreductive surgery. The mean TBR of 
the false positive lesions was 5.4 (SD: 2.0, range: 1.8-9.3), which did not dier 
suciently from true positive lesions (mean: 4.4, range: 1.7-9.8) to allow us to 
dierentiate between false positive and true positive lesions based solely on TBR. 
We observed only two false negative lesions. Finally, uorescence microscopy 
revealed the accumulation of OTL38 in the membrane and cytoplasm of FRα-
expressing tumor cells (for representative images, see Figure 5).
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Figure 4. Histopathological evaluation and uorescence signal of a false positive lymph node
The images show a uorescent lymph node (bottom right panel) that did not contain ovarian cancer 
metastases on hematoxylin and eosin (H&E) staining (upper left panel) and was negative for FRα 
immuno staining (upper right panel). Immunostaining for FRβ showed positive staining in the sinuses, 
but not in the follicles (lower left panel). The magnied image at the right shows that the uorescence 
pattern was localized to the sinuses, consistent with FRβ staining. 
Figure 5. Histopathological evaluation and uorescence signal in ovarian cancer
Representative samples from two dierent patients. Fluorescence microscopy (left column) shows clear 
membranous and cytoplasmic accumulation of OTL38 in tumor cells. The uorescence signal is indicated 
in green, and the nuclei were counterstained with DAPI (blue). The uorescence pattern is consistent 
with FRα expression measured using immunohistochemistry (middle column), which corresponds to 
the anatomical site containing a serous ovarian adenocarcinoma metastasis visible on hematoxylin and 
eosin (H&E) staining (right column, dashed outline).
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Visual detection
The examination of tumor deposits based on color images obtained from the 
intraoperative videos allowed us to identify an average of 8.3 (SD: 5.4, range: 
1-18) lesions per image. In contrast, performing the same assessment using 
the matching NIR uorescence images allowed us to identify an average of 
17.6 (SD: 10.8, range: 5-45) lesions per image, reecting a more than two-fold 
improvement in our ability to detect tumor lesions (Figure 2). 
Practical evaluation
The use of uorescence imaging did not interfere with the surgeon’s ability 
to perform cytoreductive surgery, and the majority of participating surgeons 
reported that they found the technique to be useful (Supplementary Materials 
and Methods).
DISCUSSION
Here, we report the successful use of the rst tumor-specic NIR uorescence-
based imaging agent to target FRα in ovarian cancer, signicantly increasing 
removal of tumor lesions. 
In healthy volunteers, OTL38 caused moderate hypersensitivity; however, 
these reactions were easily managed. Given their symptomology, these 
reactions were likely pseudoallergic, a nding that has been described 
previously by Szebeni with respect to radiocontrast media25. Moreover, 
investigating the cause of this hypersensitivity led to the development of 
procedures designed to minimize or eliminate this reaction in our subsequent 
study with cancer patients. This was likely related to aggregation of OTL38 
rather than a classic allergic response to the drug, suggesting that the severity 
may be reduced further by modifying the drug’s formulation. Regardless, even 
these reactions were not severe enough to preclude the administration of a 
single dose of OTL38. 
In healthy volunteers, the agent was essentially cleared from the plasma 
within 2-3 hours of intravenous delivery; however, a stable signal remained 
visible in the skin for at least six hours after dosing. This information was 
extremely valuable for determining the optimal time window for intraoperative 
imaging in patients, in which a favorable TBR was required during the surgical 
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procedure. Our assessment of TBR at all doses revealed that the TBR of 
uorescent lesions was maintained throughout the surgical procedure (i.e., 2-6 
hours after dosing). However, because the uorescent lesions were resected 
during surgery, we were unable to track the TBR of individual lesions over time. 
A suciently high TBR is needed in order to optimally detect the tumor; 
in our study, a TBR of approximately 4.4 allowed the clear detection of tumor 
deposits. Higher doses (non-quenched) of OTL38 may translate into higher 
TBR, assuming linear binding of the agent to the tumor and background 
tissue. However, because the tumor contains a xed number of receptors, it 
is conceivable that even with a low dose, the majority of FRα molecules in 
the tumor tissue will be bound by the agent. Therefore, higher doses will not 
necessarily increase the tumor-specic signal but might lead to increased 
nonsaturable, nonspecic background binding, resulting in a less favorable 
TBR at higher doses. Indeed, the highest dose used in this study (0.05 mg/kg) 
resulted in a high background signal and lower TBR value, whereas the lowest 
dose tested (0.0125 mg/kg) yielded the highest TBR and—most importantly—
the mildest symptoms. To obtain the best imaging results, the exposure times 
diered between the dierent dosing groups; thus, the lowest dose (0.0125 
mg/kg) required the longest exposure time (75 ms). Nevertheless, even this 
relatively longer exposure time enabled us to perform real-time imaging.
When translated to our patient cohort, the optimal dose of OTL38 (i.e., 
0.0125 mg/kg) enabled the surgeons to successful identify malignant lesions 
with reasonably high sensitivity and specicity. Moreover, 29% of all resected 
malignant lesions would have gone undetected without the aid of uorescence-
based imaging. Unfortunately, the relatively low number of patients precluded 
our ability to calculate the specicity and sensitivity of the technique. Moreover, 
our inability to study true negatives precluded a clear assessment of specicity. 
Nevertheless, both the in situ and ex vivo visual detection of lesions were 
clearly improved by the use of uorescence-based imaging. With respect to 
in situ detection, 29% more lesions were resected. However, even this increase 
may underestimate the total number of lesions that could be detected during 
surgery, as resection is dependent upon several factors other than detection. 
Lastly, our ex vivo visual detection was performed using still images, as it was not 
feasible to count lesions during surgery. Although this approach is commonly 
used and yields useful information, it may be considered suboptimal, as three-
dimensional and tactile information is lost.
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Although epithelial ovarian cancer cells overexpress FRα, this receptor is 
also expressed—albeit it to a lesser extent—at the apical membrane of various 
non-cancerous epithelial cells. During surgery, we noted mild, homogenous 
uorescence of the uterus and the fallopian tubes, and biopsy revealed FRα 
expression in these non-malignant tissues, consistent with previous reports17;26. 
The uorescence signal in these tissues was homogenous and was clearly 
distinguishable from the uorescence measured in the tumor deposits. 
In the majority of our patients, we detected brightly uorescent lymph 
nodes, and only a small number of these lymph nodes actually contained 
ovarian cancer metastases. The uorescence measured in the non-cancerous 
lymph nodes was likely due to OTL38 binding to activated macrophages, 
which express FRβ27-30. On the other hand, the formation of OTL38 aggregates 
and nonspecic uptake by lymph nodes is unlikely, as dissolving the agent at 
7.5 µM in 5% dextrose did not lead to the formation of measurable aggregates. 
Indeed, given that only three of the 12 patients received the highest dose (0.05 
mg/kg), corresponding to a molarity slightly higher than 7.5 µM (9.5-11.8 µM 
OTL38), the presence of aggregates in the infusion solution is highly unlikely. 
In addition, to further minimize the likelihood of aggregate formation in the 
circulation, the solution was infused for 60 minutes. Although this apparent 
false positive uorescence in the lymph nodes could be considered a drawback 
of this imaging agent, activated macrophages may actually be tumor-
associated macrophages that play a role in preparing the tumor environment 
for metastasis31-33. This notion is supported by our nding that FRβ-expressing 
macrophages were also found in primary tumors as well as in lymph nodes 
that did contain metastasized tumor cells (Figure S7, online available). Until the 
precise role of FRβ-expressing macrophages in the lymph nodes is determined, 
lymph nodes should be resected solely on the basis of standard clinical 
assessments. 
The use of uorescent light in the near-infrared spectrum allowed us 
to detect lesions beneath the tissue surface, which is a major improvement 
over agents that use light outside the NIR spectrum23;34;35. For example, in our 
study malignant lesions were visible up to ~1 cm below the tissue surface. In 
addition, most biological tissues have extremely low autouorescence when 
excited by light in the NIR spectrum36;37. OTL38 also has several advantageous 
pharmacokinetic properties, including long residence time in the tumor and 
relatively rapid clearance from plasma; these properties provide the surgeon 
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with a long window of time in which the tumor lesions can be detected. Unlike 
uorescent antibodies—which have a much longer terminal half-life—OTL38 
can be administered shortly before surgery 38. 
Although more tumor deposits can be visualized and resected using 
intraoperative uorescence imaging with OTL38 compared to conventional 
methods, more prospective research is necessary to establish the eect on 
overall survival. In addition, the diagnostic accuracy of uorescence imaging 
with OTL38 should be further assessed in a larger patient group. 
In conclusion, we provide the rst evidence that a specic intraoperative 
NIR imaging agent can be used to increase the ecacy of tumor removal in 
patients with ovarian cancer. Our approach to clinical translation using both 
healthy subjects and patients in the same Phase I protocol allowed us to rapidly 
determine the optimal dose, formulation, and time window for intraoperative 
imaging, thereby greatly increasing the level of cytoreduction achieved in 
patients with ovarian cancer.
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SUMMARY
The quality of cancer surgery can be improved by assisting the surgeon with 
better and more objective, real time visual information during the procedure. 
Fluorescence-guided surgery can play a pivotal role in the intraoperative 
detection of tumor tissue, lymph nodes and vital structures. 
This thesis focuses on a number of important indications in cancer surgery 
where clinically available near-infrared (NIR) uorescence contrast agents can 
be used to improve surgical practice (Part 1) and the clinical translation (rst in 
human study) of newly developed tumor-specic uorescent contrast agents 
to improve the real time detection of tumor tissue (Part 2).
Part 1:  Exploring clinical available uorescent contrast agents in cancer 
surgery
In chapter 2, the detection of sentinel lymph nodes in gastric cancer is 
demonstrated. The lymph drainage pattern in gastric cancer is dicult to 
predict. Therefore, a total or partial gastrectomy is often combined with 
extensive lymphadenectomy. In the present study, indocyanine green (ICG) was 
adsorbed to nanocolloid to increase its hydrodynamic diameter and to improve 
retention in rst draining lymph nodes. Subsequently, the ICG-Nanocolloid 
complex was then subserosally injected around the tumor, followed by 
detection of lymphatic vessels and lymph nodes. In 21 of 22 patients, at least 1 
sentinel lymph node was identied using this technique. Interestingly, in 8 of 
the 21 patients, SLNs outside the standard plane of resection were identied, 
and tumor involvement was found in 2 of these nodes (in two patients).
Chapter 3 focused on the intraoperative detection of breast cancer using 
methylene blue (MB). Although the exact mechanism is not exactly clear, 
we hypothesized that breast cancer could be visualized using MB, based on 
physicochemical similarities of MB and 99mTc-MIBI. 99mTc-MIBI is a SPECT 
radiodiagnostic agent with a sensitivity of 83 - 90% to detect breast cancer 
preoperatively. In 20 out of 24 patients, we successfully identied breast cancer 
lesions in the resection specimen. And in 2 patients breast cancer tissue was 
identied in the wound bed using uorescence imaging. Although MB is a 
promising agent for breast cancer detection, tumor-ligand specic contrast agents 
could further improve the accuracy of intra-operative breast cancer imaging.
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Chapter 4 described the identication of hepatic metastases from uveal 
melanoma during laparoscopic liver surgery. ICG was administered 24 hours 
before surgery. The dye gets excreted by healthy liver into bile, but is trapped 
in the transition zone between healthy liver and metastatic lesions. At the day 
of surgery, a clear uorescent rim around the tumor was seen. Even lesions not 
detected by pre-operative CT-scan, intraoperative inspection or laparoscopic 
ultrasound were identied. Therefore, NIR uorescence imaging during 
laparoscopic liver surgery is a minimal invasive way to determine whether 
patients could potentially benet from a metastasectomy. Moreover, it might 
help to obtain clear resection margins.
In chapter 5, ICG was administered to patients suering from a pituitary 
gland adenoma. We hypothesized that ICG could improve distinction between 
normal and abnormal pituitary gland tissue during transnasal transsphenoidal 
selective adenomectomy, based on dierences in tissue vascularization. In nine 
out of 10 patients with a histologically proven pituitary adenoma, the normal 
pituitary gland showed a stronger uorescent signal than the adenoma. In two 
patients, adenoma resection actually took place under direct NIR uorescence 
guidance. The available endoscopic imaging system didn’t allow simultaneous 
imaging of color video and uorescence, which limited the additional value 
of uorescence imaging. Introduction of ligand-specic contrast agents 
and improved imaging systems could further improve uorescence-guided 
pituitary gland surgery.
Chapter 6 described a clinical case in which MB was used to identify a 
paraganglioma, a rare neuro-endocrine tumor. It even allowed the detection 
of a local metastasis, which was not detected by preoperative imaging and 
intraoperative inspection. 
Based on the principle of comparable biodistribution of MB and the 99mTc-
MIBI tracer, chapter 7 elaborated on the intraoperative uorescence guidance 
during parathyroid surgery. MB allowed not only identication of parathyroid 
adenomas, but also identied normal parathyroid glands that were otherwise 
not detectable. Although promising results with newly developed structure 
inherent contrast agents are reported, MB can play a vital role in parathyroid 
surgery until newer probes enter the clinic. 
In chapter 8, the enhanced permeability and retention (EPR) eect in ovarian 
cancer was explored. This eect is based on the fact that macromolecules, such 
as protein bound ICG, accumulate in tumor tissue due to increased vascular 
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permeability and reduced drainage. In the current study, several malignant 
lesions were identied using uorescence imaging. However, also 13 non-
malignant lesions were uorescent, resulting in a false-positive ratio of 62%. 
This lack of specicity of the EPR eect shows that it is not suitable for daily 
clinical practice. A more tumor-specic accumulation prole or ligand-binding 
mechanism could overcome this limitation.
Part 2:  Clinical translation of innovative tumor-specic uorescent contrast 
agents
Chapter 9 described the use of EC17, a folate analogue coupled to uorescein, 
for the identication of folate receptor alpha (FRα) positive ovarian and breast 
cancer. Intravenous administration of EC17, 2-3 hours before surgery, resulted 
in clear, bright uorescent metastatic lesions of ovarian cancer. It resulted in 
an increased resection of 16% more malignant lesions, and a 70% increase in 
detection of metastatic lesions on post-operative analyzed images. In breast 
cancer, the overexpression of FRα is lower than in ovarian cancer. Therefore, 
preoperative obtained biopsies were stained for receptor expression. This 
personalized approach guarantees that only patients that can potentially 
benet from uorescence-guided surgery are included in trials using a 
tumor-specic contrast agent. Also in breast cancer, a clear uorescent signal 
was seen in the tumor. Notwithstanding, autouorescence signal of healthy 
tissue at 500nm caused false-positive lesions in breast cancer. In addition, 
this autouorescence made it dicult to discriminate breast cancer-specic 
uorescence from background uorescence. Imaging in the NIR uorescence 
light spectrum could solve this problem.
In chapter 10, we used a newly developed FRα specic contrast agent. 
This agent, OTL38, consists of a folate analogue coupled to a NIR uorescent 
contrast agent (uorescent at 800nm). First, tolerability and pharmacokinetics 
in blood and skin were assessed in a randomized, placebo-controlled, dose-
ascending trial in healthy subjects. Hereafter three intravenous doses, selected 
based on the results from the healthy subject study, were administered to 
12 patients with epithelial ovarian cancer, and scheduled for cytoreductive 
surgery. Clear accumulation of OTL38 in FRα positive tumors and metastases 
was seen, leading to the resection of 29% additional malignant lesions that 
were not identied by inspection and palpation. Almost no background 
uorescence was seen.
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GENERAL CONCLUSION
Intraoperative NIR uorescence imaging using ICG and MB was explored in 
multiple important indications in cancer surgery. Imaging using ICG resulted in 
accurate tumor imaging of liver metastases and SLN detection in gastric cancer, 
with high TBRs and a prolonged uorescent signal. For these indications, 
our data suggests that uorescence imaging should be implemented in the 
clinic to improve patient care. MB allowed successful imaging of parathyroid 
adenomas, neuro-endocrine tumors and breast cancer lesions, but accuracy 
and imaging characteristics can probably be improved by the introduction of 
more tumor-specic contrast agents. However, in the meantime MB can be 
used for intraoperative guidance in for instance dicult cases. 
Intraoperative imaging of ovarian cancer using the FRα specic EC17 
and OTL38 showed highly specic and accurate tumor imaging with a high 
TBR and prolonged uorescent signal in malignant lesions. Administration of 
these low molecular weight contrast agents resulted in rapid accumulation 
in tumor tissue and fast clearance from the rest of the body. Moreover, with 
the NIR uorescent contrast agent OTL38 almost no background signal or 
autouorescence was seen. Clinical translation using both healthy subjects and 
patients allowed a rapid determination of the optimal dose, formulation, and 
time window for intraoperative imaging, facilitating a fast clinical introduction 
of newly developed contrast agents in clinical trials. 
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FUTURE PERSPECTIVES
Over the past years several indications are identied to use clinical available 
contrast agents for image-guided surgery. ICG and MB have the potential to 
improve cancer surgery by identifying more malignant lesions, speed up time 
of surgery, and avoid iatrogenic injury due to better identication of vital 
structures. Although the number of indications is limited due to the intrinsic 
characteristics of these contrast agents, uorescence-guided surgery can 
directly be implemented in daily clinical care in for example liver surgery, SLN 
imaging and expected dicult bile duct surgeries. Until newly developed 
ligand-binding, tumor-specic contrast agents have been developed and 
introduced in the clinic, tumor identication can be improved in for example 
breast cancer surgery, parathyroid surgery and paraganglioma surgery, as 
discussed in this thesis.
The introduction of ligand-binding, tumor-specic contrast agents have 
opened new possibilities for more accurate intraoperative tumor imaging. 
As long as appropriate tumor or tissue specic ligands will be discovered, it 
will be possible to identify almost any structure a surgeon wants to identify 
during surgery. As shown in our studies, investigating EC17 and OTL38, both 
folate analogues coupled to uorescent contrast agents resulted in highly 
specic tumor imaging, within 2-3 hours after administration. Moreover, the 
uorescent signal and TBR remained excellent for up to at least 6 hours.
Contrast agents
To achieve accurate tumor detection, it is important to optimize binding 
capacity, biodistribution and pharmacokinetics of a contrast agent. Multiple 
compounds as monoclonal antibodies, antibody fragments, such as single-
chain antibody fragments and small peptides are therefore being investigated1-5. 
These dierent compounds all have their own pharmacokinetic proles, 
and thereby dierent intervals for imaging based on the half-life of the 
agent. Rosenthal et al.5 reported the imaging of head and neck cancer using 
cetuximab-IRDye800. Surgery was scheduled 3 days after administration of 
the compound because of the pharmacokinetic prole of this monoclonal 
antibody based contrast agent (half life 24 – 32 hours; molecular weight 150 
kDa)6. Moreover, relatively high dosages were needed to achieve sucient 
TBRs (up to 25% of therapeutic dose; 62,5 mg/m2). 
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Administration of the folate analogue OTL38 (half life 2-3 hours; molecular 
weight 1.4 kDa) showed a high uorescent signal in malignant lesions after 
only 2-3 hours, which prolonged for at least 6 hours (optimal dose 0.0125 
mg/kg). Due to the fast clearance of the agent, low background signals were 
observed. It seems that these properties are ideal for accurate tumor imaging. 
Future studies will show which compounds are favorable, and this may even 
dier for dierent surgical indications. 
One would ideally develop one contrast agent that targets almost all solid 
tumors. It remains however challenging to develop a contrast agent that is 
highly specic for cancer tissue, while gets excreted from the rest of the body. 
Receptor expression proles in tumors can thereby dier. In ovarian cancer for 
example, over 90% of patients are positive for the FRα, and almost all patients 
are likely to benet from treatment with an FRα specic contrast agent. In 
cancers where expression proles are more divers, other strategies must be 
applied. Preoperative obtained biopsies could be used to explore the receptor 
expression prole of a specic tumor, introducing personalized medicine for 
precision surgery. This was for example done for the breast cancer patients in 
our EC17 study. Besides, cocktails with multiple ligand-binding agents can be 
administered based on biomarker proles, or so-called multi-headed tumor-
specic contrast agents can be developed. These are compounds that have 
multiple ligands bound to one uorophore to enlarge the number of receptors 
that can be bound. A very important hurdle for the design of these agents is that 
all changes to such molecules can inuence binding capacity and uorescent 
properties.  
One of the main limitations of uorescence imaging is related to tissue 
penetration. In the visible light spectrum this is in the order of micrometers, 
improving to approximately 10 mm in the NIR spectrum. To overcome this 
limitation, contrast agents that combine uorescence imaging with other 
diagnostic imaging modalities are being developed (multimodal imaging, 
combined optical positron emission tomography (PET) or single-photon 
emission computed tomography (SPECT) agents)7. These types of agents allow 
pre-operative surgical planning, intraoperative guidance towards deeper 
located targets and real-time visual discrimination of tumors from healthy 
tissue. In literature, combinations with photoacoustic imaging, magnetic 
resonance imaging, PET, SPECT and even triple-modal imaging are described8. 
However, most of these agents are still in a pre-clinical phase of development.
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Imaging systems
Successful uorescence-guided surgery depends on the combination of both 
contrast agents and imaging systems. Therefore, the development of imaging 
systems is crucial for the wide acceptance of uorescence-guided surgery. 
Over the last years, multiple companies and institutes have launched imaging 
systems, all with their pros and cons9. Especially in endoscopic imaging there is 
much to gain, as suggested in chapter 4 and 5 of this thesis. Moreover, a more 
standardized approach to compare systems could assist in the development of 
new improved systems10.
Clinical implementation
To provide guidance in the clinical implementation of image-guided surgery, 
cooperation is necessary, and international society’s, like the International 
Society of Image Guided Surgery, are formed to discuss regulatory pathways 
and clinical trial design11;12. Endpoints in phase 1 studies should focus not only 
on safety, but also on imaging endpoints. 
There is a promising role for the development of pharmacokinetic and 
pharmacodynamic models13-15. These models could give more insight in all the 
dierent variables that play a role in the mechanism of action in tumor imaging. 
Information on compound size, half-life, clearance, receptor density, tumor 
volume, binding constant, protein binding and so on could be combined in a 
model. Even imaging characteristics as quantum yield and wavelength can be 
added. This could potentially predict safety and imaging outcomes of newly 
designed compounds and could provide information on the optimal dose of a 
drug. The information obtained from these models could lead to exposure of 
less healthy subject and patients in rst in human studies. It could even predict 
which imaging system performs best for a specic indication with a specic 
compound. This would make phase 1 studies more ecient, and lower the 
hurdle for promising compounds to enter the clinic. 
New clinical indications
Cancer treatment requires a multidisciplinary approach where surgery, systemic 
chemotherapy or immunotherapy and radiotherapy all play a signicant 
role16;17. Recent developments in neoadjuvant chemo-radiation therapy have 
resulted in an increase in the number of complete pathological response in 
for example rectal and oesophageal cancer18-20. These patients won’t benet 
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from a surgical resection, while no vital tumor tissue is present at pathological 
examination. On the contrary, these surgical resections are associated with 
morbidity and mortality, and safely avoiding such procedures would have a 
major impact on quality of life. This has resulted in a paradigm swift toward 
omitting surgery in patients with a complete clinical response and facilitating 
organ-preservation. Hereby it’s essential to select patients with a complete 
clinical response after neoadjuvant therapy and to monitor them. There are 
several studies reporting on this “Watch and Wait” policy in rectal cancer21, and 
an international database was recently established to monitor the results of 
this strategy22. Molecular imaging could have major impact on the selection 
and monitoring of a patient, because it could give more precise and objective 
information on the presence of vital tumor tissue in for example the scar tissue 
after chemo-radiation therapy. 
CONCLUSIONS 
Fluorescence-guided surgery has shown its potential in visualizing tumor 
tissue and increasing the number of detected malignant lesions that are 
otherwise undetectable. Besides, it assists in the identication of lymph nodes 
and vitals structures. Further studies, preferably randomized controlled trials, 
should validate whether improved tumor detection results in better patient 
outcomes by means of improved survival and reduced morbidity. Combined 
eorts in the rapidly expanding eld of uorescence-guided surgery hopefully 
leads to clinical implementation and determining its place in standard of care 
treatment of cancer patients in the near future. 
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Wanneer de chirurg tijdens het opereren wordt voorzien van betere en meer 
objectieve visuele informatie, kan dit de kwaliteit van de oncologische chirurgie 
verbeteren. Fluorescentie-geleide chirurgie kan hierbij een belangrijke rol 
spelen, doordat het tijdens operaties tumor weefsel, lymfklieren en vitale 
structuren kan identiceren.
Dit proefschrift bespreekt een aantal belangrijke indicaties binnen de 
oncologie chirurgie, waarbij klinisch beschikbare nabij-infrarode (NIR) 
uorescente contrastmiddelen gebruikt kunnen worden om operaties te 
optimaliseren (Deel 1). Daarnaast wordt de klinische translatie besproken van 
nieuw ontwikkelde tumor-specieke, uorescente contrastmiddelen, die de 
intra-operatieve tumordetectie verbeteren (Deel 2).
Deel 1:   Toepassingen van klinisch beschikbare uorescente 
contrastmiddelen in de oncologische chirurgie
Hoofdstuk 2 beschrijft de detectie van de schildwachtklier tijdens maagkanker 
operaties. Het lymfe drainage patroon bij maagkanker laat zich lastig voorspellen. 
Daarom wordt naast een totale of partiële gastrectomie vaak een uitgebreide 
lymfadenectomie uitgevoerd. In onze studie werd indocyanine groen (ICG) 
gekoppeld aan een nanocolloid. Hierdoor wordt de hydrodynamische diameter 
vergroot, en verbetert de opname in de schildwachtklier. ICG-Nanocoll werd 
vervolgens subserosaal geïnjecteerd rond de tumor, waarna beeldvorming 
van lymfvaten en –klieren plaatsvond. In 21 van de 22 patiënten werd op zijn 
minst één schildwachtklier gevonden. Daarbij viel het op dat in 8 van de 21 
patiënten schildwachtklieren buiten het geplande resectievlak gevonden 
werden, waarvan er bij twee patiënten tumorcellen bevatten.
In hoofdstuk 3 wordt de intra-operatieve beeldvorming van borstkanker 
met behulp van methyleen blauw (MB) beschreven. Alhoewel het exacte 
mechanisme van accumulatie van MB niet geheel duidelijk is, werd op basis 
van preklinisch onderzoek de hypothese gevormd dat het met behulp van 
MB mogelijk zou kunnen zijn om borstkanker te identiceren. Methyleen 
blauw heeft dezelfde fysisch-chemische eigenschappen als 99mTc-MIBI, een 
SPECT radiodiagnosticum dat met een sensitiviteit van 83 - 90% borstkanker 
kan identiceren in preoperatieve setting. In onze studie werd bij 20 van de 
24 patiënten met succes de borstkanker laesie geïdenticeerd in het resectie 
preparaat. Daarbij werd bij 2 patiënten uorescent borstkanker weefsel in het 
46151 Quirijn Tummers.indd   197 16-08-17   13:01
Appendices198
wondbed gezien. En hoewel MB een veelbelovend middel is om borstkanker 
zichtbaar te maken, kan de introductie van nieuwe stoen die speciek aan 
een bepaalde tumorreceptor binden de intra-operatieve beeldvorming van 
borstkanker nog nauwkeuriger maken.
In hoofdstuk 4 wordt de identicatie van levermetastasen van 
oogmelanoom tijdens laparoscopische leverchirurgie beschreven. Door ICG 
24 uur voor operatie toe te dienen, vormt zich een uorescente ring rondom 
een maligne laesie. Dit komt doordat ICG uitgescheiden wordt door gezonde 
levercellen, maar gevangen raakt in de overgangszone tussen gezonde lever en 
metastase. Zelfs afwijkingen die onzichtbaar waren voor het menselijk oog, en 
die niet gevonden werden met preoperatieve CT of intra-operatieve echograe 
konden worden geïdenticeerd. Op deze manier maakte uorescente 
beeldvorming het mogelijk om op een minimaal-invasieve manier patiënten 
te identiceren, die potentieel baat hebben bij een resectie, en hielp het bij het 
verkrijgen van tumorvrije resectie marges.
Hoofdstuk 5 beschrijft de studie waarbij ICG werd gebruikt om hypofyse 
adenomen te identiceren tijdens transnasale transsfenoïdale selectieve 
adenomectomie. Gezonde hypofyse en hypofyse adenoom verschillen van 
elkaar in vascularisatie, wat mogelijk tot identicatie met ICG zou kunnen leiden. 
Bij 9 van de 10 patiënten met een microscopisch bewezen hypofyse adenoom 
werd een sterker uorescent signaal gezien in de gezonde hypofyse dan in het 
adenoom. Bij twee patiënten kon de daadwerkelijke resectie van het adenoom 
onder uorescentie-geleide plaatsvinden. Een van de beperkingen bij deze 
studie was dat de beschikbare endoscoop nog geen gelijktijdige weergave 
van kleur en uorescentie beelden kon laten zien. Verdere optimalisatie van 
contrastmiddelen en camerasystemen kan de toegevoegde waarde van 
uorescente beeldvorming tijdens hypofyse chirurgie nog verder verbeteren.
In hoofdstuk 6 wordt een klinische casus gepresenteerd waarbij MB 
gebruikt werd om een paraganglioom, een zeldzame neuro-endocriene tumor, 
te detecteren. Tijdens operatie bleek het zelfs mogelijk een lokale metastase te 
identiceren, die niet zichtbaar was voor het menselijk oog.
Voortgaand op de vergelijkbare biodistributie van MB en 99mTc-MIBI, wordt 
in hoofdstuk 7 de uorescente beeldvorming tijdens bijschildklierchirurgie 
beschreven. Het bleek niet alleen mogelijk om bijschildklier adenomen 
te detecteren, maar ook normale schildklieren van slechts een millimeter 
groot werden gevonden. En hoewel recente ontwikkelingen met nieuwe 
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contrastmiddelen veelbelovend zijn, kan uorescente beeldvorming met MB 
een belangrijke rol spelen tijdens bijschildklierchirurgie, totdat deze nieuwe 
stoen daadwerkelijk klinisch gebruikt kunnen worden.
Hoofdstuk 8 beschrijft het enhanced permeability and retention (EPR) eect, 
en de mogelijkheden hiervan bij de detectie van ovarium carcinoom. Het EPR 
eect is gebaseerd op het principe dat macromoleculen, zoals eiwitgebonden 
ICG, zich ophopen in tumor weefsel. Dit komt omdat tumor weefsel zich vaak 
kenmerkt door een toegenomen vasculaire permeabiliteit en verminderde 
lymfdrainage. Meerdere maligne laesies werden succesvol geïdenticeerd in 
onze studie. Het probleem daarentegen was dat er ook 13 niet-maligne laesies 
uorescent werden. Dit resulteerde in een fout-positieve ratio van 62%. Door 
dit gebrek aan speciciteit is uorescente tumor beeldvorming gebaseerd op 
het EPR eect niet toepasbaar in de kliniek. Stoen die speciek tumorweefsel 
binden, bijvoorbeeld door een bepaalde tumor-receptor te binden, kunnen dit 
probleem oplossen.
Deel 2:  Klinische translatie van innovatieve tumor-specieke 
uorescente contrastmiddelen
Hoofdstuk 9 beschrijft het gebruik van EC17, een folaat analoog gekoppeld 
aan uoresceïne, voor de intra-operatieve detectie van folaat receptor alfa 
(FRα) positieve ovarium- en mammacarcinomen. EC17 werd 2 tot 3 uur 
voor operatie intraveneus toegediend, wat resulteerde in helder uorescent 
ovariumcarcinoom weefsel tijdens operatie. Hierdoor konden 16% meer 
maligne laesies gereseceerd worden, en konden zelfs 70% meer laesies 
gedetecteerd worden op postoperatieve beeldanalyse. Bij mammacarcinoom 
is de over-expressie van de FRα lager dan bij ovariumcarcinoom. Daarom 
werd op preoperatief verkregen biopten eerst het expressie proel van de FRα 
bepaald, alvorens patiënten denitief te includeren. Deze aanpak, waarbij de 
specieke eigenschappen van de tumor van een individuele patiënt centraal 
staan, garandeert dat alleen patiënten geïncludeerd worden die potentieel 
baat hebben bij het gebruik van het tumor-specieke contrastmiddel. Net als 
bij ovariumcarcinoom werd bij mammacarcinoom een duidelijk uorescent 
signaal in de tumor gezien. Er werd echter ook autouorescentie van gezond 
weefsel gezien op een golengte van 500nm, wat resulteerde in fout-
46151 Quirijn Tummers.indd   199 16-08-17   13:01
Appendices200
positieve laesies. Daarnaast bemoeilijkte de autouorescentie het maken 
van onderscheid tussen maligne weefsel en gezond weefsel. Dit probleem 
zou opgelost kunnen worden door uorescente beeldvorming in het nabij-
infrarode lichtspectrum te doen. 
In hoofdstuk 10 wordt daarom het gebruik van een nieuw ontwikkeld FRα 
speciek contrastmiddel beschreven. OTL38 bestaat uit een folaat analoog, 
maar nu gekoppeld aan een NIR uorescente stof (uorescent op 800nm). Eerst 
werden verdraagbaarheid en farmacokinetiek in huid en bloed onderzocht 
in een gerandomiseerde, placebo-gecontroleerde studie in gezonde 
vrijwilligers, waarbij oplopende doseringen getest werden. Op basis van dit 
onderzoek werden 3 doseringen geselecteerd en vervolgens toegediend aan 
12 patiënten met ovariumcarcinoom, die gepland stonden voor debulking 
chirurgie. Er werden duidelijke uorescente FRα positieve ovariumcarcinomen 
en metastasen gezien. Dit resulteerde in de resectie van 29% meer maligne 
laesies, die niet met het blote oog gezien of gevoeld konden worden. Bij het 
gebruik van OTL38 werd nauwelijks achtergronduorescentie gezien. 
ALGEMENE CONCLUSIE
Het gebruik van ICG en MB bij intra-operatieve uorescente beeldvorming werd 
onderzocht voor een aantal belangrijke indicaties binnen de oncologische 
chirurgie. Beeldvorming met behulp van ICG resulteerde in accurate detectie 
van lever tumoren, en identicatie van schildwachtklieren bij maagkanker 
met hoge contrastratio’s en langdurig uorescent signaal. Op basis van onze 
gegevens zou uorescente beeldvorming moeten worden toegepast in de 
kliniek voor deze indicaties om de kwaliteit van zorg voor kankerpatiënten 
te verbeteren. Met het gebruik van MB konden bijschildklier adenomen, 
neuro-endocrine tumoren en borstkanker laesies succesvol geïdenticeerd 
worden. De introductie van meer tumor-specieke contrastmiddelen kan de 
nauwkeurigheid en beeldvorming waarschijnlijk verder verbeteren, maar tot 
die tijd kan MB gebruikt worden als ondersteuning bij bijvoorbeeld lastige 
casuïstiek. 
Het gebruik van EC17 en OTL38 zorgde voor nauwkeurige en zeer specieke 
intra-operatieve beeldvorming van ovariumcarcinoom. Daarbij werden hoge 
contrastratio’s gezien, en bleef het uorescente signaal langdurig aanwezig. 
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Het gebruik van deze contrastmiddelen van laagmoleculair gewicht zorgde 
voor snelle ophoping in tumorweefsel, terwijl het snel werd uitgescheiden 
uit de rest van het lichaam. Daarnaast werd bij beeldvorming in het nabij-
infrarode spectrum nauwelijks achtergrond signaal of autouorescentie 
gezien. Wanneer binnen nieuwe studies zowel gezonde personen als 
patiënten betrokken worden, kan op snelle en eciënte manier onderzoek 
gedaan worden naar de optimale dosis, bereiding van het contrastmiddel 
en tijdsspanne van beeldvorming. Dit bespoedigt de introductie van nieuw 
ontwikkelde contrastmiddelen in klinische studies. 
TOEKOMSTPERSPECTIEVEN
De afgelopen jaren zijn er meerdere indicaties vastgesteld waarbij klinisch 
beschikbare uorescente contrastmiddelen gebruikt kunnen worden. ICG 
en MB hebben de potentie om de kwaliteit van oncologische operaties te 
verbeteren, doordat meer maligne laesies gevonden kunnen worden, de 
operatietijd verkort kan worden en iatrogeen letsel voorkomen zou kunnen 
worden door betere identicatie van vitale structuren. En hoewel het aantal 
indicaties beperkt is door de intrinsieke eigenschappen van deze reeds 
beschikbare contrastmiddelen, kan de techniek wel direct worden toegepast 
bij bijvoorbeeld leverchirurgie, schildwachtklierprocedures of lastige operaties 
aan de galwegen. Totdat nieuw ontwikkelde ligand-bindende, tumor-specieke 
stoen ontwikkeld zijn en gebruikt mogen worden in patiënten, kan tumor 
identicatie verbeterd worden bij bijvoorbeeld borstkanker-, bijschildklier- en 
paraganglioom chirurgie, zoals beschreven in dit proefschrift. 
De introductie van ligand-bindende, tumor-specieke contrastmiddelen 
heeft de deur geopend naar nog preciezere intra-operatieve tumor identicatie. 
Zolang de juiste tumor- of weefsel specieke liganden maar gevonden worden, 
kan zo mogelijk elke structuur zichtbaar gemaakt worden die een chirurg wil 
zien tijdens een operatie.  Zoals beschreven in onze EC17 en OTL38 studies, 
waarbij een folaat analoog gekoppeld werd aan een uorofoor, bleek het 
mogelijk zeer specieke tumor imaging te verzorgen, binnen 2 tot 3 uur na 
toediening. Bovendien bleef het uorescente signaal en de contrastratio voor 
minstens 6 uur van zeer goede kwaliteit.
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Contrast middelen
Wanneer men nauwkeurige tumor detectie wil verkrijgen, is het belangrijk 
om bindingscapaciteit, biodistributie en de farmacokinetiek van een 
contrastmiddel te optimaliseren. Daarom worden veel verschillende soorten 
stoen onderzocht, zoals monoclonale antilichamen, antilichaam fragmenten 
zoals enkel-stengs antilichaam fragmenten en peptiden1-5. 
Al deze stoen hebben hun eigen farmacokinetische proel en half-waarde 
tijd, en daarmee verschillende optimale momenten voor beeldvorming. 
Rosenthal et al.5 hebben het gebruik van cetuximab-IRDye800 bij hoofd-
hals tumoren beschreven, waarbij de operatie 3 dagen na toediening van 
de stof moest plaatsvinden vanwege de lange half-waarde tijd van deze op 
een monoklonaal antilichaam gebaseerde stof (half-waarde tijd 24 – 32 uur, 
moleculair gewicht 150 kDa)6. Daarbij moesten relatief hoge doseringen 
gebruikt worden om een adequate contrastratio te krijgen (tot wel 25% van de 
therapeutische dosis; 62,5 mg/m2).
Toediening van het folaat analoog OTL38 (half-waarde tijd 2 – 3 uur, 
moleculair gewicht 1.4 kDa) resulteerde in een sterk uorescent signaal na 
slechts 2 tot 3 uur, wat aanhield voor minstens 6 uur (optimale dosis 0,0125 
mg/kg). En vanwege de snelle klaring van de stof werd een laag achtergrond 
signaal gezien. Het lijkt dat deze eigenschappen ideaal zijn voor nauwkeurige 
tumor imaging. Toekomstige studies zullen moeten uitwijzen welk soort stof 
optimaal is, en mogelijk verschilt dit ook per chirurgische indicatie.
Idealiter zou men één stof ontwikkelen die bijna alle tumoren bindt. 
Het blijft echter een enorme uitdaging om een stof te ontwikkelen die zeer 
speciek kankerweefsel bindt, en daarnaast uitgescheiden wordt uit de rest 
van het lichaam. Bovendien kunnen de expressie proelen van receptoren 
sterk wisselen. Bij ovarium carcinoom bijvoorbeeld, is meer dan 90% van alle 
tumoren FRα positief. Het voordeel hiervan is dat bijna alle patiënten baat 
hebben bij het gebruik van een FRα bindend contrastmiddel. Bij tumoren 
waarbij het expressie proel meer divers is, moet een andere benadering 
worden gekozen. Zo kunnen preoperatief verkregen biopten gebruikt 
worden voor het bepalen van het expressie proel, wat resulteert in een zeer 
precieze benadering per individuele patiënt. Dit werd bijvoorbeeld gedaan 
bij de borstkanker patiënten in onze EC17 studie. Daarnaast kunnen cocktails 
van verschillende contrastmiddelen gebruikt worden, of stoen ontwikkeld 
worden die tegelijkertijd meerdere receptoren kunnen binden, doordat ze 
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multipele liganden hebben gekoppeld aan één uorofoor. Dit zijn interessante 
ontwikkelingen, waarbij bedacht moet worden dat elke verandering aan een 
stof consequenties voor bindingscapaciteit en uorescente eigenschappen 
heeft.
Een van de belangrijkste beperkingen van uorescente beeldvorming 
heeft betrekking op de dieptepenetratie. In het zichtbare licht bedraagt deze 
enkele micrometers, en dit verbetert tot ongeveer een centimeter in het NIR 
lichtspectrum. Om deze beperking te overwinnen zijn er ontwikkelingen 
gaande waarbij uorescente beeldvorming gecombineerd wordt met andere 
diagnostische modaliteiten, de zogenaamde multimodale beeldvorming 
(beeldvorming gecombineerd met bijvoorbeeld positron emission tomography 
(PET) of single-photon emission computed tomography (SPECT) stoen)7. Door 
deze combinaties wordt het mogelijk om zowel preoperatieve chirurgische 
planning te verzorgen, als tijdens operaties naar dieper gelegen laesies te 
navigeren, terwijl daarbij real-time onderscheid gemaakt wordt tussen tumor 
en gezond weefsel. In de literatuur zijn inmiddels combinaties beschreven 
met foto-acoustische beeldvorming, magnetic resonance imaging, PET, SPECT 
en zelf tri-modale beeldvorming8. De meeste van deze stoen bevinden zich 
momenteel echter nog in preklinische fase van ontwikkeling.
Camerasystemen
Succesvolle uorescente beeldvorming is afhankelijk van de combinatie 
van zowel contrastmiddel als camerasysteem. Daarom is de ontwikkeling 
van camerasystemen essentieel voor de algemene acceptatie en introductie 
van uorescentie-geleide chirurgie. De afgelopen jaren zijn door meerdere 
bedrijven en instituten camerasystemen ontwikkeld, allemaal met hun eigen 
voor- en nadelen9. Vooral in de endoscopische beeldvorming is nog veel 
te verbeteren, zoals aangegeven in hoofdstuk 4 en 5 van dit proefschrift. 
Bovendien kan het ontwikkelen van een meer gestandaardiseerde manier 
om camera’s te vergelijken bijdragen aan het maken van nieuwe, verbeterde 
camerasystemen10.
Klinische implementatie
Om de klinische implementatie van uorescentie-geleide chirurgie te 
stroomlijnen is samenwerking essentieel. Daarom worden internationale 
verenigingen opgericht, zoals de International Society of Image Guided 
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Surgery, om wet- en regelgeving omtrent klinisch onderzoek en studieontwerp 
te bespreken en optimaliseren11;12. Zo moeten eindpunten in fase 1 studies 
bijvoorbeeld niet alleen focussen op veiligheid, maar ook op kwaliteit en 
eigenschappen van de beeldvorming. 
Er is daarnaast een veelbelovende rol weggelegd voor de ontwikkeling 
van farmacokinetische en farmacodynamische modellen13-15. Deze modellen 
kunnen ons meer inzicht geven in alle verschillende variabelen die een rol 
spelen bij optimale tumor beeldvorming. Door informatie over grootte, 
halfwaardetijd en klaring van een stof, receptor dichtheid, tumorgrootte, 
bindingsconstante en eiwitbinding te combineren in een model, eventueel 
aangevuld met beeldvorming-specieke eigenschappen als quantum yield en 
golengte, kunnen mogelijk voorspellingen gedaan worden over de veiligheid 
en mogelijkheid tot tumor beeldvorming van een nieuw ontwikkelde stof. Ook 
zou eventueel een optimale dosis voorspeld kunnen worden. Hierdoor kunnen 
mogelijk fase 1 studies gedaan worden, waarbij minder gezonde vrijwilligers 
en patiënten nodig zijn. Ook zouden er misschien voorspellingen gedaan 
kunnen worden over welk camerasysteem het meest geschikt is voor een 
specieke indicatie met een speciek contrastmiddel. Op deze manier worden 
fase 1 studies veel eciënter, en wordt de drempel om veelbelovende stoen 
naar de kliniek te brengen lager. 
Nieuwe klinische indicaties
De behandeling van kanker vraagt om een multidisciplinaire aanpak waarbij 
chirurgie, systemische chemotherapie of immunotherapie en radiotherapie 
allemaal een belangrijke rol spelen16;17. Constant verbeterende neoadjuvante 
chemo- en radiotherapie hebben ertoe geleid dat er een toenemend aantal 
complete pathologische responses wordt gezien, in bijvoorbeeld rectum en 
slokdarm kanker18-20. Bij deze patiënten is geen vitaal tumor weefsel meer 
aanwezig, en zij hebben dus ook geen baat meer bij chirurgische resectie, 
terwijl deze procedures wel geassocieerd zijn met morbiditeit en mortaliteit. 
Wanneer een resectie bij de juiste patiënten achterwege kan blijven, heeft dit 
grote impact op de kwaliteit van leven van deze mensen. 
Dit heeft geleid tot een cultuurverandering binnen de behandeling van 
kanker, waarbij ernaar gestreefd wordt om chirurgie achterwege te laten 
bij patiënten met een complete klinische respons, en zo orgaan-sparende 
behandeling mogelijk te maken. Hiervoor is het echter wel essentieel om 
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patiënten adequaat te selecteren, die een complete klinische respons hebben, 
en om ze te vervolgen. Meerdere studies beschrijven deze “Watch and Wait” 
policy bij rectum kanker21, en recent werd een internationale database opgericht 
om de resultaten van dit beleid te monitoren22. Moleculaire beeldvorming kan 
een grote rol spelen bij het selecteren en monitoren van patiënten, omdat het 
nog preciezere en objectievere informatie kan geven over de aanwezigheid 
van vitaal tumorweefsel in bijvoorbeeld littekenweefsel na chemoradiatie.
CONCLUSIES
Met behulp van uorescentie-geleide chirurgie kan tumorweefsel zichtbaar 
gemaakt worden, en kunnen meer maligne laesies gevonden worden, die 
anders onzichtbaar waren gebleven. Daarnaast ondersteunt de techniek de 
identicatie van lymfeklieren en vitale structuren. Nu moeten aanvullende 
studies, bij voorkeur gerandomiseerde onderzoeken, uitwijzen of deze 
verbeterde tumordetectie ook daadwerkelijk leidt tot verbeterde overleving 
en verminderde morbiditeit. Fluorescentie-geleide chirurgie wint snel 
aan populariteit, en hopelijk leidt een gezamenlijke aanpak tot verdere 
klinische implementatie en het verwerven van een standaard plek binnen de 
behandeling van kanker op korte termijn. 
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Om te beginnen wil ik alle patiënten en gezonde vrijwilligers die deelgenomen 
hebben aan de verschillende studies hartelijk bedanken. Zonder deelname 
was dit proefschrift er niet geweest. Voor alle patiënten in het bijzonder gold 
dat zij niet wisten of onze onderzoekstechnieken zouden bijdragen aan hun 
eigen behandeling. Ik heb diep respect voor de bereidheid om in deze vaak 
zeer moeilijke levensfase deel te nemen aan wetenschappelijk onderzoek.
Promoveren is teamsport, maar er zijn een aantal mensen die ik in het bijzonder 
heel hartelijk wil bedanken voor de totstandkoming van dit proefschrift.
Prof. Van de Velde, beste Professor; ik beschouw het als een zeer grote eer dat 
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bewondering voor uw staat van dienst, heb genoten van al uw bijzondere 
anekdotes, en vond het mooi om te zien dat u ondanks al uw prestaties uit het 
verleden, altijd uw blik op de toekomst hield.
Beste Xandra, heel veel dank voor jouw hulp bij het uitspelen van Converis, en 
eigenlijk bij alles wat geregeld moest worden rond mijn promotie.
Dr. Vahrmeijer, allerbeste Lex; als pater familias gaf jij op onnavolgbare wijze 
leiding aan onze onderzoeksgroep. Altijd op de hoogte van wat er speelde, 
en vooral heel goed op de hoogte van wat er nog meer uitgezocht kon 
worden. Jouw vermogen om 100 balletjes tegelijk hoog te houden is zeer 
bewonderenswaardig. Dank voor het vertrouwen, voor de begeleiding, en 
voor alles wat je teruggaf als beloning voor onze inspanningen.
Prof. Burggraaf, beste Koos; met de samenwerking tussen de Heelkunde van het 
LUMC en het CHDR is het niveau van onze onderzoeken nog verder gestegen. 
Ik wil je bedanken voor deze fantastische samenwerking en de begeleiding. 
Prof. Cohen, beste Adam; ook jou wil ik bedanken voor alle mogelijkheden die 
mij geboden zijn door samen met het CHDR onderzoek te doen.
Professor Frangioni, dear John; thank you for your introduction and guidance in 
the NIR uorescence imaging research world. Your motivating, sharp, positive 
and visionary view on science has been a great inspiration to me. 
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te groot om iedereen persoonlijk te bedanken, maar ik heb genoten, veel van 
jullie geleerd, en ik heb veel vertrouwen in de toekomst van onze groep. Mark, 
ik wil jou in het bijzonder bedanken voor de fantastische tijd die we samen 
hebben meegemaakt. En Charlotte, voor de schitterende samenwerking die 
we tot stand hebben gebracht tussen LUMC en CHDR.
Matthijs en Joost, mijn paranimfen, dank voor jullie hulp en steun in de eindfase 
van mijn promotie. Ik vind het mooi dat wij in 2004 samen begonnen aan onze 
studie, en nu als goede vrienden dit mogen meemaken. 
Tom, Bram, Wouter en Erik, ik voel me vereerd dat ik al mijn hele leven met 
jullie bevriend ben. We hebben het er vaak over gehad, maar mooi dat jullie nu 
eindelijk in het echt een Leidse promotie meemaken!
Tom, Kaa, Ruud en Luc, naast Matthijs en Joost als harde kern van Kanon Select 
wil ik jullie bedanken voor al jullie steun, het informeren naar en meeleven met 
mijn promotietraject. Mooi dat we dit feest met zijn allen kunnen vieren.
Lieve mam en pap, dank voor jullie onvoorwaardelijke steun en trots bij mijn 
promotietraject (en alles daarbuiten). Jullie hebben de basis gelegd voor alles 
wat ik bereikt heb, zonder jullie was dit nooit gelukt.
Lieve Johanneke, Willemieke en Fokkedien, dank voor al jullie steun en 
medeleven. Ik ben trots op jullie.
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